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ABSTRACT
Prolyl oligopeptidase (POP) is a widely distributed and highly conserved serine endopeptidase.
It is ubiquitous in the human body and one of the most abundant peptidases in the human brain.
POP degrades oligopeptides after internal prolyl residues including a prolinamide terminus.
POP inhibitors have been shown to ameliorate amnesia in several animal models. This was first
explained by the elevation of the brain levels of certain neuropeptides, which are in vitro
substrates of POP. However, the results from the in vivo studies have been contradictory. Later,
an inverse relationship between the concentration of the intracellular inositol-1,4,5-
trisphosphate and POP was found. It was proposed that the effect of POP on the
phosphatidylinositol pathway might explain the effects of POP inhibitors. POP inhibitors have
also been shown to prevent in vitro the host-cell invasion of Trypanosoma cruzi, which causes
Chagas disease.
A series of symmetrical dicarboxylic acid bis(L-prolyl-pyrrolidine) amides was modified at
the P3 position and beyond it, resulting in dicarboxylic acid azacycle L-prolyl pyrrolidine
amides. The novel compounds had lower molecular weights but their POP inhibitory activities
did not differ from the parent compounds. A comparative molecular similarity indices analysis
model was created in order to explain the structure-activity relationships (SAR) of these atypical
POP inhibitors. Two different binding modes were found: one that favors lipophilic structures
and one that favors nonhydrophobic structures. In the typical POP inhibitor structure, there is a
phenyl-alkanoyl group at the P3 position. The phenyl group was replaced by pyridyl groups in
order to introduce an ionizable group into the structure.  The 3-pyridyl group gave compounds
that were equipotent with their phenyl analogs. The 3-pyridyl group increased the water
solubility but decreased the lipophilicity. However, when it was combined with the 5-tert-butyl-
L-prolyl group at the P2 position, the theoretical optimum for lipophilicity was reached. An L-
prolyl group is the favored structure at the P2 position of POP inhibitors and it forms an amide
bond with the P3 aryl-alkanoyl group. The P2 L-prolyl residue was replaced by a cyclopent-2-
enecarbonyl group in order to replace the P3-P2 amide bond. The a,b-unsaturated carbonyl
group was a good mimetic for the amide bond. The novel compounds were equipotent but more
lipophilic than their parent compounds. A pyrrolidine group is the favored structure at the P1
position of POP inhibitors and it forms an amide bond with the P2 L-prolyl group. Different 1-
cycloalkenyl and aryl groups were studied in the place of the P1 pyrrolidine group. The 1-
cyclopentenyl and the 2-thienyl groups were able to mimic the P1 pyrrolidine group and proved
that the P1 nitrogen can be removed.
The present study provided new information of the SAR of POP inhibitors. Novel groups
that were able to mimic their parent structures were found for all studied positions. The physico-
chemical properties were determined for the selected compounds and it was shown that the
studied groups can be used to modify these properties. However, pharmacological studies are
needed to prove the usefulness of these novel groups in vivo.
National Library of Medicine Classification: QU 34, QU 136, QU 143, QV 744
Medical Subject Headings: Serine Endopeptidases; Enzyme Inhibitors; Serine Proteinase
Inhibitors; Amides; Structure-Activity Relationship; Memory Disorders; Amnesia;
Neurodegerative Diseases; Trypanosoma cruzi; Phosphatidylinositols; Drug Therapy
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1 INTRODUCTION
Prolyl oligopeptidase (POP) is a proline-specific peptidase that was found in the
beginning of the 1970’s (Walter et al. 1971). After that, the enzyme has been well-
characterized and the crystal structure was published in 1998 (Fülöp et al. 1998).
Several studies with specific POP inhibitors in different animal models have associated
POP with memory impairments and cognitive disturbances. POP has also been
implicated in mood disorders, Chagas disease and celiac disease. However, the full
biological role and the different mechanisms of actions still need further studies. Some
POP inhibitors have entered clinical studies but none of them has entered the market.
Thus, the suggested indication(s) for the prolyl oligopeptidase inhibitors needs to be
confirmed.
At the starting point of this work, a lot was known about the structure-activity
relationships (SAR) of POP inhibitors. Many potent inhibitors had been published in the
literature and some had also been developed by our own group. The best inhibitors had
subnanomolar IC50 values and the focus was shifted to other issues. The aim was to
introduce replacements in the typical POP inhibitor backbone that would make the
molecular structure more drug-like and could be used to modify the physico-chemical
properties of the inhibitors. The replacements were planned to mimic the replaced group
in the POP inhibitor structure in order to maintain the POP inhibitory activity.
The first part of the dissertation is a literature review that summarizes the current
knowledge of POP and its biological relevance. The amino acid proline and the
properties of drug-like compounds are also briefly discussed. A more detailed summary
is given about the SAR of POP inhibitors. After the literature review, each of the four
articles that are included in this dissertation has its own chapter. The first and the third
of the articles deal with the modifications of POP inhibitors at the P3 position and
beyond it, where the structural variation is explored. The second and the fourth of the
articles deal with the replacement of the P3-P2 and P2-P1 amide groups.
14
2 LITERATURE REVIEW
2.1 Nomenclature and classification
Prolyl oligopeptidase (EC 3.4.21.26) is classified as a serine endopeptidase. The name
and the classification describe the ability of POP to degrade oligopeptides after internal
prolyl residues. POP is a member of peptidase family S9, which belongs to clan C of
serine peptidases. Peptidase family S9 is often referred to as prolyl oligopeptidase
family and other representative members of this family are oligopeptidase B (EC
3.4.21.83), dipeptidyl-peptidase IV (DPP IV, EC 3.4.14.5) and acylaminoacyl-peptidase
(EC 3.4.19.1). POP is also known as prolyl endopeptidase and post-proline cleaving
enzyme in older literature (Nomenclature Committee of the International Union of
Biochemistry and Molecular Biology 2006, Rawlings et al. 2006).
2.2 Distribution of prolyl oligopeptidase
POP is a highly conserved enzyme that is widely distributed. It has been found in all
three domains of life; Archaea, Bacteria and Eukarya. Among Eukarya, the sequences
of POP have been resolved for many animals and plants (Venäläinen et al. 2004a).
Among fungi, the existence of POP has been unclear. A similar enzyme to POP has
been purified from a fungus Agaricus bisporus (Yoshimoto et al. 1990). Recently,
sequences from fungi with significant alignments with human POP could also be
retrieved from the NCBI protein database (National Center for Biotechnology
Information 2006).
When over 20 human tissues were studied, POP activity was found in all of them
(Kato et al. 1980). The highest activity was found in the skeletal muscle. In the brain,
the highest enzyme activity was found in the frontal cortex where the activity was one
sixth of that in the skeletal muscle. In another study, the highest POP activity in the
human brain was found in the cortices (Irazusta et al. 2002). In rat, which is often used
as the model animal in different performance tasks, the highest POP activity was found
in the brain and the activity was distributed more homogenously throughout the brain.
POP has mainly been described as a cytosolic enzyme but a membrane bound form
has also been reported (O'Leary et al. 1996). The membrane bound form was purified
from the bovine brain and it had many characteristics similar to the cytosolic POP
although some differences were also found. However, the sequence of this enzyme has
not been resolved. When 12 eukaryotic POP sequences were studied,
transmembraneous regions or lipid anchors that would indicate about the membrane
15
bound form were not found (Venäläinen et al. 2004a). Furthermore, it seems that a
secreted form of POP also exists (Siviter and Cockle 1995, Venäläinen et al. 2004a).
2.3 Biological relevance of prolyl oligopeptidase
2.3.1 Memory impairments and neurodegenerative disorders
Several studies suggest that POP could be related to neurodegeneration and disturbances
in memory and cognition. The expression of the POP gene was up-regulated 11-fold in
the hypothalamus (Jiang et al. 2001) and the POP protein level was 1.3 times higher in
the hippocampus (Roßner et al. 2005) of aged mice as compared to young and adult
mice, respectively. The results of the cortex were contradictory. Furthermore, a
stimulating environment decreased POP expression in the cortex of adult mice (Rampon
et al. 2000).
Amyloid b plaques are often found in the brains of Alzheimer's disease (AD)
patients. The expression of POP was studied in adult and aged transgenic mice, which
express amyloid precursor protein (Roßner et al. 2005). In the hippocampus of the adult
mice, POP expression was increased in parallel with memory deficits but before
appearance of the amyloid b plaques. In contrast, the aged mice with the amyloid b
deposits did not have altered enzymatic activity, which was confirmed with the AD
patients. Instead, negative correlation of POP activity with the scores of senile/neuritic
plaques and neurofibrillary tangles was found in the AD patients, which was suggested
to reflect the extent of neuronal damage (Laitinen et al. 2001). Furthermore, individual
neurons with strong immunohistochemical staining of POP were found to have
shrunken appearance (Roßner et al. 2005). Two specific POP inhibitors, JTP-4819 1
and Y-29794 2 (Table 1), prevented accumulation of amyloid b protein in vitro and in
vivo, respectively (Kato et al. 1997, Shinoda et al. 1997), although another POP
inhibitor S 17092 3 (Table 1) failed to affect amyloid b formation in vitro (Petit et al.
2000). Instead, S 17092 3 and another POP inhibitor Z-Pro-prolinal 4 (Table 1) were
able to protect cells from death in cell cultures (Shishido et al. 1999, Odaka et al. 2002).
Several POP inhibitors (Table 1) have prevented amnesia and improved
performance in different memory tasks. JTP-4819 1 improved performance of aged and
adult rats, which suffered from scopolamine- or ischemia-induced amnesia (Toide et al.
1997). S 17092 3 alleviated scopolamine-induced amnesia in rats and mice and
improved performance of aged mice (Morain et al. 2002). S 17092 3 also improved
cognition of the MPTP-treated monkeys, which serve as a model for the early
Parkinsonism. Some enhancement was also seen in verbal memory tests in healthy
16
Table 1. The structures and the potencies of POP inhibitors, which have undergone in
vivo studies.
Compound Name Structure Inhibitory activitySource of POP Reference
1 JTP-4819 NN
O O
OH
O
N
H
IC50 = 0.83 nM
rat brain
Toide
et al. 1995
2 Y-29794 N
S
O
S
N
Ki = 0.95 nM
rat brain
Nakajima
et al. 1992
3 S 17092
N N
S
OO
H
H
Ki = 1.5 nM
human
Barelli
et al. 1999
4 Z-Pro-prolinal NN
O O
H
O
O
Ki = 0.5 nM
human brain
Bakker
et al. 1990
5 ZTTA N
S
N
S
OO
O
O
O
Ki = 2.9 mM
rat brain
Shishido
et al. 1996
6 Z-321 NN
S
OO
IC50 = 10 nM
canine brain
Tanaka
et al. 1994
7 ONO-1603 NNH O
O
O
H
Cl
Ki = 12 nM
rat brain
Katsube
et al. 1999
8 KYP-2047 NN
OO
CN
Ki = 0.023 nM
porcine brain
Venäläinen
et al. 2006
humans during the phase I study (Morain et al. 2000). ZTTA 5 improved performance
of rats after cerebral ischemia (Shishido et al. 1996) and basal forebrain lesion
(Shishido et al. 1998). Z-Pro-prolinal 4 prevented scopolamine-induced amnesia in rats
(Yoshimoto et al.1987) and KYP-2047 8 improved performance of young but not old
scopolamine-treated rats (Jalkanen et al. 2006).
Taken together, several studies suggest that POP inhibitors might be beneficial in
the treatment of age-related memory disorders or neurodegenerative diseases, like
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Alzheimer's disease. Indeed, four POP inhibitors, JTP-4819 1, S 17092 3, Z-321 6 and
ONO-1603 7, have entered clinical trials (Umemura et al. 1997, Katsube et al. 1999,
Umemura et al. 1999, Morain et al. 2000). However, their mechanism(s) of action is not
fully understood, i.e. the secondary effects of POP inhibition are not known for sure. At
the moment, there are two main theories for the memory-improving effects of POP
inhibitors: elevation of the neuropeptide levels in the central nervous system (CNS) and
elevation of the intracellular inositol-1,4,5-trisphosphate (IP3) level.
Certain neuropeptides, like substance P (SP), arginine-vasopressin (AVP) and
thyroliberin (TRH) (Figure 1), are in vitro substrates of POP (Knisatschek and Bauer
1979, Blumberg et al. 1980, Yoshimoto et al. 1981). These neuropeptides have been
shown to improve learning and memory (Griffiths 1987, Kovacs and De Wied 1994,
Huston and Hasenöhrl 1995). Consequently, it was concluded that inhibition of POP
might increase concentrations of these peptides in the CNS and thus, counteract
memory disturbances. Several studies have been performed to verify this theory. A 21-
day treatment with JTP-4819 1 increased the SP and the TRH level in the cortex and the
hippocampus of aged rats, while the AVP level was unaffected (Toide et al. 1997). In
humans, a 7-day treatment with JTP-4819 1 did not affect the plasma concentration of
SP, although a small increase was seen after a single dose (Umemura et al. 1997). A
single dose of S 17092 3 increased the SP level in the frontal cortex and the
hypothalamus of rats while an 8-day treatment did not have any effect (Bellemère et al.
2003). Also the TRH level in the cerebral cortex and the AVP level in the hippocampus
of rats were increased after the single dose of S 17092 3 but only the TRH level in the
cerebral cortex was increased after the 8-day treatment (Bellemère et al. 2005). A single
dose of Z-321 6 or Z-Pro-prolinal 4 increased the AVP level in the septum of rats
(Miura et al. 1995). Instead, a 7-day treatment with Z-321 6 did not affect the plasma
levels of SP, TRH or AVP in humans (Umemura et al. 1999). A single dose or a 10-day
treatment with KYP-2047 8 or JTP-4819 1 did not affect the SP level in the cortex,
hippocampus or hypothalamus of rats (Jalkanen et al. 2006). The single dose of
(a) Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met
(b) Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly
(c) (pyro)Glu-His-Pro-NH2
Figure 1. The sequences of three neuropeptide-substrates of POP. The scissile bonds
are shown in bold. (a) Substance P; (b) Arginine-vasopressin; (c) Thyroliberin.
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KYP-2047 8 slightly increased the neurotensin level in the hypothalamus of rats but not
dose-dependently. The chronic administration instead, decreased the neurotensin
concentration. JTP-4819 1 did not affect the neurotensin level in the hypothalamus of
rats. The expression of the POP gene was also reported to overlap with the receptors of
SP, TRH and AVP in the rat brain (Bellemère et al. 2004).
However, the different location of POP, which is mainly described as the cytosolic
enzyme, and the neuropeptides, which are located in transcellular space, has questioned
the role of POP in neuropeptide metabolism. The membrane bound form of POP might
offer an answer to this discrepancy, and indeed, it has been reported to have a higher
affinity towards neuropeptides than the cytosolic POP has (O'Leary et al. 1996).
However, this approach does not explain the role of the cytosolic POP and also ignores
the effect of other peptidases.
At the end of the 1990's some light was shed on the intracellular functions of POP
when it was linked to the phosphatidylinositol (PI) pathway. Williams et al. (1999)
studied the molecular basis of the properties of Li+, which is used in bipolar affective
disorder. They screened through the Li+ resistant mutants of Dictyostelium and found
that one mutant was lacking the POP gene. Further studies revealed that the lack of the
POP gene or inhibition of POP by specific inhibitors elevated the IP3 concentration by
dephosphorylation of inositol-1,3,4,5,6-pentakisphosphate (IP5) and thus, counteracted
the effect of Li+, which inhibits the PI pathway (Figure 2). Later it was verified that
POP is linked to the PI pathway also in mammalian cells (Williams et al. 2002). The
mechanism behind the inverse relationship of the IP3 concentration and POP activity is
IP3
IP2Inositol
PIP2
IP5
POP
Li+
PLC
Figure 2. The interaction of POP and lithium with the phosphatidylinositol pathway.
Phospholipase C (PLC) cleaves phosphatidylinositol-4,5-bisphosphate (PIP2) to
inositol-1,4,5-trisphosphate (IP3). POP inhibits the formation of IP3 from inositol-
1,3,4,5,6-pentakisphosphate (IP5) and the formation of  inositol-4,5-bisphosphate (IP2)
from IP3. Lithium inhibits the formation of inositol from IP2. Modified from Williams et
al. 1999.
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still unknown. However, the increase of the IP3 concentration was delayed after the
inhibition of POP and it was suggested that the proteolytic activity of POP is behind this
phenomenon, although IP5 is not a substrate of POP (Schulz et al. 2002). Furthermore,
Z-Pro-prolinal 4 (Table 1) prevented the translocation of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) into the nucleus of monkey fibroblasts, which had been
exposed to 6-hydroxydopamine (Puttonen et al. 2006) and ONO-1603 7 (Table 1)
suppressed the overexpression of GAPDH in cultured neurons (Katsube et al. 1999).
The GAPDH translocation leads to apoptosis in some circumstances and is dependent
on PI-3-kinase, which is a phosphorylating enzyme in the PI pathway. In addition,
Z-Pro-prolinal 4 prevented the 6-hydroxydopamine-induced formation of reactive
oxygen species in monkey fibroblasts (Puttonen et al. 2006). However, the IP3
concentration in the hippocampus or the cortex of rats was not elevated in vivo after
treatment with JTP-4819 1.  Recently, POP was also found to be closely associated with
tubulin, and was proposed to have a role in protein trafficking and secretion (Schulz et
al. 2005). Indeed, inhibition of POP and antisense mRNA expression of POP both
increased protein secretion, the latter having more evident effect. This led to the
conclusion, that the effect of POP on protein secretion may be independent of its
peptidase function.
2.3.2 Psychiatric disorders
Altered serum POP activity has been reported in many psychiatric disorders. Lowered
serum POP activity was found in anorexia nervosa and bulimia nervosa patients (Maes
et al. 2001), as well as in unmedicated depressed patients as compared to normal
volunteers. In the depressed patients, antidepressants increased POP activity. Increased
serum POP activity was found in patients with bipolar disorder (manic) who had been
deprived from any medication for at least seven days, but short valproate treatment
decreased activity. Increased serum POP activity was also found in schizophrenic
patients (Maes et al. 1995) and in persons with stress-induced anxiety (Maes et al.
1998). It is somewhat unclear how the serum POP activity correlates with the POP
activity in the brain and whether the altered POP activity is the cause or the
consequence of the disorders. However, the criticism towards these results has mainly
originated from the substrate, N-Z-Gly-Pro-7-amino-4-methylcoumarin, which was used
to determine the serum POP activity in these studies. It has been shown that two distinct
enzymes are responsible for the N-Z-Gly-Pro-7-amino-4-methylcoumarin-hydrolyzing
activity in the bovine serum. One enzyme is prolyl oligopeptidase and the other was
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originally named as Z-Pro-prolinal insensitive peptidase (ZIP), because it could not be
inhibited by the specific POP inhibitor Z-Pro-prolinal 4 (Cunningham and O'Connor
1997). ZIP was later identified as a seprase with the properties of a proline specific
serine protease (Collins et al. 2004). However, when an assay that distinguishes
between POP and ZIP activities was used, it was found that the activities of the both
enzymes were lowered in the serum of bipolar disorder patients that were receiving
lithium-treatment and had euthymic mood. On the other hand, no changes were
observed in the POP or ZIP activity in the serum of schizophrenic patients (Breen et al.
2004).
Interestingly, valproate decreases POP activity in manic patients (Maes et al. 1995).
The effect of valproate on the phosphatidylinositol pathway has been studied and a dual
action was proposed: valproate directly inhibits POP and thus increases PI signalling
but in other conditions it inhibits PI signalling by an unknown mechanism. This theory
of dual action was used to explain why valproate can prevent swings to both mania and
depression. It was suggested that POP inhibitors could be used in the treatment of
bipolar disorders. However, it is contradictory that PI signalling is high in manic
persons and a decrease in POP activity would still increase it (Cheng et al. 2005).
2.3.3 Other disorders
Trypanosoma cruzi is a parasitic protozoan that causes Chagas disease, a disease that is
prevalent in Latin America. In 1997, T. cruzi was found to secrete an 80 kDa protein
that was able to degrade collagen and had a high specificity for proline residues. The
enzyme was mainly secreted by trypomastigotes, the infective form of T. cruzi. It was
suggested that this enzyme might participate in the host-cell infection by degradation of
the extracellular collagen matrix (Santana et al. 1997). Later, this enzyme was verified
to be the POP of T. cruzi (POP Tc80), even though it was able to degrade proteins in
contrast to mammalian POP (see section 2.4.2). The POP Tc80 had a 43% identity with
the porcine POP. The inhibitors of the POP Tc80 prevented the actual invasion phase of
trypomastigotes into host-cells but not the parasite attachment to the host-cell
membrane (Bastos et al. 2005). These results suggest that the inhibitors of the POP
Tc80 have potential as antiprotozoal drugs.
Celiac disease is an autoimmune disease that is caused by the ingestion of gluten
proteins, gliadins and glutenins. Celiac disease leads to the destruction of the small
intestine villi and the only effective therapy at the moment is a gluten-free diet. When
a-gliadin was exposed to digestive enzymes, a proline-rich peptide was one of the
products (Shan et al. 2002). This peptide was resistant to further hydrolyzation and it
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was stated to have "an exceptional toxic potency". However, the peptide could be
hydrolyzed by bacterial POP and it was suggested that celiac disease patients might
benefit from peptidase therapy.
2.4 Substrates
2.4.1 Proline
Proline is often referred to as an imino acid because its side chain is bonded, not only to
the a-carbon, but also to the a-amino group (Yaron and Naider 1993, Vanhoof et al.
1995, Cunningham and O'Connor 1997). Consequently, proline has a cyclic structure,
which prevents free rotation around the ?-bond and, in a peptide sequence proline does
not have a main chain NH proton that could form intramolecular hydrogen bonds. These
features make proline unique amongst the 20 natural a-amino acids. Proline causes
bends in the peptide or protein chains and often breaks repeated structures. It does not
participate in hydrogen bonding and can also prevent hydrogen bonding of the
neighbouring residues. Peptide bonds are mainly in trans conformation but the bond
preceding a prolyl residue makes an exception. This bond can be both in cis and trans
conformations (Figure 3), which are separated by an energy barrier of 20 kcal/mol. The
isomerization of this bond is thought to be a rate-limiting step in protein folding and
degradation. Another important function of prolyl residues in peptide sequences is the
protection of biologically active peptides from non-specific degradation. The ability of
prolyl residues to protect peptides has led to the evolution of proline specific peptidases,
like prolyl oligopeptidase.
2.4.2 Substrate specificity
POP was first recognized as a human uterine enzyme that hydrolyzes the prolyl-leucyl
bond in oxytocin (Walter et al. 1971). Since then, different mammalian POPs have been
N
O
R2
O
R1
N
O
R1
O
R2
cis Xaa-Protrans Xaa-Pro
Figure 3. Cis and trans conformations of the peptide bond preceding a prolyl residue.
R1 = peptide sequence in the amino terminus; R2 = peptide sequence in the carboxyl
terminus.
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shown to hydrolyze oligopeptides up to about 30 amino acids at the carboxyl side of a
prolyl (or a prolinamide) residue (Wilk 1983, Cunningham and O'Connor 1997). In
some cases, POP can also hydrolyze oligopeptides after an alanine residue but not as
efficiently as after a proline residue. Recently, a post-cysteine cleavage site was also
reported (Bär et al. 2006). There are some restrictions too; POP does not hydrolyze a
bond between two prolyl residues or the first two bonds of the N-terminus (Wilk 1983,
Cunningham and O'Connor 1997). L-Amino acids are also required at the P1 and P2
positions.
2.5 Structure and substrate binding
The sequence analysis of the POP gene of human lymphocytes revealed that the gene
codes for an 80 kDa protein that consists of 710 amino acids (Vanhoof et al. 1994).
Human POP shares 97% identity with the porcine brain POP (Rennex et al. 1991) and
95% identity with the rat POP (Kimura and Takahashi 2000), which are often used to
determine in vitro and in vivo effects of POP inhibitors. Furthermore, all 19 differences
in the sequences of the porcine and the human POPs are far from the active site (Fülöp
et al. 1998) and thus, porcine POP can be considered as a good model for the human
POP. Instead, the POPs of Flavobacterium meningosepticum and Trypanosoma cruzi
share only about 40% identity with the mammalian POPs (Yoshimoto et al. 1991a,
Bastos et al. 2005).
The crystal structures of the porcine muscle POP and its complex with a transition
state analog inhibitor, Z-Pro-prolinal 4, have been resolved (Fülöp et al. 1998, Figures 4
and 5). No differences between the porcine muscle and the porcine brain POP were
found. The enzyme has two domains. The catalytic domain consists of residues 1-72
and 428-710 and the C-terminal part of it forms an a/b-hydrolase fold. The noncatalytic
b-propeller domain consists of residues 73-427. The b-propeller is 7-bladed and each
blade is formed by a four-stranded antiparallel b-sheet. The blades are arranged around
the central tunnel and the whole structure is stabilized by hydrophobic interactions.
The substrates of the mammalian POP are restricted to peptides up to about 30
amino acid residues. The mechanism of the restriction of the substrate size is probably
related to the entrance of the substrate because the cavity inside POP could
accommodate larger substrates. At the moment it seems that the entrance is between the
two domains and not through the b-propeller as was originally suggested (Fülöp et al.
1998, Szeltner et al. 2004, Fuxreiter et al. 2005, Juhász et al. 2005). A crystallized open
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Figure 4. The crystal structure of the porcine muscle POP with the transition state
analog inhibitor Z-L-Pro-L-prolinal bound to its active site at the interface of the
catalytic domain and the b-propeller domain. The picture was kindly created by Dr.
Maija Lahtela-Kakkonen.
Figure 5. The binding of Z-L-Pro-L-prolinal to the active site of POP. The picture was
kindly created by Dr. Maija Lahtela-Kakkonen.
catalytic domain
b-propeller domain
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form of the unbound POP of Sphingomonas capsulata was recently reported (Shan et al.
2005). It was suggested that the substrate causes conformational changes which open
the domain interface and that the substrate-protein interactions stabilize the open form.
A limited surface area created by the domain opening was postulated to restrict the
substrate size. However, care should be taken when extrapolating these results to
mammalian enzymes, and indeed, it has been pointed out that the role of the b-propeller
domain may have changed during evolution (Venäläinen et al. 2004a).
The active site of POP is at the interface of the two domains and contains the
catalytic triad, Ser554, Asp641 and His680 (Fülöp et al. 1998, Figure 5). Ser554 is
easily accessible and it is surrounded by small residues. The other carboxylate oxygen
of Asp641 is hydrogen bonded to His680 and a water molecule. The other oxygen is
hydrogen bonded to two main chain NH groups of POP. The nucleophilic hydroxyl
group of Ser554 attacks the carbonyl group of the scissile bond (or the aldehyde
carbonyl group of the transition state analog inhibitor) and a covalent bond is formed.
The carbonyl oxygen forms an oxyanion, which is stabilized by two hydrogen bonds;
one to a main chain NH group and one to the phenolic hydroxyl group of Tyr473. The
S1 subsite has evolved to fit the five-membered ring of the prolyl residue and further
stabilization is gained from ring stacking between the P1 prolyl residue and the indole
group of Trp595. The S2 subsite is less specific and the P2 residue is stabilized by a
hydrogen bond between the P2 carbonyl oxygen and the guanidine group of Arg643.
The S3 subsite is located at a large cavity and the S3-P3 hydrogen bond is formed
between the P3 carbonyl oxygen and the side chain of Trp595. Also the subsites P4, P1'
and P2' have been reported for longer substrates (Fülöp et al. 2001).
2.6 Prolyl oligopeptidase inhibitors
A wide variety of POP inhibitors has been described in scientific publications and
patents. The aim of this chapter is not to cover all of them but to give an overview of the
structure-activity relationships of POP inhibitors. Most of the published inhibitors are
substrate-like inhibitors that are based on the N-acyl-L-prolyl-pyrrolidine structure and
their binding mode is known (Figure 6). A number of atypical POP inhibitors which
have been extracted from different plant sources have also been published. Their
inhibitory activities are usually rather low and their binding modes unknown. These
compounds are not discussed herein. Direct comparisons will be made only between
inhibitors that have been tested in the same test system.
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Figure 6. The structures and the binding modes of substrates and substrate-like
inhibitors of POP. R = amino acid side chain; R'CO = an N-acyl group; A = generally
H, CHO, CN or COCH2OH (other groups are discussed in section 2.6.1.).
2.6.1 The P1 site
The S1 binding site of prolyl oligopeptidase is a specific pocket for the five-membered
ring of a prolyl residue (Fülöp et al. 1998) and therefore most of the POP inhibitors
have a pyrrolidine or a substituted pyrrolidine ring at the P1 site (Table 2). If the ring
size of pyrrolidine is decreased (Goossens et al. 1997) or increased (Tsuru et al. 1988)
by one methylene group the inhibitory activity decreases, as is exemplified by
compounds 9-11. Pyrrolidine can be replaced by other five-membered rings as
thiazolidine (as in compound 3), isoxazolidine, pyrrole, 2,3-dihydropyrrole and
Table 2. The effect of the ring size and ring opening at the P1 position on the potency
of POP inhibitors.
Number NR2 IC50 (nM) Source of POP Reference
NR2N
OO
O
9
N
600
540
human platelets
bovine brain
Goossens et al. 1997
Tsuru et al. 1988
10 N 3000 human platelets Goossens et al. 1997
11
N
1000000 bovine brain Tsuru et al. 1988
NR2N
OO
H
H
12
N
1.2 rat cortex Portevin et al. 1996
3 (S 17092)
N
S
1.3 rat cortex Portevin et al. 1996
13 N > 2000 rat cortex Portevin et al. 1996
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Table 3. The effect of the carbon rings at the P1 position on potency of POP inhibitors.
N
O O
R
Compound R IC50 (nM) Source of POP Reference
14 (SUAM-1221)
N
2.0
15 30
16 1100
17 23
porcine brain Wallén et al. 2002b
2,5-dihydropyrrole (Portevin et al. 1996). However, ring opening (as in compound 13)
abolishes the inhibitory activity.
The evolution of the specific S1 pocket is explained by the lack of the main chain
NH proton. Consequently, the amide nitrogen of the P1 prolyl residue is not stabilized
by hydrogen bonding to the surroundings (Fülöp et al. 1998) and the P1 pyrrolidine
nitrogen of POP inhibitors can be removed (Table 3). The pyrrolidine ring of the well-
known POP inhibitor SUAM-1221 14 has been replaced by a cyclopentane ring in
compound 15 (Wallén et al. 2002b). The inhibitory activity decreased to some extent,
which may result from the replacement of the amide nitrogen, which is sp2 hybridized,
by an sp3 hybridized carbon. The replacement with a cyclohexane ring (compound 16)
decreased the inhibitory activity significantly but the replacement with a benzene ring
gave compound 17, which was equipotent with the cyclopentane derivative 15.
Substituents at the 3-position of the P1 pyrrolidine ring are rare. Fluorine is the only
substituent at this position that has been shown to improve potency (Goossens et al.
1997). On the other hand, substituents at the 2-position are not rare and provide the
most efficient method to improve the potency of POP inhibitors. Three most studied
substituents are the electrophilic 2(S)-formyl, 2(S)-cyano and 2(S)-hydroxyacetyl
groups.
 Z-Pro-prolinal 4 has the 2(S)-formyl group at the 2-position of the P1 pyrrolidine
ring. It was originally synthesized as a transition state analog inhibitor (Wilk and
Orlowski 1983) and the crystal structure confirmed that the 2(S)-formyl group forms a
hemiacetal adduct with Ser554 of POP (Fülöp et al. 1998, Figure 7a). Later it was
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Figure 7.  (a) Hemiacetal formation of a 2(S)-formyl group and (b) a suggested imidate
formation of a 2(S)-cyano group with Ser554 of POP.
shown that Z-Pro-prolinal is a slow- and tight-binding competitive inhibitor of POP
(Bakker et al. 1990). It was 40 times more potent inhibitor of canine POP than Z-L-Pro-
pyrrolidine 9 (Tanaka et al. 1994).
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The 2(S)-cyano group increases the potency of POP inhibitors (Tanaka et al. 1994).
The cyano group also increases the potency of DPP IV inhibitors, although it is
generally considered to give poor serine protease inhibitors (Li et al. 1995). KYP-2047
8 was 40 times more potent than SUAM-1221 14, the Ki values were 0.023 and 0.97,
respectively (Venäläinen et al. 2006). The inhibition of cystein proteases by nitriles has
been studied. Cystein proteases have a similar catalytic mechanism to serine proteases
and the cyano group forms a covalent, reversible thioimidate adduct with the thiol group
of the active site cysteine (Dufour et al. 1995). There is most likely a similar interaction
between the hydroxyl group of the catalytic Ser554 of POP and a cyano group (Figure
7b).
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OO
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OO
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The 2(S)-hydroxyacetyl group can be considered to be an activated ketone. While
the reported IC50 value for SUAM-1221 14 was 2.0 nM, the corresponding analog 18
with the 2(S)-hydroxyacetyl group was over 10 times more potent (Wallén et al. 2002b).
However, the removal of the hydroxyl group resulted in compound 19 with a
28
significantly decreased potency, the IC50 value was 170 nM. This series of compounds
shows that the activation of the ketone is crucial for the inhibitory activity. The
interaction of the ketone function with POP has not been studied but the 2(S)-
hydroxyacetyl group might form a hemiketal adduct with the active site serine 554,
analogously to the hemiacetal adduct of the 2(S)-formyl group.
NN
OO
NN
OO O
OH
NN
OO O
14 18 19
Recently, the binding kinetics of a series of isophthalic acid bis-(L-prolyl-
pyrrolidine) amides 20-23 to POP was studied (Venäläinen et al. 2004b, Table 4). The
formyl, the cyano and the hydroxyacetyl groups increased the potency by two orders of
magnitude as compared to an unsubstituted pyrrolidine. They also caused a slow-
binding inhibition by reversible covalent binding in contrast to the fast binding of
compound 20. However, differences between compounds 21-23 were found in
dissociation half-lives. While compound 21 with the 2(S)-cyano group had a
dissociation half-live of 25 minutes, the corresponding value for compounds 22 and 23
was over 5 hours. It was suggested that these groups can be used to optimize the
duration of POP inhibition. Later it was shown that the duration of POP inhibition in rat
tissues can be estimated from the dissociation half-lives of the enzyme-inhibitor (EI)
complexes (Venäläinen et al. 2006).
Table 4. The kinetic parameters of the binding of isophthalic acid bis-(L-prolyl-
pyrrolidine) amides to POP.a
N N
O O
NN
OO
R
Compound R Ki (nM)b EI half-lifeb
20 H 11.8 ± 0.5 -
21 CN 0.39 ± 0.03 25 ± 3 min
22 CHO 0.15 ± 0.01 5.4 ± 0.5 h
23 COCH2OH 0.079 ± 0.010 5.2 ± 0.7 h
a Modified from Venäläinen et al. 2004b; b Determined with the purified porcine POP.
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Figure 8. Different groups that have been used to activate the P1 ketone carbonyl of
POP inhibitors.
In addition to the 2(S)-hydroxyacetyl group, many other activated ketones have also
been studied (Figure 8). These are for example 2(S)-chloroacetyl, 2(S)-acetoxyacetyl
(Vendeville et al. 2002), 2(S)-diazoacetyl (Stone et al. 1992), and 2(S)-
pentafluoropropanoyl groups (De Nanteuil et al. 1998), different N-cycloalkylated
amino-oxo-acetyl groups (Tsuda et al. 1996a) and heterocyclic ketones (Tsutsumi et al
1994). The activation of the ketone may be caused by an inductive effect because all
groups have an electronegative atom near the ketone carbonyl function. Furthermore, in
the series of heterocyclic ketones, improvement in potency was observed when
compounds 24-26 were studied (Tsutsumi et al. 1994). One nitrogen at the ?-position
from the carbonyl group gave only weak inhibitory activity (IC50 of 24 was 2290 nM)
but the addition of the second nitrogen improved activity significantly (IC50 of 25 was
61 nM). However, the most potent inhibitor was obtained when the nitrogen atom was
changed to the b-position from the ketone carbonyl group (IC50 of 26 was 6.9 nM).
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It has been suggested that the aldehydes and the activated ketones may be too
reactive to be used as drugs and a series of acetals was synthesized to overcome this
problem (Augustyns et al. 1995). These acetals proved to be stable and did not act as
prodrugs of aldehydes. The dimethyl acetal 27 was the most potent compound. It was 5
times more potent than the corresponding compound 9 with an unsubstituted
pyrrolidine; the IC50 values against human POP were 120 nM and 600 nM, respectively.
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Figure 9. The P1 groups that resulted in loss of POP inhibitory activity.
Other structures that have been studied at the P1 position are presented in Figure 9.
These were pyrrolidin-2-one (Arai et al. 1993), L-prolinol, L-proline (Wilk and
Orlowski, 1983), L-prolyl methylester (Tsuru et al. 1988) and D-prolinal (Nishikata et
al. 1986). All these groups resulted in significant decrease in potency.
2.6.2 The P2 site
The S2 binding site of POP is not as specific as the S1 pocket (Fülöp et al. 1998) and
consequently, much more structural variation is tolerated at the P2 position of POP
inhibitors. Among the natural a-amino acids, the cyclic L-proline is preferred (Saito et
al. 1991). L-Proline is found at the P2 position of many typical POP inhibitors like
Z-Pro-prolinal 4 or SUAM-1221 14. The achiral glycine gives poor POP inhibitors
while the other studied amino acids fall between these two extremes. However, it is
intriguing to notice that the change of the amide nitrogen of glycine to an sp3 hybridized
carbon, gives quite potent compounds. Compound 28 was reported to have a Ki value of
70 000 nM against bovine POP, while the reported Ki value for ONO-1603 7 was 12
nM against rat POP (Yoshimoto et al. 1987, Katsube et al. 1999). Although the
compounds cannot be directly compared, it is unlikely that this large difference in in
vitro activities could only be explained by different source of POP or other structural
differences.
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It is important that the P2 prolyl residue has an L-configuration, because the
replacement with a D-prolyl residue strongly reduced the inhibitory activity. The
replacement of the P2 carbonyl group by a methylene group also strongly reduces the
inhibitory activity (Yoshimoto et al. 1991b). This is understandable because the P2
carbonyl oxygen is needed for hydrogen bonding (Fülöp et al. 1998).
Only few other 5-membered rings besides the L-prolyl group have been studied at
the P2 position. The L-prolyl group could be replaced by an L-thioprolyl group as in
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Z-321 6 (Tanaka et al. 1994). The replacement by a cyclopentane ring was also
tolerated; the IC50 value of compound 29 against bovine POP was 14 nM (Ohno et al.
1988a). 4-Oxo-L-proline, 5-oxo-L-proline, trans- and cis-4-hydroxy-L-proline
decreased the potency (Yoshimoto et al. 1987, Saito et al. 1991).
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On the other hand, 5-alkyl-L-prolines gave compounds that were slightly more
potent than the corresponding L-prolyl analogs (Wallén et al. 2003). The IC50 values of
compounds 14 and 30-32 against porcine POP were 2.2 nM, 1.2 nM, 0.71 nM and 1.4
nM, respectively. Later it was shown that compound 30 had a 10 times longer
dissociation half-life than compound 14 (Venäläinen et al. 2006).
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14 30; R = tert-Bu
31; R = Me
32
Unlike at the P1 position, a 6-membered ring was tolerated at the P2 position,
although it slightly decreased the potency (Saito et al.1991). Compound 33 has a
piperidine group at the P2 site and it was reported to be 5 times less active than SUAM-
1221 14 against bovine POP. Trans- and cis-cyclohexyl rings were also tolerated, the Ki
value was 3.0 nM for both compounds 34 and 35 against mouse POP (Bakker et al.
1991). It remained unclear whether the cyclohexyl groups were mixtures of trans- and
cis- compounds or had they pure S,S- and R,S-stereocenters as drawn below.
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Different kinds of bridged and fused rings have also been studied at the P2 position.
Azabicyclo[2.2.2]octane (36), azabicyclo[2.2.1]heptane (37) and perhydroindole (38)
gave potent compounds, the last two were slightly better than the first one. The IC50
values against rat POP were 5, 1.4 and 1.2 nM, respectively (Portevin et al. 1996).
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Compound 39 with 2,3-dihydroindole at the P2 position was over 200 times less
potent than SUAM-1221 14 against bovine POP (Saito et al. 1991). 1,2,3,4-
Tetrahydroisoquinoline has been utilized to give the selective inhibition of T. cruzi POP
(Vendeville et al. 2002). Compound 40 was 78 times more potent against T. cruzi POP
that human POP. However, the selectivity decreased when 1,2,3,4-
tetrahydroisoquinoline was combined with other types of P3 structures.
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2.6.3 The P3 site and beyond it
The S3 subsite is the least specific binding site of POP. A wide variety of groups has
been studied at the P3 position of POP inhibitors and some large structures reach even
beyond the P3 site. This chapter covers only a small part of the studied structures to
give a general overview of the SAR of the P3 site.
The P3 carbonyl oxygen is important for good inhibitory activity. The IC50 value of
compound 41 was only 130 nM despite the 2(S)-formyl substituent at the P1 ring (Ohno
1988b). Practically all POP inhibitors have an N-acyl group attached to the P2 nitrogen
and they can be roughly divided in two groups: compounds with an aliphatic acyl group
and compounds with an aryl-alkanoyl group. The latter group is preferred.
N
O O
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The aliphatic chain can be straight, branched, cyclic, saturated or unsaturated. The
relative potency of aliphatic acyl groups in relation to aryl-alkanoyls is difficult to
define. In the study of Saito et al. (1991) aliphatic alkanoyls and alkenoyls, whose
lengths ranged between 6 and 18 carbons, were all less potent than SUAM-1221 14.
The best compound was compound 42; the IC50 value was 420 nM while the IC50 of
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SUAM-1221 14 was 190 nM against bovine POP. However, Kánai et al. (1997) tested a
series of alkanoyl-L-thioprolyl-pyrrolidines against rat POP. The lengths of the alkanoyl
chains ranged between 4 and 20 carbons. In their study, the best compound 43 was more
potent that SUAM-1221 14; the IC50 values were 11 and 30 nM, respectively.
NN
OO
NN
OO
NN
S
OO
14 42 43
In the study of Vendeville et al. (2002) compound 40 with an aryl-alkanoyl group
was less potent against human POP and more potent against T. cruzi POP than
compound 44 with an aliphatic group. When the chain was extended by one methylene
group, the situation changed. Compound 45 was more potent against both human and T.
cruzi POP than compound 46.
N
OO
N
n
N
OO
N
n
40; n = 3
45; n = 4
44; n = 3
46; n = 4
Amongst the aryl-alkanoyl groups, 4-phenylbutanoyl and benzyloxycarbonyl are
probably the two most utilized groups and are found for example in SUAM-1221 14
and Z-Pro-prolinal 4, respectively. The effect of the chain length has been studied but
the comparison suffers from that POPs from different species have been used. In
general, it can be said that the 4-phenylbutanoyl or 5-phenylvaleryl groups give more
potent compounds that the shorter aryl-alkanoyl groups (Arai et al. 1993, Saito et al.
1990, Vendeville et al.2002, Yoshimoto et al. 1991b). There is also some discrepancy
about the effect of heteroatoms in the chain. According to Yoshimoto et al. (1991b) the
Z-group is superior to the 3-phenylpropionyl group and superior or equally good with
the 4-phenylbutanoyl group. However, in the study of Tanaka et al. (1994) the 4-
phenylbutanoyl group was superior to the Z-group. According to our own studies,
neither an oxygen nor a nitrogen atom next to the P3 carbonyl group has a significant
effect on POP inhibitory activity.
In an attempt to increase the potency of POP inhibitors, the P3 chain has been made
more rigid. This approach has sometimes been successful and compound 47 was over
10 times more potent than SUAM-1221 14 (Tanaka et al. 1994). However, also the
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stereochemistry plays a role here; the other diastereomer 48 was equipotent with
SUAM-1221. Compound 49 was almost 3 times more potent than SUAM-1221 14.
NN
OO
NN
OO
NN
OO
*
14 47; S,S
48; R,S
49
The incorporation of a cyclopropane ring into the P3 chain gave also potent
compounds but the stereochemistry was crucial also in this case. The R,R,S-
diastereomer 36 was shown to inhibit rat POP in vivo while the S,S,S-diastereomer 50
was totally inactive (Portevin et al. 1996).
N
OO
N N
OO
N
36 50
Differently substituted phenyl moieties have also been studied at the P3 position. A
series of para-substituted 4-phenylbutanoyls were studied against canine POP (Arai et
al. 1993). All substituents decreased the potency (1.5-24 times) and the inhibitory
activities decreased in the order: -CH3, -Cl, -OH > -OCH3, -NO2 >>> -NH2. A series of
phenyl-cyclopropanoyls was studied against rat POP (Portevin et al. 1996). The p-
fluoro and p-methyl substituted compounds had comparable potencies to their
unsubstituted counterparts while the m-trifluoromethyl group slightly increased and p-
methoxy group decreased potency. In the study against human and T. cruzi POPs, both
p-nitro and p-methoxy substituted 4-phenylbutanoyls increased the potency against the
former and decreased the potency against the latter enzyme (Vendeville et al. 2002).
Besides the phenyl group, also other aromatic structures have been studied at the P3
position and beyond it (Table 5). The 2-thienyl and 1-pyrenyl groups improved potency
one order of magnitude and the 3-pyridyl group slightly decreased potency when
compared to the phenyl group (Vendeville et al. 2002). The replacement of the phenyl
group by the phenoxy group decreased potency. However, the larger 2-styrylphenoxy
and 2-benzylphenoxy groups gave compounds with comparable IC50 values to SUAM-
1221 14. The 5-isoquinolinoxy group was comparable to the phenoxy group (Saito et al.
1991).
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Table 5. Aromatic groups at the P3 position.
N
OO
N
R n
NN
OO
R
Compound R n IC50(nM)a Compound R
IC50
(nM)b
40 Phenyl 3 550 14 Phenyl 190
51 2-Thienyl 3 55 55 Phenoxy 450
52 1-Pyrenyl 3 50 56 2-Styrylphenoxy 140
53 Phenyl 1 400 57 2-Benzylphenoxy 210
54 3-Pyridyl 1 600 58 5-Isoquinolinoxy 400
a The IC50 values were determined against human POP and were published in Vendeville et al.
2002; b The IC50 values were determined against bovine POP and were published in Saito et al.
1991.
Compounds 59-61 and related structures are an exceptional series of POP inhibitors
because they do not have any P3 group (assuming that the prolyl group binds to the S1
subsite). They were relatively potent but the elongated compounds 62-64 with the P3
structure were 10-100 times more potent against porcine POP (Tsuda et al. 1996a,
Tsuda et al. 1996b).
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59; X = CH, R = H
60; X = N, R = H
61; X = CH, R = Phenoxy
62; X = CH, R = H
63; X = N, R = H
64; X = CH, R = Phenoxy
POP inhibitors which reach beyond the P3 site have also been made. One group of
compounds is represented by compound 65. These compounds had an L-phenylalanine
or L-b-alanine moiety at the P3 position and a Z-group reaching beyond that. These
inhibitors had strongly reduced inhibitory activities as compared to compounds where
the L-phenylalanine or the L-b-alanine was removed and the Z-group was directly
attached to the P2 residue (Tsuru et al. 1988).  Another relatively potent group of
compounds was based on a symmetrical structure and is represented by compound 20
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(Wallén et al. 2002a). These compounds had a dicarboxylic acid spacer at P3 site
connecting two L-Pro-pyrrolidine groups. Concequently, the direction of the peptide
bonds was reversed beyond the P3 position. These inhibitors are included in the
CoMSIA model described in Chapter 5.
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2.6.4 Atypical POP inhibitors
There are two interesting atypical POP inhibitors. The first is poststatin 66, which was
isolated from the fermentation broth of Streptomyces viridochromogenes (Aoyagi et al.
1991). It is a relatively potent natural product and the IC50 value against porcine POP
was reported to be 0.03 mg/ml which makes 55 nM. The design of the previously
described compounds 59-64 was based on poststatin. It can be assumed that the N-
terminal L-valine binds to the S3 subsite and the a-ketoamide group reacts with Ser554
of POP. The second compound is Y-29794 2, which at the first glance does not
resemble typical POP inhibitors. Its pharmacological properties were reviewed in
section 2.3.1. and the reported Ki value against rat POP was 0.95 nM (Nakajima et al.
1992). It is probable that the thiophene ring forms the P1 site and the pyridine ring the
P2 site. However, this is one of the few POP inhibitors which have an ionizable group
included in the structure.
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2.7 Drug-like properties
The chemical space is vast and it has raised the question; how can we differentiate
between drug-like and non-drug compounds? Lipinski suggested that drug-like
compounds form small clusters in the chemical space (Lipinski 2000). To make a drug
we need high affinity to the target protein and also suitable absorption, distribution,
excretion, metabolism and toxicity (ADMET) properties. The further suggestion of
37
Lipinski was that “ADME chemistry space is much simpler than pharmacological target
chemistry space” (Lipinski 2000). In the past, several drug development projects have
failed because pharmacokinetic and safety properties have been ignored. Nowadays,
ADMET properties are considered, alongside the potency, from the early stages of drug
development (Kerns and Di 2003).
What are these drug-like properties that we can use to discriminate between a drug-
like and a non-drug compound? A set of molecular properties are size and shape,
lipophilicity, polarity, hydrogen bonding and charge (Lipinski 2000, Kerns and Di 2003,
van de Waterbeemd 2003). These define structural and physico-chemical properties
like, solubility, permeability and stability which in turn define ADMET properties.
Lipinski suggested that simple rules can be used for ADME (Lipinski 2000) and one of
the simplest is the rule of 5 (Lipinski et al. 1997). This thumb-rule tells that the
compound is likely to have poor absorption or permeation if two of the following rules
are exceeded; £ 5 hydrogen bond donors, £10 hydrogen bond acceptors, MW £ 500,
ClogP £ 5. Several other filters have also been developed (Walters and Murcko 2002).
For a CNS targeted drug, the limits are narrower because the blood-brain barrier
(BBB) protects the brain from xenobiotics. BBB is formed by endothelial tight junction
in the brain capillary, efflux proteins and enzymatic activity. The tight junctions block
the paracellular route to the brain. In several studies, different molecular properties have
been used to predict passive penetration through the BBB. Some limits have also been
set. The log P for the optimal brain penetration was found to be 1.5-2.7 while the mean
was 2.1 (Pajouhesh and Lenz 2005). The molecular weight should be below 400-600
and the number of rotatable bonds should be 5 or less. High hydrogen bonding potential
decreases brain penetration and polar surface area should be less than about 90 Å2. The
pKa value should fall between 4 and 10.
In conclusion, the most potent compound in vitro may not be the best candidate for
further development. All the described properties need to be optimized and a
compromise in one property may be a gain in another. Drug design is like the dance on
a trapeze - you must not loose the balance.
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3 THE AIMS OF THE STUDY
The aim of the study was to design and synthesize new, low molecular weight POP
inhibitors, which have an inhibitory activity in the low nanomolar range and to increase
the knowledge of the structure-activity relationships and physico-chemical properties of
POP inhibitors. More specifically:
1.  To explore different replacements at the P3 position and beyond it.
2. To study amide bond replacements of the P3-P2 and P2-P1 amide bonds.
3. To study the effect of the structural changes on physico-chemical properties of the
compounds with the focus on drug-like properties.
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4 EXPERIMENTAL PROCEDURES
4.1 General synthetic procedures
This section describes only the general synthetic procedures. The detailed synthetic
procedures are given in Chapters 5-8.
Reagents and solvents were of the commercial high purity quality and did not need
purification prior to use. When needed, the solvents were dried over 3 Å or 4 Å
molecular sieves or dried over the sieves and then distilled. Ethers for the reactions with
organometallic reagents or in low temperatures were dried over sodium and distilled
under argon or nitrogen. For the moisture sensitive reactions, the glassware was dried at
140 °C and cooled in a desiccator or under argon and the reactions were performed
under argon or nitrogen.
When possible, the reactions and the purifications were first monitored by thin layer
chromatography (Silica gel 60 F254, aluminium sheets, Merck 1.05554.0001). The spots
were visualized by UV light (254 nm), iodine, heating, ninhydrin, anisaldehyde or
potassium permanganate. Purifications by flash chromatography were performed on J.
T. Bakers silica gel for chromatography (pore size 60 Å, particle size 50 mm). The
chromatotron plates were made of Merck silica gel 60 PF254-containing gypsum
(particle size 5-40 mm).
4.2 Analytical procedures
Nuclear magnetic resonance (NMR) spectroscopy. 1H and decoupled 13C NMR
spectra were recorded on a Bruker AM 400 WB (400.1 MHz and 100.6, respectively) or
a Bruker Avance 500 spectrometer (500.1 MHz and 125.1, respectively). CDCl3 was
used as solvent and tetramethylsilane (TMS) as an internal standard, unless otherwise
stated. When the solvent was used as an internal standard, its chemical shift was set
according to Gottlieb et al. 1997. The FID files were processed with MestRe-C (version
4.3.6.0 or earlier, Mestrelab Research) or TopSpin software (version 1.3, Bruker
Biospin) to obtain NMR spectra. Chemical shifts (d) are given in ppm downfield from
TMS (d 0.00).
The N-amide bond of a proline residue or a 2-substituted pyrrolidine moiety has
energetically similar cis and trans isomers (rotamers). These rotamers have slightly
different shifts. Minor rotamers that are less than 20% of the major rotamers are not
reported for 13C NMR spectra.
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Electrospray ionization mass spectrometry (ESI-MS). ESI-MS spectra were
obtained on a LCQ ion trap mass spectrometer equipped with an ESI source (Finnigan
MAT, San Jose, CA, USA).
Elemental analysis. Elemental analyses (C, H, N) were carried out with a Thermo
Quest CE Instruments EA 1110 CHNS-O elemental analyzer at the University of
Kuopio or a comparable equipment at the University of Oulu. For the analyses which
agree calculated data within ±0.4 percentage units the results are reported "Anal.
(molecular formula) C, H, N". For the analyses which do not agree the calculated data
within ±0.4 percentage units the calculated and the found results are reported separately.
4.3 In vitro assay for POP activity
The whole porcine brains, excluding cerebellum and most of the brain stem, were
placed in liquid nitrogen within 30 min after the animals were killed and stored at -80
°C until homogenized. The brains were homogenized in 3 volumes (w/v) of ice-cold 0.1
M sodium-potassium phosphate buffer (pH 7.0), and the homogenates were centrifuged
for 20 min at 4 °C at 10000 g. The supernatants were pooled and stored in small
aliquots at -80 °C until used. The supernatant was thawed in ice just before it was used
in the activity assay and diluted in a ratio 1:2 with homogenization buffer.
In the microplate assay, 10 ml of the enzyme preparation was preincubated with 460
ml of 0.1 M sodium-potassium phosphate buffer (pH 7.0) and 5 ml of a solution of the
compound dissolved in dimethyl sulfoxide (DMSO) and diluted with 0.1 M sodium-
potassium phosphate buffer at 30 °C for 30 min (final DMSO concentration was less
than 0.1%). The controls contained 10 ml of enzyme preparation and 465 ml of 0.1 M
sodium-potassium phosphate buffer (pH 7.0). The reaction was initiated by adding 25 ml
of 4 mM Suc-Gly-Pro-AMC dissolved in 0.1 M sodium-potassium phosphate buffer
(pH 7.0), and the mixture was incubated at 30 °C for 60 min. The reaction was
terminated by adding 500 ml of 1 M sodium acetate buffer (pH 4.2).
The formation of 7-amido-4-methylcoumarin was determined fluorometrically with
microplate fluorescence reader (excitation at 360 nm and emission at 460 nm). In the
uninhibited reaction, the specific POP activity was 3.8 nmol/min/mg protein. Five to
seven inhibitor concentrations were used to determine the IC50 values and the final
concentration of the compounds in the assay mixture varied from 10-12 to 10-4 M. Two
to four independent measurements were made for each inhibitor. The inhibitory
activities (percent of control) were plotted against the log concentration of the
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compound, and the IC50 value was determined by nonlinear regression utilizing Graph-
Pad Prism 3.0 software.
4.4 Determination of the Ki values
Expression and purification of porcine prolyl oligopeptidase. Porcine brain RNA
was obtained by the Trizol reagent protocol (Life technologies). POP cDNA was
generated by the reverse transcriptase (AMV) reaction using the primer 5'-
GATAAAAATCCCCGAGGCAGT-3'. The entire coding region, including the stop
codon, was amplified by PCR (Pfu DNA polymerase) and NcoI/HindIII sites were
introduced at the 3'- and 5'-ends respectively. Primers were: sense, 5'-
CCCCAGCCATGGTGTCCTTCC-3'; antisense, 5'-TTAAGCTTATGGAATCC-3'. The
NcoI/HindIII digested PCR product was then cloned into the NcoI/HindIII site of
pBAD/myc-HisA (Invitrogen) obtaining pBADPigPOP. The recombinant plasmid was
used to transform E. coli TOP10 competent cells. For expression, a colony of E. coli
TOP10 harboring pBADPigPOP was grown 12 h in 50 ml of Luria broth containing
ampicillin 50 ?g/ml. A total of 30 ml of this culture were used to inoculate 1 l of Luria
broth supplemented with ampicillin 50 ?g/ml, and grown until an OD600 ~0.5, then
arabinose was added to 0.02% and the growth continued for additional 4–6 h. Cells
were harvested and the pellet resuspended in 280 ml 10 mM Tris, 100 mM NaCl,
0.5 mM EDTA, pH 8. Cells were treated with lysozyme (0.5 mg/ml) for 30 min at 37
°C. Sphaeroplasts were centrifuged and the pellets frozen at -70 °C. Pellet was
resuspended in 30 ml 10 mM Tris, pH 8 by sonication (three times for 5 s), and the
debris was removed by centrifugation (5 min, 5,000 g). Supernatant was then used
immediately for POP purification. POP was purified from cell suspension by following
the procedure of Szeltner et al. (2000). Practically pure POP was obtained after DEAE
and Blue Sepharose chromatography with yield of 68%. The active enzyme
concentration was determined by utilizing Morrison equation (Copeland 2000).
Determination of the Ki values. Purified porcine POP (0.57 nM) was incubated in
465 ?l of 0.1 M sodium-potassium buffer (pH 7.0) containing 0.1 mM of dithiothreitol
for 2 h in the presence of various concentrations of inhibitors at room temperature. The
reaction was started with 25 µl of 200 µM Z-Gly-Pro-AMC and the reaction was
monitored every 1 min for 30 min. Over that time scale, the product formations were
linear, indicating that the inhibitors did not dissociate markedly from the enzyme. Ki
values were calculated using the Morrison equation that takes the tight binding
inhibition into account (Copeland 2000):
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where v0 and vi are reaction velocities in the absence and presence of the inhibitor (I),
respectively, Ki is the inhibition constant of the inhibitor and E is the active enzyme
concentration in the reaction medium. Since the inhibitor did not dissociate from the
enzyme during the measurement, competition of binding between substrate and
inhibitor did not occur and hence the calculated Ki value is the real dissociation constant
of the inhibitor (Gutheil and Bachovchin 1993).
4.5 Determination of the log P values by the shake-flask method
A known concentration of an inhibitor in phosphate buffer, pH 7.4 (saturated with 1-
octanol) was shaken with a suitable volume of 1-octanol (saturated with phosphate
buffer, pH 7.4) for 60 min at room temperature. The phases were separated by
centrifugation for 5 min at 2000 rpm, and the aqueous phase was analyzed with HPLC.
In the HPLC methods, the mobile phase consisted of 20 mM KH2PO4 (pH 7) and 90%
acetonitrile aq. The methods were tested for linearity and repeatability. The partition
coefficient was calculated in relation to a control that was treated as the samples but
without 1-octanol. Each partition coefficient was determined at least in triplicate. The
Merck Hitachi HPLC system consisted of a UV detector (L-7400), an interface module
(D-7000), a pump (L-7100), an autosampler (L-7250), and a Purospher RP-C18e
column (125 × 4 mm, 5 µm).
4.6 Determination of the pKa values and the log P values by the
Sirius PCA200 automatic titrator
The titrations were performed according to the Sirius PCA instruction manual at 25 °C
(Sirius 2000). 0.15 M KCl aq. solution was used as the ionic strength adjusted (ISA)
matrix in all titrations. The blank titrations were done every day to test the proper
function of the electrode and the Four-Plus parameters were checked to fall into the
acceptable limits. The reported pKa and log P values were obtained from the Multisets
as described below.
Determination of the pKa values. 2-5 mg of the sample was placed in a beaker and
dissolved in 10 or 12 ml of ISA water. The sample was titrated two or three times
(Multititration) from pH 1.8 to pH 10.0 with the Sirius PCA200 automatic titrator
(Sirius, Forest Row, UK). The individual titrations were refined with the Refine200
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software (Sirius, Forest Row, UK). The Goodness-of-Fit (GOF) values ranged from
0.23 to 1.45. The individual titrations of each sample were combined into a Multiset that
was refined with the Refine200 software to give the final pKa value. The GOF values of
the Multisets ranged from 0.37 to 1.07.
Determination of the log P values. 2-6 mg of the sample was placed in a beaker
and dissolved in 5-10 ml of ISA water. The same sample was multititrated 2-3 times or
2-3 individual samples were each titrated once. In all titrations, the volume of 1-octanol
was chosen on the basis of the expected log P values according to the Sirius PCA
instruction manual. The individual titrations were refined and the GOF values ranged
from 0.37 to 1.35. The individual titrations of each sample were combined into a
Multiset that was refined to give the final log P value. The GOF values of the Multisets
ranged from 0.49 to 2.08.
4.7 Determination of water solubilities
The Merck Hitachi HPLC system consisted of a UV detector (L-7400), an interface
module (D-7000), a pump (L-7100), an autosampler (L-7250), and a Supelcogel ODP50
column (150 × 4 mm, 5 µm). In the HPLC methods, the mobile phase consisted of 20
mM KH2PO4 (pH 7) and 90% acetonitrile aq., and the flow rate was 1 ml/min. The
methods were tested for linearity and the calibration curves were obtained. The methods
were also tested for repeatability.
To three samples of a compound was added 1000 µl of 50 mM phosphate buffer (pH
7.4, ion strength 0.15). The samples were shaken 72 h and filtered through 0.45 µm
filter. Compounds were checked not to be adsorbed by the filter. The filtered samples
were diluted with the HPLC-eluent and analyzed with the HPLC. The concentrations
were calculated from the equations of the calibration curves.
4.8 Preparation of the CoMSIA model
Unless noted otherwise, molecular modeling was performed using Sybyl 6.9.0 and 6.9.1
(Tripos Inc. SYBYL, S. H. R., St. Louis, MO) with default options. To prepare the
enzyme structure, the POP structure was derived from PDB (ID code 1QFS, resolution
2.0 Å). Prior to docking, the cocrystallized inhibitor was removed from the structure,
and the hydrogen atoms were added using Sybyl Biopolymer module. Because the X-
ray structure may also contain energetic tensions, an energetically favorable
conformation of the suggested active site was searched by carrying out a molecular
mechanics minimization using the MMFF94 force field (Halgren 1990). Nitrogen NE2
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of histidine 680 was not protonated while ND1 was protonated thus allowing interaction
with Asp641.
The inhibitor structures (total number 52) were created using automatic translation
from in-house ISIS database to mol2-files, using CONCORD software (Pearlman
2004). After that, it was verified that the inhibitors had right configurations. The
resulting structures were minimized using the MMFF94S force field as implemented in
Sybyl. The following structures were docked into the active site of POP model using the
GOLD program (Jones et al. 1995, Jones et al. 1997), version 2.2, with standard default
settings unless otherwise mentioned. The docking area was defined using NE atom of
Arg643 as a center, with a radius of 20 Å. Because the current docking programs cannot
automatically take into account a possible covalent interaction between a ligand and a
host and several of the compounds possibly have a covalent interaction, two violations
for steric clashes were allowed. The docking procedure was repeated 10 times for each
inhibitor using default parameters. All dockings, except for compound 32 in Chapter 5,
were ranked using GOLD score, and the best alternatives were visually inspected. For
compound 32 in Chapter 5, a CSCORE calculation within Sybyl was carried out.
The selected docking modes were further analyzed using the CoMSIA method. The
CoMSIA descriptor fields (steric, electrostatic, hydrophobic, acceptor, donor) were
calculated in a 3D cubic box extending 4 Å beyond the aligned inhibitors. Atomic point
charges for inhibitors were calculated using the Gasteiger-Hückel model as
implemented in Sybyl. pIC50 values were used as dependent variables in the PLS
statistical analysis of the resulting data. The predictive value of the PLS model and the
optimum number of the PLS components were evaluated by the progressive scrambling
method (Clark and Fox 2004). The final noncross-validated model was developed using
the optimal number of components that had both the highest scrambled q2 value and the
smallest value of the estimated crossvalidated standard error with the slope of q2 under
1.1.
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5 DICARBOXYLIC ACID AZACYCLE L-PROLYL-
PYRROLIDINE AMIDES AS PROLYL OLIGOPEPTIDASE
INHIBITORS AND THREE-DIMENSIONAL QUANTITATIVE
STRUCTURE-ACTIVITY RELATIONSHIP OF THE ENZYME-
INHIBITOR INTERACTIONS*
Abstract. A series of dicarboxylic acid azacycle L-prolyl-pyrrolidine amides was
synthesized, and their inhibitory activity against prolyl oligopeptidase (POP) from
porcine brain was tested. Three different azacycles were tested beyond the P3 position
and six different dicarboxylic acids at the P3 position. L-Prolyl-pyrrolidine and L-
prolyl-2(S)-cyanopyrrolidine were used at the P2-P1 positions. The IC50 values ranged
from 0.39 to 19000 nM. The most potent inhibitor was the 3,3-dimethylglutaric acid
azepane L-prolyl-2(S)-cyanopyrrolidine amide. Molecular docking (GOLD) was used to
analyze binding interactions between different POP inhibitors of this type and the POP
enzyme. The data set consisted of the novel inhibitors, inhibitors published previously
by our group, and well-known reference compounds. The alignments were further
analyzed using comparative molecular similarity indices analysis. The binding of the
inhibitors was consistent at the P1-P3 positions. Beyond the P3 position, two different
binding modes were found, one that favors lipophilic structures and one that favors
nonhydrophobic structures.
* Reproduced with permission from: Jarho EM, Wallén EAA, Christiaans JAM,
Forsberg MM, Venäläinen JI, Männistö PT, Gynther J, Poso A: Journal of Medicinal
Chemistry 48: 4772-82, 2005
 Copyright ã 2005 American Chemical Society
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5.1 Introduction
The novel inhibitors that are described in this chapter were developed from the series of
large, symmetrical POP inhibitors (I in Figure 1) that were published by Wallén et al.
(2002a). These large inhibitors were very potent, and another series of large inhibitors
were later developed from the first set of compounds (Wallén et al. 2003a). To diversify
the compound set for the three-dimensional (3D) quantitative structure-activity
relationship (QSAR) study, two series of smaller compounds were synthesized. The
removal of the pyrrolidine-1-carbonyl group from both ends (II in Figure 1, not
published) decreased strongly the potency. The succinic acid dipyrrolidine amide was
the only compound with a weak inhibitory activity and it had an IC50 value of 13 mM
against POP from rat brain. (Inhibitory activities against POP from rat brain and porcine
brain are similar in our test system.) These compounds were not included in the 3D
QSAR study. However, removal of the pyrrolidine-1-carbonyl group from only one end
resulted in the novel inhibitors, most of them having the IC50 value in the nanomolar
range (III in Figure 1).
The 3D QSAR models were created using the comparative molecular similarity
indices analysis (CoMSIA) method, which produces information of the favored and
disfavored properties of the examined compound set (Klebe et al. 1994). The compound
set consisted of the novel inhibitors (Table 1) and the previously published inhibitors
and reference compounds (Table 2). These data are useful to explain and predict
activities of different POP inhibitors and to find out how different types of POP
inhibitors may bind to the active site of the enzyme. To our knowledge, this is the first
time when the systematic molecular docking and 3D QSAR studies have been described
for POP inhibitors.
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Figure 1. Rationale behind the novel inhibitors. (I) A series of large symmetrical POP
inhibitors (Wallén et al. 2002a). (II) A series of small symmetrical compounds, which
were very poor POP inhibitors. (III) A series of the novel POP inhibitors.
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5.2 Methods
Synthetic chemistry. A series of dicarboxylic acid azacycle L-prolyl-pyrrolidine
amides was synthesized (Table 1). L-Pro-pyrrolidine and L-Pro-2(S)-cyanopyrrolidine
were used at the P2-P1 positions and different dicarboxylic acids as coupled to different
azacycles were used at the positions P3 and beyond P3. The inhibitors were synthesized
via the synthetic routes described in Schemes 1 and 2 using a similar set of chemical
reactions. The building blocks were coupled to each other by amide bonds, which were
synthesized in two different ways: the carboxylic acid was activated with
trimethylacetyl chloride and reacted with the amine, or the dicarboxylic anhydride was
reacted with the amine. The only problematic step was the deprotection of Boc-2(S)-
cyanopyrrolidine. The cyano group reacted to some extent during the deprotection and,
consequently, the yields of these coupling reactions were low, ranging from 10% to
45% for compounds 11, 12, 17, 19 and 20. Therefore, the cyano group was introduced
in the last synthetic step of the compounds that were made in the later part of the study
(14, 15 and 18). The compounds in Table 2 were synthesized as described previously
(Wallén et al. 2002a, 2002b, 2003a, 2003b, Jarho et al. 2004).
Molecular modeling. The structure of prolyl oligopeptidase, 1QFS (native, Fülöp et
al. 1998) was derived from PDB and the co-crystallized inhibitor (Z-L-Pro-L-prolinal)
was removed from the crystal structure. The POP inhibitors in Table 1, and the
previously published compounds in Table 2 were docked into this crystal structure of
POP using GOLD program (Jones et al. 1997). The docking area was defined using NE
atom of Arg643 as a center, with a radius of 20 Å. Unfortunately current docking
programs cannot automatically take into account a possible covalent interaction between
a ligand and a host. Since several of the compounds possibly have a covalent
interaction, two violations for steric clashes were allowed. With these settings all the
compounds were docked succesfully into the active site of POP.
The dockings were further analyzed using the CoMSIA method (Klebe et al. 1994)
and a statistically valid 3D QSAR model was created. Originally CoMSIA was carried
out by using all five different field types, namely steric, electrostatic, hydrophobic,
acceptor and donor fields. Even this model was statistically valid (q2 close to 0.7 with 6
components). However, a closer inspection revealed that most of the model was
explained by the acceptor, electrostatic and hydrophobic fields, which were then used in
the final models. The selection of the PLS components was based on Scrambling
stability test, as proposed by Clark and Fox (2004). This test yields adapted q2, CSDEP
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Table 1. Structures and inhibitory activities (95% confidence intervals are presented in
parentheses) of the synthesized compounds.
NN
O
R
O
R'
O
N
Compd N R R’ IC50 (nM)
3 N -CH2-CH2- H 110  (110 – 120)
4 O N -CH2-CH2- H 1200 (940 – 1400)
5 N -CH2-CH2- H 41 (35 – 48)
11 N -CH2-CH2- CN 2.9 (1.9 – 4.4)
12 N -CH2-CH2- CN 0.76 (0.50 – 1.2)
13 N -CH2-CH2-CH2- H 28 (17 – 44)
14 N -CH2-CH2-CH2- CN 1.2 (0.70 – 2.0)
15 N -CH2-C(CH3)2-CH2- CN 0.39 (0.27 – 0.56)
16 N H 19000 (14000 – 27000)
17 N CN 1500 (1300 – 1700)
18 N CN 1.6 (1.3 – 2.0)
19 N CN 6.9 (6.2 – 7.8)
20 N CN 4.6 (3.4 – 6.2)
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and dq**2/dr2yy values. CSDEP had the optimum with 3 PLS-components, and the
dq**2/dr2yy well below 1 (0.91), indicating low enough PLS component number.  The
final CoMSIA model had the following leave-one-out PLS statistics: q2 = 0.69, SPRESS =
0.65, 3 PLS components. The final non-validated model resulted in r2 = 0.91, F-value =
175 and s-value = 0.34.
5.3 Results and discussion
Molecular Docking. All compounds were successfully docked into the binding cavity
of POP. When selected dockings are analyzed together, it is obvious that most of the
compounds occupy in general the same binding area. Because GOLD produces usually
several alternative binding modes, other binding modes were also detected, but in all
cases, the selection was based on the scoring function of GOLD. The only exception
was compound 32, where the GOLD-proposed docking was replaced by the CSCORE-
proposed docking. The binding mode that GOLD proposed to be the best for compound
32 differed in the P1-P2 area from the rest of the compounds. To obtain a better mode, a
CSCORE calculation within Sybyl was carried out.
The data set consisted of POP inhibitors with varying inhibitory activities. There
was not much structural variation at the P1 and P2 positions and without exception,
these positions were bound as in the original crystal structure (Fülöp et al. 1998). Most
of the variation was at the P3 position and beyond it. However, there is a S3 binding site
for the P3 position, which is occupied by all ligands. This position is surrounded by the
lipophilic residues Ile591, Ala594, Cys259, and Phe173. Beyond the P3 position,
conformational freedom increases and one consistent binding site was not found.
Instead, two binding modes, which are clearly favored, were found. Each of them is
represented by one inhibitor in Figure 2a. The more populated binding mode is called
binding mode A (compound 15 in Figure 2a). It is occupied by 60% of the ligands, and
it is surrounded by Gly254, Cys255, Arg252, and Met245. The less populated binding
mode is called binding mode B (compound 14 in Figure 2a), and it is occupied by 40%
of the ligands. Both binding modes resulted in equal inhibitory activities.
The novel inhibitors (Table 1) and most of the previously synthesized compounds
(21-51 in Table 2) do not have an aryl-alkanoyl structure, typical to POP inhibitors, at
the P3 and beyond P3 positions. Instead, they have rather hydrophilic P3 and beyond P3
positions, due to the amide and ketone carbonyl oxygens and the amide nitrogens.
However, their modes of binding do not seem to differ from that of the typical POP
inhibitors. For example, SUAM-1221 (compound 55) occupies the binding mode A.
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A B
C D
Figure 2. Most favored binding modes and the CoMSIA fields. The model compounds
14 and 15 are docked into the active site of POP. (a) Binding modes A and B are
represented by compounds 15 and 14, respectively. Ile591 and Ala594 are in blue,
Met235 is in yellow, and Arg643 is in red. (b) Hydrogen bond acceptor properties.
Favored areas are in magenta, and disfavored areas are in red. (c) Electrostatic
properties. The partial negative charge is favored in red areas, and the partial positive
charge is favored in blue areas. (d) Hydrophobic properties. Hydrophobic properties are
favored in yellow areas, and hydrophilic properties are favored in white areas.
CoMSIA. The properties of the CoMSIA model are in agreement with the known
SAR of POP inhibitors and the 3D structure of the POP enzyme (Fülöp et al. 1998).
Hydrogen bond acceptor properties (Figure 2b) are important near the electrophilic
2(S)-substituent of the P1 pyrrolidine ring. In the crystal structure, this substituent forms
a hemiacetal bond with Ser554 of POP. The thus formed oxyanion is stabilized by two
hydrogen bonds to the main chain NH group of Asn555 and to the hydroxyl group of
Tyr473 (Fülöp et al. 1998). The P2 carbonyl oxygen is hydrogen bonded to Arg643 and
the P3 carbonyl oxygen to Trp595. The P2 hydrogen bond has been proven to be crucial
for the inhibitory activity (Yoshimoto et al. 1991). However, in the model, these
hydrogen bonds seem to have only a small contribution to the activity. This misinform
arises from the lack of structural variation in these positions within the data set, and
consequently, the real contribution to the activity cannot be revealed by the model. The
binding mode B includes an area, near Arg128, where hydrogen bond acceptor
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properties are also favored. The formation of the hydrogen bond is not probable due to
internal hydrogen bonds of POP, but the protein surface is positively charged in this
area. The same area also favors partial negative charge.
Hydrogen bond acceptor properties are disfavored in the area located near the
residues that do not have any hydrogen bond donors, especially the residues Ile591
(blue in Figure 2a), Ala594 (blue in Figure 2a), and Met235 (yellow in Figure 2a). Any
hydrogen bond acceptor atom that points toward this area is entropically nonfavorable,
since typically all polar atoms of the bound ligand have a high tendency to interact
either with the receptor residues or with the surrounding water molecules.
Partial negative charge (Figure 2c) is favorable near Arg643 (red in Figure 2a),
Arg128 and surprisingly near Met235 (yellow in Figure 2a). While the area near
Arg643 is explained by the P2 carbonyl oxygen of an inhibitor that forms a hydrogen
bond with Arg643, the area near Met235 does not seem to have a clear explanation. It
may be an artifact arising from the fact that many potent inhibitors have carbonyl
oxygen located in this area even though the oxygen cannot form a hydrogen bond with
the enzyme. The tendency to favor partial positive charge over the carbons of the P1
prolyl ring and partial negative charge over the 2(S)-substituent (Figure 2c) is easily
understood via the polarization between the substituent and the ring. When this
polarization is strong, the interaction between the inhibitor and the Ser554 becomes
stronger.
Hydrophobic properties (Figure 2d) are clearly divided; the hydrophobic nature of
the inhibitors is disfavored at the P1-P2 area, near the residue Arg643. The P3 position
favors lipophilic aliphatic structures. Lipophilic aromatic structures with negative p-
electrons are not optimal structures but are tolerated. Beyond the P3 position, the
binding mode A shows a clear hydrophobic area. The binding mode B, on the other
hand, favors nonhydrophobic structures near the residue Arg128.
SARs. Three different azacycles, pyrrolidine, morpholine, and azepane, were
studied at the position beyond P3, resulting in compounds 3, 4, and 5 respectively. A
succinic acid residue was located at the P3 position and L-Pro-pyrrolidine at the P2-P1
positions. The morpholine moiety caused considerably lower potency than the azepane
and pyrrolidine moieties. The replacement by the azepane moiety resulted in a more
potent inhibitor than the replacement by the pyrrolidine moiety. This difference was
also observed in compounds 11 and 12, which have a 2(S)-cyanopyrrolidine moiety at
the P1 position. When the flexible succinic acid residue was changed to the rigid
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isophthalic acid residue (19 and 20), the azepane and pyrrolidine moieties gave
equipotent compounds.
The polar oxygen of the morpholine ring is located in an area that favors lipophilic
structures. This explains the significant decrease in inhibitory activity caused by
morpholine. However, the increased lipophilicity of azepane does not explain the
difference between the IC50 values of compounds 3 and 5. In compound 3, the carbonyl
group next to the pyrrolidine moiety is located in an area that disfavors hydrogen bond
acceptors. The carbonyl oxygen points toward the enzyme surface, which lacks
hydrogen bond donors to form a bond with, and this results in an unfavorable entropic
effect. In compound 5, the larger ring size of azepane distorts the carbonyl oxygen in a
different direction, toward an open cavity. The cavity is large enough to include a water
molecule that may form a hydrogen bond with the oxygen. In compounds 19 and 20, the
rigid isophthalic acid residue fixes the conformation and the inhibitors bind in a similar
way to the enzyme. The phenyl group is located in an area that disfavors both lipophilic
structures and negative charge, and this may explain the lower activity of compounds 19
and 20 as compared to compound 12.
Three aliphatic chains, succinic acid, glutaric acid and 3,3-dimethylglutaric acid,
were studied at the P3 position, resulting in compounds 12, 14, and 15, respectively.
Azepane was used at the position beyond P3 and L-Pro-2(S)-cyanopyrrolidine at the P2-
P1 positions. The elongation of the chain from succinic acid to glutaric acid decreased
the potency. 3,3-Dimethylglutaric acid, on the other hand, increased the potency
slightly.
Compound 14 (orange in Figure 2a) seems to have a different binding mode from
compounds 12 and 15 (violet in Figure 2a); the molecule turns toward the open cavity.
However, the slight decrease in potency cannot be explained with the CoMSIA model.
On the other hand, the increased lipophilicity of compound 15 in comparison to
compound 14 may explain the increased potency in this case.
Three different substitution patterns of the phenylene moiety were studied at the P3
position, resulting in compounds 17, 18, and 19. Pyrrolidine was used at the position
beyond P3 and an L-Pro-2(S)-cyanopyrrolidine group at the P2-P1 positions. The ortho-
substituted inhibitor 17 had strikingly 3 orders of magnitude lower activity than the
para- and meta-substituted analogues 18 and 19, respectively. The para-substitution
resulted in the best inhibitory activity.
A rigid phenylene ring fixes the conformation, and the inhibitor cannot adjust itself
to a more favorable conformation. In compound 17, the phenylene ring is located in an
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area that favors hydrophilic structures. In addition, both carbonyl oxygens of the ortho-
phthalic residue are located in the area that disfavors hydrogen bond acceptors.
Pyrrolidine and 2(S)-cyanopyrrolidine moieties were studied at the P1 position of
the novel inhibitors. Inhibitors containing a 2(S)-cyanopyrrolidine group at the P1
position are very potent POP inhibitors (Tanaka et al. 1994). Also in this study, the
2(S)-cyanopyrrolidine group increased the potency significantly as compared to a
pyrrolidine group (3 vs 11, 5 vs 12, 13 vs 14, and 16 vs 17). The interaction of the
cyano group with the cystein protease papain has been studied. Cystein proteases have a
similar catalytic mechanism to serine proteases. The cyano group forms a covalent,
reversible thioimidate adduct with the thiol group of the active site cysteine (Brisson et
al. 1986, Liang and Abeles 1987). A similar interaction between the hydroxyl group of
the catalytic Ser554 and a cyano group is possible. Recently, the binding kinetics of
compound 37 to POP was studied (Venäläinen et al. 2004). It was found to be slow
binding, and the inhibition was suggested to be a direct binding process.
The role of the molecular size was studied, and the novel inhibitors were compared
to the previously synthesized compounds. The removal of the pyrrolidine-1-carbonyl
group from compounds 21 (flexible P3 moiety) and 37 (rigid P3 moiety) resulted in
compounds 3 and 19, respectively. In both cases, the potency decreased slightly. The
replacement of the L-Pro-pyrrolidine group beyond the P3 position of compounds 21,
22 and 37 with azepane resulted in compounds 5, 13, and 20, respectively. Compounds
5 and 13 have flexible P3 moieties, and in both cases, the replacement increased the
inhibitory activity. On the other hand, in the case of compound 20 with a rigid P3
moiety, the inhibitory activity decreased. Compound 20 is also less potent than the other
large compounds of the same series as compound 37 (38-42). Interestingly, also, the
small compound 54, having only a benzoyl group at the P3 position, was slightly more
active than compound 20. The differences in the inhibitory activities between the novel
compounds and the previously synthesized larger compounds were rather small and
could not be explained with the CoMSIA model.
5.4 Conclusions
The P1 and P2 positions of the docked ligands were bound to POP in the same way as
Z-L-prolyl-L-prolinal in the crystal structure. A consistent P3 position was also found.
This position is surrounded by lipophilic residues, and lipophilic aliphatic structures are
favored. Lipophilic aromatic structures with a p-electron cloud can also be used, but
then, the substitution pattern becomes crucial. Beyond the P3 position, the docked
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ligands divided into two different binding modes A and B, which were occupied by 60
and 40% of the inhibitors, respectively. According to the previously postulated idea of
the lipophilic cavity, the binding mode A favors lipophilic structures. The binding mode
B instead favors nonhydrophobic structures, and partial negative charge is favored near
Arg128, where the protein surface has a partial positive charge. The P3 and beyond P3
area is sufficiently large, and the interactions between POP and the ligands are weak.
This area can accommodate several different groups without affecting the inhibitory
activity and could be a valuable modification site for the optimization of ADME
properties. The docking studies with the 3D QSAR models are helpful in the design of
new compounds.
5.5 Synthetic procedures and analytical data
General Synthetic Procedure A: A solution of 1.0 eq trimethylacetyl chloride in
dichloromethane (DCM) is added to a solution of 1.0 eq carboxylic acid and 1.1 eq
triethylamine in DCM at 0 °C. The reaction mixture is stirred at 0 °C for 1 h. A solution
of 1.1 eq triethylamine and 1.0-1.1 eq amine in DCM is slowly added at 0 °C (if the
amine is in the form of a trifluoroacetic acid salt or HCl salt, then 3.3 eq triethylamine is
used and the triethylamine is added separately before the amine is added). The reaction
mixture is stirred 2 h or overnight at rt. The DCM solution is washed with 30% citric
acid aq, saturated NaCl aq and saturated NaHCO3 aq, dried over anhydrous Na2SO4 and
evaporated, yielding the crude product.
General Synthetic Procedure B: 1.0-1.5 eq LiOH×H2O is added to a solution of 1.0
eq carboxylic acid methyl ester in 20-30% water in methanol. The reaction mixture is
stirred 2 h or overnight at rt. The solvent (methanol) is evaporated and the residue is
dissolved in water. The aqueous phase is washed with DCM. The aqueous phase is
made acidic with 2-3 M HCl aq, and the product is extracted with DCM. The organic
phase is dried over anhydrous Na2SO4 and evaporated, yielding the product.
General Synthetic Procedure C: 2-4 ml ethyl acetate saturated with dry HCl is
added to 1.0 mmol Boc protected amine at rt. The reaction mixture is stirred at rt for 30
min. Another way to proceed is to dissolve 1.0 mmol Boc protected amine in 5-10 ml
DCM and add 2-4 ml trifluoroacetic acid at 0°C. The reaction is stirred at 0°C for 2-2.5
h. In both cases the solvent is removed and the product is finally evaporated in vacuo,
yielding the corresponding amine HCl salt or TFA salt.
Boc-L-prolyl-pyrrolidine (1). Boc-L-proline (7.97 g, 37.0 mmol) and pyrrolidine
(3.09 ml, 37.0 mmol) were coupled according to procedure A. The product was purified
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by flash chromatography (2.5-5% MeOH in DCM). Yield 8.31 g, 84%. 1H NMR d 1.40
(4.5 H, s), 1.46 (4.5 H, s), 1.77-2.21 (8 H, m), 3.37-3.76 (6 H, m), 4.35 (0.5 H, dd, J =
5.0 Hz, 8.0 Hz), 4.48 (0.5 H, dd, J = 3.1 Hz, 7.7 Hz).
Succinic acid monomethyl ester L-prolyl-pyrrolidine amide (2). Boc-L-prolyl-
pyrrolidine (1.98 g, 7.38 mmol) was deprotected using 30 ml HCl saturated ethyl
acetate according to procedure C. Succinic acid monomethyl ester (0.98 g, 7.42 mmol)
and the L-prolyl-pyrrolidine HCl salt were coupled according to procedure A. The
product was purified by flash chromatography (5-10% MeOH in EtOAc). Yield 1.81 g,
86%. 1H NMR d 1.79-2.17 (7 H, m), 2.21-2.35 (1 H, m), 2.45-2.63 (2 H, m), 2.68-2.86
(2 H, m), 3.35-3.51 (2 H, m), 3.52-3.63 (2 H, m), 3.68 (3 H, s), 3.70-3.82 (2 H, m), 4.58
(0.1 H, dd, J = 3.0 Hz, 8.5 Hz), 4.66 (0.9 H, dd, J = 3.6 Hz, 8.3 Hz).
Succinic acid pyrrolidine L-prolyl-pyrrolidine amide (3). The methyl ester group
of 2 (750 mg, 2.7 mmol) was hydrolyzed using LiOH×H2O (170 mg, 4.1 mmol)
according to procedure B. Yield 360 mg, 1.3 mmol, 45%. The obtained product was
coupled with pyrrolidine (0.11 ml, 1.3 mmol) according to procedure A. The product
was purified by flash chromatography (25% MeOH in EtOAc). Yield 170 mg, 41%. 1H
NMR d 1.79-2.18 (10 H, m), 2.23-2.45 (2 H, m), 2.47-2.68 (2 H, m), 2.78-2.92 (2 H,
m), 3.39-3.62 (7 H, m), 3.64-3.84 (3 H, m), 4.68 (dd, 0.9 H, J = 3.8 Hz, 8.4), 4.77 (dd,
0.1 H, J = 3.0 Hz, 8.8 Hz); 13C NMR d 24.1, 24.4, 24.8, 26.0, 26.2, 28.9, 29.2, 29.3,
45.7, 45.9, 46.2, 46.4, 47.3, 57.8, 170.5, 170.7, 170.8; MS (ESI, +) m/z 322 [M + H]+;
Anal.(C17H27N3O3) C, H, N.
Succinic acid morpholine L-prolyl-pyrrolidine amide (4). The methyl ester group
of 2 (560 mg, 2.0 mmol) was hydrolyzed using LiOH×H2O (84 mg, 2.0 mmol) in 10 ml
20% water in MeOH at rt. After 4 h the solvent was evaporated and the residue was
dissolved in DCM. The organic phase was dried and evaporated. The obtained product
was coupled with morpholine (0.18 ml, 2.05 mmol) according to procedure A. The
product was purified by flash chromatography (20-25% MeOH in EtOAc). Yield 330
mg, 49%. 1H NMR d 1.80-2.05 (6 H, m), 2.08-2.35 (2 H, m), 2.39-2.64 (2 H, m), 2.78-
2.95 (2 H, m), 3.35-3.81 (14 H, m), 4.64 (0.9 H, dd, J = 3.8 Hz, 8.3 Hz), 4.69 (0.1 H,
dd, J = 3.8 Hz, 8.5 Hz); 13C NMR d 24.1, 24.8, 26.2, 27.7, 28.9, 29.3, 42.2, 45.8, 46.1,
46.4, 47.4, 58.0, 66.6, 66.9, 170.9, 171.0, 171.1; MS (ESI, +) m/z 338 [M + H]+; Anal.
(C17H27N3O4·0.3H2O) C, H, N.
Succinic acid azepane L-prolyl-pyrrolidine amide (5). The methyl ester group of
2 (560 mg, 2.0 mmol) was hydrolyzed using LiOH×H2O (84 mg, 2.0 mmol) in 10 ml
20% water in MeOH at rt. After 3 h the solvent was evaporated and the residue was
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dissolved in DCM. The organic phase was dried and evaporated. The obtained product
was coupled with azepane (0.23 ml, 2.04 mmol) according to procedure A. The product
was purified by flash chromatography (20% MeOH in EtOAc). Yield 350 mg, 50%. 1H
NMR d 1.51-1.61 (4 H, m), 1.64-1.77 (4 H, m), 1.81-2.45 (8 H, m), 2.51-2.64 (2 H, m),
2.80-2.88 (2 H, m), 3.36-3.90 (10 H, m), 4.65 (0.9 H, dd, J = 3.8 Hz, 8.4 Hz), 4.71 (0.1
H, dd, J = 3.1 Hz, 8.6 Hz); 13C NMR d 24.1, 24.8, 26.2, 26.9, 27.1, 27.6, 28.0, 28.9,
29.0, 29.6, 45.9, 46.0, 46.3, 47.2, 47.7, 57.8, 170.7, 170.9, 171.6; MS (ESI, +) m/z 350
[M + H]+; Anal. (C19H31N3O3·0.2H2O) C, H, N.
Phthalic acid mono-(L-proline methyl ester) amide (6). Phthalic anhydride (7.4 g,
45 mmol) was added to a solution of L-proline methyl ester HCl salt (7.4 g, 45 mmol)
and triethylamine (13.8 ml, 99.0 mmol) in DCM at 0°C. The reaction mixture was
stirred 4 h at rt. The organic phase was extracted with saturated NaHCO3 aq. The
aqueous phase was acidified with 3 M HCl aq. and extracted with chloroform. The
chloroform phase was dried and evaporated. Yield 6.53 g, 51%.
Succinic acid mono-pyrrolidine amide (7a). Succinic acid monomethyl ester (1.98
g, 14.9 mmol) and pyrrolidine (1.3 ml, 15 mmol) were coupled according to procedure
A. The product was purified by flash chromatography (EtOAc). Yield 1.75 g, 63%. 1H
NMR d 1.82-1.89 (2 H, m), 1.94-2.01 (2 H, m), 2.56-2.59 (2 H, m), 2.67-2.70 (2 H, m),
3.44-3.48 (4 H, m), 3.69 (3 H, s). The methyl ester group of the product was hydrolyzed
using LiOH×H2O (0.44 g, 10.4 mmol) according to procedure B. Yield 1.37 g, 85%.
Isophthalic acid mono-pyrrolidine amide (7b). Isophthalic acid monomethyl ester
(2.25 g, 12.5 mmol) and pyrrolidine (1.04 ml, 12.5 mmol) were coupled according to
procedure A. The product was purified by flash chromatography with 30% petroleum
ether (PE) in EtOAc as the eluent. Yield 1.75 g, 60%. 1H NMR d 1.83-2.02 (4 H, m),
3.43 (2 H, t, J = 6.6 Hz), 3.66 (2 H, t, J = 6.9 Hz), 3.93 (3 H, s), 7.50 (1 H, td, J = 7.7
Hz, 0.6 Hz), 7.73 (1 H, ddd, J = 7.7 Hz, 1.2 Hz, 1.7 Hz), 8.09 (1 H, ddd, J = 7.7 Hz, 1.2
Hz, 1.7 Hz), 8.19 (1 H, td, J = 1.7 Hz, 0.6 Hz). The methyl ester group of the product
was hydrolyzed using LiOH×H2O (470 mg, 11.3 mmol) according to procedure B. Yield
1.49 g, 91%.
Terephthalic acid mono-pyrrolidine amide (7c). Terephthalic acid monomethyl
ester (1.08 g, 5.99 mmol) and pyrrolidine (0.50 ml, 6.0 mmol) were coupled according
to procedure A. The product was purified by flash chromatography (EtOAc). Yield 0.50
g, 36%. 1H NMR d 1.87-1.92 (2 H, m), 1.95-2.00 (2 H, m), 3.38 (2 H, t, J = 6.7 Hz),
3.66 (2 H, t, J = 7.0 Hz), 3.94 (3 H, s), 7.56-7.57 (1 H, m), 7.58-7.59 (1 H, m), 8.06-
8.07 (1 H, m), 8.08-8.09 (1 H, m). The methyl ester group of the product was
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hydrolyzed using LiOH×H2O (135 mg, 3.2 mmol) according to procedure B. Yield 0.41
g, 87%.
Succinic acid mono-azepane amide (8a). Succinic acid monomethyl ester (1.98 g,
15.0 mmol) and azepane (1.7 ml, 15 mmol) were coupled according to procedure A.
The product was purified by flash chromatography (30% PE in EtOAc). Yield 2.48 g,
78%. 1H NMR d 1.52-1.62 (4 H, m), 1.67-1.78 (4 H, m), 2.62-2.70 (4 H, m), 3.46 (2 H,
t, J = 6.1 Hz), 3.53 (2 H, t, J = 6.1 Hz), 3.69 (3 H, s). The methyl ester group of the
product was hydrolyzed using LiOH×H2O (540 mg, 12.9 mmol) according to procedure
B. Yield 2.34 g, 100%.
Isophthalic acid mono-azepane amide (8b). Isophthalic acid monomethyl ester
(2.25 g, 12.5 mmol) and azepane (1.41 ml, 12.5 mmol) were coupled according to
procedure A. The product was purified by flash chromatography (40% PE in EtOAc).
Yield 2.02 g, 62%. 1H NMR d 1.57-1.69 (6 H, m), 1.83-1.89 (2 H, m), 3.35-3.37 (2 H,
m), 3.68-3.71 (2 H, m), 3.93 (3 H, s), 7.49 (1 H, dd, J = 7.6 Hz, 8.2 Hz), 7.57-7.60 (1 H,
m), 8.05-8.08 (2 H, m). The methyl ester group of the product was hydrolyzed using
LiOH×H2O (490 mg, 11.7 mmol) according to procedure B. Yield 1.89 g, 99%.
Glutaric acid mono-azepane amide (8c). To a solution of azepane (4.5 ml, 40
mmol) in 40 ml tetrahydrofuran (THF) was added glutaric anhydride (2.3 g, 20 mmol)
in 15 ml THF dropwise and the solution was stirred for 2 days. The reaction mixture
was evaporated, dissolved in 0.025 M NaOH aq., and washed with DCM. The aqueous
phase was acidified with 3 M HCl and the product was extracted with DCM. The
combined organic phases were dried and evaporated. Yield 1.61 g, 38%. 1H NMR d
1.52-1.62 (4 H, m), 1.68-1.78 (4 H, m), 1.99 (2 H, qui, J = 7.0 Hz), 2.46 (2H, t, J = 7.0
Hz), 2.47 (2H, t, J = 7 Hz), 3.44 (2 H, t, J = 6.1 Hz), 3.54 (2 H, t, J = 6.1 Hz).
3,3-Dimethylglutaric acid mono-azepane amide (8d). To a solution of azepane
(1.74 ml, 15.4 mmol) in 10 ml THF was added 3,3-dimethylglutaric anhydride (1.0 g,
7.0 mmol) in 10 ml THF dropwise at 0 °C. The reaction mixture was stirred overnight at
rt, evaporated and dissolved in 0.025 M NaOH aq. The aqueous phase was washed with
DCM, acidified with 3 M HCl aq. and extracted with DCM. The organic phase was
dried and evaporated, yielding solid product, 1.53 g, 90%. 1H NMR d 1.13 (6 H, s),
1.56-1.64 (4 H, m), 1.74-1.79 (4 H, m), 2.45 (2 H, s), 2.50 (2 H, s), 3.56-3.58 (2 H, m),
3.60-3.62 (2 H, m), 13.79 (1 H, br s).
Succinic acid pyrrolidine L-proline amide (9a). 7a (1.37g, 8.00 mmol) was
coupled with proline methyl ester HCl salt (1.3 g, 8.0 mmol) according to procedure A.
The product was purified by flash chromatography (5% MeOH in DCM). Yield 1.45 g,
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64%. The methyl ester group of the product was hydrolyzed using LiOH×H2O (0.32 g,
7.65 mmol) according to procedure B. Yield 1.32 g, 96%. 1H NMR d 1.81-2.08 (7 H,
m), 2.22-2.40 (1 H, m), 2.53-2.64 (2 H, m), 2.66-2.81 (2 H, m), 3.39-3.70 (6 H, m),
4.52-4.59 (1 H, m).
Isophthalic acid pyrrolidine L-proline amide (9b). 7b (1.49 g, 6.80 mmol) and
proline methyl ester HCl salt (1.13 g, 6.82 mmol) were coupled according to procedure
A. The product was purified by flash chromatography (10% MeOH in EtOAc). Yield
1.83 g, 81%. 1H NMR d 1.85-2.11 (7 H, m), 2.19-2.38 (1 H, m), 3.41 (2 H, t, J = 6.4
Hz), 3.50-3.56 (1 H, m), 3.60-3.69 (3 H, m), 3,78 (3 H, s), 4.29-4.33 (0.2 H, m), 4.67
(0.8 H, dd, J = 5.3 Hz, 8.3 Hz), 7.46 (1 H, t, J = 7.8 Hz), 7.58-7.60 (1 H, m), 7.61-7.64
(1 H, m), 7.71-7.73 (1 H, m). The methyl ester group of the product was hydrolyzed
using LiOH×H2O (350 mg, 8.3 mmol) according to procedure B. Yield 1.58 g, 91%.
Terephthalic acid pyrrolidine L-proline amide (9c). 7c (0.41 g, 1.87 mmol) and
L-proline methyl ester HCl salt (0.31 g, 1.87 mmol) were coupled according to
procedure A. The product was purified by flash chromatography (10% MeOH in
EtOAc). Yield 0.54 g, 87%. 1H NMR d 1.86-2.13 (7 H, m), 2.19-2.36 (1 H, m), 3.39 (2
H, t, J = 6.6 Hz), 3.47-3.52 (1 H, m), 3.60-3.67 (3 H, m), 3.79 (3 H, s), 4.29-4.31 (0.2 H,
m), 4.68 (0.8 H, dd, J = 5.2 Hz, 8.5 Hz), 7.39-7.41 (0.4 H, m), 7.50-7.52 (0.4 H, m),
7.54-7.56 (1.6 H, m), 7.59-7.61 (1.6 H, m). The methyl ester group of the product was
hydrolyzed using LiOH×H2O (103 mg, 2.45 mmol) according to procedure B. Yield 0.50
g, 97%.
Phthalic acid pyrrolidine L-proline amide (9d). 6 (4.25 g, 17.0 mmol) and
pyrrolidine (1.6 ml, 18.7 mmol) were coupled according to procedure A. The product
was purified by flash chromatography (5-20% MeOH in EtOAc). Yield 4.77 g, 85%.
The methyl ester group of the product was hydrolyzed using LiOH×H2O (906 mg, 21.6
mmol) according to procedure B. Yield 3.42 g, 75%.
Succinic acid azepane L-proline amide (10a). 8a (2.34 g, 11.7 mmol) was coupled
with proline methyl ester HCl salt (1.9 g, 11.7 mmol) according to procedure A. The
product was purified by flash chromatography (5% MeOH in DCM). Yield 2.22 g, 61%.
1H NMR d 1.47-1.60 (4 H, m), 1.63-1.78 (4 H, m), 1.83-1.35 (4 H, m), 2.47-2.93 (4 H,
m), 3.41-3.71 (6 H, m), 2.72 (2.5 H, s), 3.76 (0.5 H, s), 4.49 (0.8 H, dd, J = 3.8 Hz, 8.7
Hz), 4.65 (0.2 H, dd, J = 2.6 Hz, 8.5 Hz). The methyl ester group of the product was
hydrolyzed using LiOH×H2O (0.45 g, 10.7 mmol) according to procedure B. Yield 2.01
g, 95%.
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Isophthalic acid azepane L-proline amide (10b). 8b (1.89 g, 7.64 mmol) and
proline methyl ester HCl salt (1.27 g, 7.67 mmol) were coupled according to procedure
A. The product was purified by flash chromatography (10% MeOH in EtOAc). Yield
2.08 g, 76%. 1H NMR d 1.55-1.67 (4 H, m), 1.81-1.94 (4 H, m), 1.98-2.10 (3 H, m),
2.20-2.37 (1 H, m), 3.35 (2 H, t, J = 5.5 Hz), 3.50-3.56 (1 H, m), 3.61-3.74 (3 H, m),
3.78 (3 H, s), 4.29-4.32 (0.1 H, m), 4.66 (0.9 H, dd, J = 5.5 Hz, 8.3 Hz), 7.44-7.46 (2 H,
m), 7.58-7.61 (2 H, m).The methyl ester group of the product was hydrolyzed using
LiOH×H2O (370 mg, 8.7 mmol) according to procedure B. Yield 1.67 g, 83%.
Glutaric acid azepane L-proline amide (10c). 8c (1.61 g, 7.55 mmol) and L-
proline methyl ester HCl salt (1.24 g, 7.49 mmol) were coupled according to procedure
A. The product was purified by flash chromatography (5-10% MeOH in EtOAc) to give
the product as colourless oil. Yield 1.8 g, 74%. 1H NMR d 1.50-1.60 (4 H, m), 1.66-
1.74 (4 H, m), 1.87-2.34 (6 H, m), 2.35-2.48 (4 H, m), 3.42-3.68 (6 H, m), 3.72 (2.5 H,
s), 3.75 (0.5 H, s), 4.45-4.49 (1 H, m). The methyl ester group of the product (1.8 g, 5.6
mmol) was hydrolyzed using LiOH×H2O (0.35 g, 8.3 mmol) according to procedure B.
Yield 1.55 g, 90%.
3,3-Dimethylglutaric acid azepane L-proline amide (10d). 8d (0.50 g, 2.07
mmol) and L-proline methyl ester HCl salt (0.34 g, 2.05 mmol) were coupled according
to procedure A. The product was purified by flash chromatography (25-50% EtOAc in
PE). Yield 0.55 g, 75%. 1H NMR d 1.19 (3 H, s), 1.20 (3 H, s), 1.50-1.58 (4 H, m),
1.66-1.74 (4 H, m), 1.84-2.26 (4 H, m), 2.43 (1 H, d, J = 15.5 Hz), 2.53 (1 H, d, J = 15.0
Hz), 2.57 (1 H, d, J = 15.5 Hz), 2.63 (1 H, d, J = 15.0 Hz), 3.44-3.70 (6 H, m), 3.71 (2.5
H, s), 3.75 (0.5 H, s), 4.46 (0.8 H, dd, J = 4.2 Hz, 8.7 Hz), 4.58 (0.2 H, dd, J = 2.4 Hz,
8.5 Hz). The methyl ester group of the product (0.55g, 1.6 mmol) was hydrolyzed using
LiOH×H2O (0.10 g, 2.4 mmol) according to procedure B.  Yield 0.52 g, 96%.
Succinic acid pyrrolidine L-prolyl-2(S)-cyanopyrrolidine amide (11). Boc-2(S)-
cyanopyrrolidine (0.96 g, 4.89 mmol) was deprotected using 20 ml trifluoroacetic acid
in 50 ml DCM according to procedure C. 2(S)-cyanopyrrolidine TFA salt was coupled
with 9a (1.32 g, 4.92 mmol) according to procedure A. The product was purified by
flash chromatography (10% MeOH in EtOAc). Yield 170 mg, 10%. 1H NMR d 1.81-
1.86 (2 H, m), 1.91-2.05 (4 H, m), 2.12-2.32 (6 H, m), 2.42-2.54 (2 H, m), 2.73-2.88 (2
H, m), 3.36-3.48 (4 H, m), 3.60-3.63 (1 H, m), 3.66-3.75 (2 H, m), 3.82-3.86 (1 H, m),
4.59 (1 H, dd, J = 4.0 Hz, 8.4 Hz), 4.78-4.82 (1 H, m); 13C NMR d 24.4, 24.8, 25.4,
26.0, 27.7, 29.1, 29.3, 29.7, 45.7, 46.3, 46.4, 46.5, 47.3, 57.5, 118.6, 170.3, 171.2,
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171.4; MS (ESI, +) m/z 369 [M + Na]+; Anal. (C18H26N4O3·0.1H2O) C, H, N: calcd,
16.09; found, 15.57.
Succinic acid azepane L-prolyl-2(S)-cyanopyrrolidine amide (12). Boc-2(S)-
cyanopyrrolidine (1.3 g, 6.8 mmol) was deprotected using 27 ml trifluoroacetic acid in
70 ml DCM according to procedure C. 10a (2.01 g, 6.78 mmol) and the 2(S)-
cyanopyrrolidine trifluoroacetic acid salt were coupled according to procedure A. The
product was purified by flash chromatography (8-10% MeOH in EtOAc). Yield 320
mg, 13%. 1H NMR d 1.47-1.59 (4 H, m), 1.62-1.76 (4 H, m), 1.92-2.06 (2 H, m), 2.10-
2.33 (6 H, m), 2.45-2.58 (2 H, m), 2.76-2.89 (2 H, m), 3.35-3.87 (8 H, m), 4.58 (1 H,
dd, J = 3.7 Hz, 8.1 Hz), 4.80-4.83 (1 H, m); 13C NMR d 24.8, 25.4, 26.9, 27.1, 27.6,
27.9, 28.7, 29.0, 29.5, 29.7, 46.0, 46.3, 46.5, 47.3, 47.7, 57.5, 118.6, 171.2, 171.3,
171.4; MS (ESI, +) m/z  375 [M + H]+;  Anal. (C20H30N4O3·0.2H2O) C, H, N.
Glutaric acid azepane L-prolyl-pyrrolidine amide (13). 10c (0.51 g, 1.64 mmol)
was coupled with pyrrolidine (0.14 ml, 1.68 mmol) according to procedure A. The
product was purified by flash chromatography (15% MeOH in EtOAc) to give the
product as colourless oil. Yield 0.34 g, 57%. 1H NMR d 1.51-1.58 (4 H, m), 1.65-1.74
(4 H, m), 1.78-2.29 (10 H, m), 2.31-2.48 (4 H, m), 3.35-3.72 (9 H, m), 3.80-3.85 (1 H,
m), 4.57 (0.1 H, dd, J = 2.8 Hz, 8.8 Hz), 4.64 (0.9 H, dd, J = 3.8 Hz, 8.4 Hz); 13C NMR
d 20.4, 24.1, 24.9, 26.2, 26.9, 27.2, 27.7, 28.9, 29.2 32.3, 33.8, 45.9, 45.9, 46.3, 47.4,
47.9, 57.7, 170.7, 171.4, 172.3; MS (ESI, +) m/z 364 [M + H]+; Anal.
(C20H33N3O3·0.1H2O) C, H, N.
Glutaric acid azepane L-prolyl-L-proline amide. 10c (0.38 g, 1.22 mmol) and L-
proline methyl ester HCl salt (0.20 g, 1.21 mmol) were coupled according to procedure
A. The product was purified by flash chromatography (10-20% MeOH in EtOAc) to
give the product as oil. Yield 0.42 g, 82%. The methyl ester group of the obtained
product was hydrolyzed using LiOH×H2O (63 mg, 1.5 mmol) according to procedure B
to give the white solid product. Yield 0.39 g, 95%. 1H NMR d 1.50-1.61 (4 H, m), 1.65-
1.77 (4H, m), 1.82-2.54 (14 H, m), 3.42 (2 H, t, J = 6.0 Hz), 3.51 (2 H, t, J = 6.0 Hz),
3.54-3.72 (3 H, m), 3.77-3.86 (1 H, m), 4.32 (0.2 H, dd, J = 3.4 Hz, 8.1 Hz), 4.44-4.48
(0.2 H, m), 4.60-4.64 (1.6 H, m).
Glutaric acid azepane L-prolyl-L-prolinamide amide. To a solution of glutaric
acid azepane L-prolyl-L-proline amide (170 mg, 0.42 mmol) and Et3N (59 µl, 0.42
mmol) in 8 ml THF was added ethyl chloroformate (40 µl, 0.42 mmol) in 4 ml THF
dropwise at  -10 °C. After 20 min 25% NH3 aq. (143 µl, 2 .1 mmol) was added and the
reaction mixture was stirred overnight at rt. The reaction mixture was evaporated,
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dissolved in DCM and filtered. The filtrate was washed with sat. NaHCO3 aq, dried and
evaporated yielding the white solid product (150 mg, 88%). 1H NMR d 1.50-1.60 (4 H,
m), 1.66-1.76 (4 H, m), 1.78-2.23 (9 H, m), 2.29-2.61 (5 H, m), 3.38-3.84 (8 H, m),
4.28-4.30 (0.4 H, m), 4.39 (0.4 H, dd, J = 5.9 Hz, 7.4 Hz), 4.61-4.68 (1.2 H, m), 5.24
(0.5 H, br s), 5.53 (0.5 H, br s), 6.91 (0.5 H, br s), 8.26 (0.5 H, br s).
Glutaric acid azepane L-prolyl-2(S)-cyanopyrrolidine amide (14). To a solution
of glutaric acid azepane L-prolyl-L-prolinamide amide (150 mg, 0.37 mmol) and Et3N
(155 µl, 1.11 mmol) in 8 ml THF was added trifluoroacetic anhydride (80 µl, 0.56
mmol) in 4 ml THF dropwise at  0 °C. The reaction mixture was stirred 2 h at rt,
evaporated and dissolved in DCM. The organic phase was washed with 30% citric acid
aq, dried and evaporated. The product was purified by flash chromatography (10%
MeOH in EtOAc) yielding colorless oil (76 mg, 53%). 1H NMR d 1.52-1.59 (4 H, m),
1.66-1.73 (4 H, m), 1.90-2.06 (4 H, m), 2.09-2.31 (6 H, m), 2.35-2.47 (4 H, m), 3.39-
3.44 (2 H, m), 3.45-3.64 (4 H, m), 3.66-3.71 (1 H, m), 3.85-3.90 (1 H, m), 4.55 (0.9 H,
dd, J = 4.2 Hz, 8.6 Hz), 4.60-4.62 (0.1 H, m), 4.65-4.68 (0.1 H, m), 4.79-4.81 (0.9 H,
m); 13C NMR d 20.3, 25.0, 25.4, 26.9, 27.2, 27.7, 28.8, 29.1, 29.7, 32.1, 33.7, 45.9,
46.3, 46.5, 47.4, 47.8, 57.4, 118.6, 171.4, 171.7, 172.1; MS (ESI, +) m/z 389 [M + H]+;
Anal. (C21H32N4O3·0.2H2O) C, H, N.
3,3-Dimethylglutaric acid azepane L-prolyl-L-proline amide. 10d (0.52 g, 1.54
mmol) and L-proline methyl ester HCl salt (0.26 g, 1.57 mmol) were coupled according
to procedure A. The product was purified by flash chromatography (10% MeOH in
EtOAc). Yield 0.54 g, 78%. 1H NMR d 1.18 (3 H, s), 1.19 (3 H, s), 1.50-1.58 (4 H, m),
1.66-1.72 (4 H, m), 1.80-2.28 (8 H, m), 2.37 (1 H, d, J = 15.2 Hz), 2.48 (1 H, d, J = 14.6
Hz), 2.59 (1 H, d, J = 15.2 Hz), 2.63 (1 H, d, J = 14.6 Hz), 3.40-3.69 (8 H, m), 3.70 (3
H, s), 3.40-3.56 (4 H, m), 3.58-3.69 (3 H, m), 3.70 (3 H, s), 3.81-3.87 (1 H, m), 4.54-
4.59 (1 H, m), 4.67 (0.9 H, dd, J = 3.8 Hz, 7.8 Hz), 4.75-4.77 (0.1 H, m). The methyl
ester group of the obtained product was hydrolyzed using LiOH×H2O (76 mg, 1.8 mmol)
according to procedure B. Yield 0.54 g, 100%.
3,3-Dimethylglutaric acid azepane L-prolyl-L-prolinamide amide. To a solution
of 3,3-dimethylglutaric acid azepane L-prolyl-L-proline amide (0.54 g, 1.24 mmol) and
Et3N (0.17 ml, 1.22 mmol) in THF was added ethyl chloroformate (0.12 ml, 1.26 mmol)
in THF dropwise at -10 °C. After 20 min 25% NH3 aq (84 µl, 1.2 mmol) was added and
the reaction mixture was allowed to warm up to rt and stirred overnight. The reaction
mixture was evaporated, dissolved in DCM and washed with saturated NaHCO3 aq. The
organic phase was dried and evaporated. Yield 450 mg, 84%.
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3,3-Dimethylglutaric acid azepane L-prolyl-2(S)-cyanopyrrolidine amide (15).
To a solution of 3,3-dimethylglutaric acid azepane L-prolyl-L-prolinamide amide (0.45
g, 1.04 mmol) and Et3N (0.43 ml, 3.09 mmol) in THF was added trifluoroacetic
anhydride (0.22 ml, 1.58 mmol) in THF dropwise at 0 °C. The reaction mixture was
stirred for 6 h at rt, and the reaction was then quenched with 5 ml of water. The reaction
mixture was evaporated, dissolved in DCM and washed with 30% citric acid aq,
saturated NaCl aq and saturated NaHCO3 aq. The organic phase was dried and
evaporated. The product was purified by flash chromatography (30-50% acetonitrile in
EtOAc), yielding white solid, 250 mg, 58%. 1H NMR d 1.17 (3 H, s), 1.18 (3 H, s),
1.51-1.58 (4 H, m), 1.67-1.73 (4 H, m), 1.90-1.98 (2 H, m), 2.09-2.28 (6 H, m), 2.35-
2.64 (4 H, m), 3.40-3.75 (7 H, m), 3.82-3.87 (1 H, m), 4.56 (0.9 H, dd, J = 4.3 Hz, 8.4
Hz), 4.73-4.86 (1.1 H, m); 13C NMR d 25.0, 25.4, 26.8, 27.0, 27.7, 28.5, 28.6, 28.7,
29.1, 29.7, 34.0, 42.1, 43.8, 45.9, 46.2, 46.5, 48.1, 48.4, 57.4, 118.7, 171.1, 171.4,
171.5; MS (ESI, +) m/z 417 [M + H]+; Anal. (C23H36N4O3·0.1H2O) C, H, N.
Phthalic acid pyrrolidine L-prolyl-pyrrolidine amide (16). 9d (0.90 g,
2.84 mmol) was coupled with pyrrolidine (0.26 ml, 3.11 mmol) according to procedure
A. The product was purified by flash chromatography (10% MeOH in EtOAc). Yield
860 mg, 83%. 1H NMR d 1.49-1.58 (1 H, m), 1.65-1.74 (1 H, m), 1.81-2.06 (8 H, m),
2.14-2.29 (1.5 H, m), 2.48-2.52 (0.5 H, m) 3.00-3.05 (0.5 H, m), 3.14-3.89 (9.5 H, m),
4.69 (0.5 H, dd, J = 3.3 Hz, 8.2 Hz), 4.79 (0.5 H, dd, J = 6.2 Hz, 8.3 Hz), 7.29-7.42 (3.5
H, m), 7.51-7.55 (0.5 H, m); 13C NMR d 23.3, 24.0, 24.2, 24.5, 24.6, 25.2, 25.9, 25.9,
26.0, 26.2, 29.2, 30.5, 45.6, 45.6, 45.7, 45.7, 46.0, 46.3, 46.8, 48.8, 48.9, 49.8, 57.6,
59.4, 125.7, 126.4, 127.4, 127.5, 128.5, 128.7, 128.9, 128.9, 135.2, 135.6, 135.7, 135.8,
168.6, 168.7, 168.8, 169.0, 170.3, 171.1; MS (ESI, +) m/z 370 [M + H]+; Anal.
(C21H27N3O3·0.2H2O) C, H, N.
Phthalic acid pyrrolidine L-prolyl-2(S)-cyanopyrrolidine amide (17). Boc-2(S)-
cyanopyrrolidine (980 mg, 5.0 mmol) was deprotected using 10 ml trifluoroacetic acid
in 50 ml DCM according to procedure C. 9d (1.58 g, 4.99 mmol) and the
2(S)-cyanopyrrolidine trifluoroacetic acid salt were coupled according to procedure A.
The product was purified with a silica plate chromatotron (2% MeOH in DCM). Yield
250 mg, 13%. 1H NMR d 1.65-2.12 (8 H, m), 2.15-2.33 (4 H, m), 3.11-3.37 (2 H, m),
3.42-3.73 (5 H, m), 3.79-3.94 (1 H, m), 4.43-4.45 (0.3 H, m), 4.72 (0.7 H, dd, J = 6.3
Hz, 8.3 Hz), 4.77 (0.3 H, dd, J = 3.4 Hz, 8.2 Hz), 4.81-4.84 (0.7 H, m), 7.26-7.33 (1 H,
m), 7.34-7.44 (2 H, m), 7.46-7.51 (1 H, m); 13C NMR d 24.6, 25.3, 25.4, 26.0, 29.2,
29.7, 45.7, 46.3, 46.6, 49.0, 49.7, 57.4, 118.6, 126.5, 127.2, 129.1, 129.1, 135.4, 135.7,
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168.6, 168.9, 171.0; MS (ESI, +) m/z 395 [M + H]+; Anal. (C22H26N4O3·0.2H2O) C, H,
N.
Terephthalic acid pyrrolidine L-prolyl-L-proline amide. 9c (0.50 g, 1.58 mmol)
and L-proline methyl ester HCl salt (0.27 g, 1.63 mmol) were coupled according to
procedure A. The product was purified by flash chromatography (5-10% MeOH in
EtOAc). Yield 0.45 g, 66%. 1H NMR d 1.82-2.01 (6.5 H, m), 2.06-2.34 (5.5 H, m),
3.17-3.39 (2 H, m), 3.46-3.51 (1 H, m), 3.61-3.71 (4 H, m), 3.73 (3 H, s), 3.77-4.00 (1
H, m), 4.26-4.28 (0.2 H, m), 4.31-4.33 (0.2 H, m), 4.61 (0.8 H, dd, J = 4.5 Hz, 8.6 Hz),
4.87 (0.8 H, dd, J = 5.0 Hz, 8.3 Hz), 7.40-7.42 (0.4 H, m), 7.46-7.47 (0.4 H, m), 7.52-
7.53 (1.6 H, m), 7.58-7.60 (1.6 H, m). The methyl ester group of the product was
hydrolyzed using LiOH×H2O (69 mg, 1.6 mmol) according to procedure B. Yield 0.43 g,
95%.
Terephthalic acid pyrrolidine L-prolyl-L-prolinamide amide. The compound
was prepared from terephthalic acid pyrrolidine L-prolyl-L-proline amide (0.43 g, 1.04
mmol) and 25% NH3 aq (71 µl, 1.0 mmol) according to the method for preparation of
3,3-dimethylglutaric acid azepane L-prolyl-L-prolinamide amide. The product was
purified by flash chromatography (10-30% MeOH in EtOAc). Yield 260 mg, 61%.
Terephthalic acid pyrrolidine L-prolyl-2(S)-cyanopyrrolidine amide (18).
Compound 18 was prepared from terephthalic acid pyrrolidine L-prolyl-L-prolinamide
amide (0.26 g, 0.63 mmol) according to the method for the preparation of 15. The
reaction time was 2 h. The product was purified by flash chromatography (30-50%
acetonitrile in EtOAc), yielding yellowish solid, 145 mg, 59%. 1H NMR d 1.86-2.33 (12
H, m), 3.22-3.26 (0.1 H, m), 3.33 (0.2 H, t, J = 6.6 Hz), 3.38 (1.8 H, t, J = 6.6 Hz), 3.50-
3.55 (1 H, m), 3.60-3.91 (4.0 H, m), 3.70-4.02 (0.9 H, m), 4.27-4.29 (0.1 H, m), 4.39-
4.41 (0.1 H, m), 4.75 (0.9 H, dd, J = 6.1 Hz, 8.0 Hz), 4.85-4.87 (0.9 H, m), 7.37-7.39
(0.2 H, m), 7.43-7.45 (0.2 H, m), 7.54-7.55 (1.8 H, m), 7.58-7.60 (1.8 H, m); 13C NMR
d 24.4, 25.4, 25.6, 26.4, 29.0, 29.8, 46.2, 46.5, 46.6, 49.5, 50.2, 58.0, 118.6, 127.1,
127.3, 137.3, 139.0, 168.8, 168.9, 171.1; MS (ESI, +) m/z 395 [M + H]+; Anal.
(C22H26N4O3·0.5H2O) C, H, N.
Isophthalic acid pyrrolidine L-prolyl-2(S)-cyanopyrrolidine amide (19). Boc-
2(S)-cyanopyrrolidine (980 mg, 5.0 mmol) was deprotected using 20 ml trifluoroacetic
acid in 50 ml DCM according to procedure C. 9b (1.58 g, 4.99 mmol) and the 2(S)-
cyanopyrrolidine trifluoroacetic acid salt were coupled according to procedure A. The
product was purified by flash chromatography (1.5-3% MeOH in DCM). Yield 730 mg,
37%. 1H NMR d 1.82-2.13 (7 H, m), 2.15-2.32 (5 H, m), 3.21-3.43 (2 H, m), 3.53-3.90
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(5 H, m), 3.98-4.02 (1 H, m), 4.25-4.27 (0.2 H, m), 4.55-4.57 (0.2 H, m), 4.75 (0.8 H,
dd, J = 6.3 Hz, 8.1 Hz), 4.85-4.87 (0.8 H, m), 7.43-7.47 (1 H, m), 7.58-7.62 (2 H, m),
7.68-7.69 (1 H, m); 13C NMR d 24.5, 25.4, 25.7, 26.4, 29.0, 29.8, 46.2, 46.5, 46.6, 49.6,
50.3, 58.0, 118.6, 125.8, 128.5, 128.6, 129.0, 136.1, 137.5, 168.8, 168.8, 171.1; MS
(ESI, +) m/z 395 [M + H]+; Anal. (C22H26N4O3·0.2H2O) C, H, N.
Isophthalic acid azepane L-prolyl-2(S)-cyanopyrrolidine amide (20). Boc-2(S)-
cyanopyrrolidine (940 mg, 4.8 mmol) was deprotected using 19 ml trifluoroacetic acid
in 50 ml DCM according to procedure C. 10b (1.67 g, 4.85 mmol) and the 2(S)-
cyanopyrrolidine trifluoroacetic acid salt were coupled according to procedure A. The
product was purified by flash chromatography (1.5-2.5% MeOH in DCM). Yield 920
mg, 45%. 1H NMR d 1.53-1.66 (6 H, m), 1.78-2.32 (10 H, m), 3.21-3.35 (2 H, m), 3.53-
3.90 (5 H, m), 3.97-4.02 (1 H, m), 4.24-4.26 (0.2 H, m), 4.53 (0.2 H, dd, J = 3.3 Hz, 6.8
Hz), 4.74 (0.8 H, dd, J = 6.4 Hz, 7.9 Hz), 4.85-4.87 (0.8 H, m), 7.42-7.45 (2 H, m),
7.56-7.60 (2 H, m); 13C NMR d 25.4, 25.7, 26.5, 27.2, 27.8, 29.0, 29.4, 29.8, 46.3, 46.5,
46.6, 49.8, 50.3, 58.0, 118.6, 125.3, 127.9, 128.3, 128.6, 136.2, 137.6, 168.8, 170.6,
171.1; MS (ESI, +) m/z 423 [M + H]+; Anal. (C24H30N4O3·0.1H2O) C, H, N.
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6 A CYCLOPENT-2-ENECARBONYL GROUP MIMICS
PROLINE AT THE P2 POSITION OF PROLYL OLIGOPEPTIDASE
INHIBITORS*
Abstract. With the aim to replace the natural amino acid proline by a proline mimetic
structure, a cyclopent-2-enecarbonyl moiety was studied at the P2 position of prolyl
oligopeptidase (POP) inhibitors. The cyclopent-2-enecarbonyl moiety proved to be an
excellent proline mimetic at the P2 position of POP inhibitors. The replacement is
particularly useful when increased lipophilicity is needed.
* Reproduced with permission from: Jarho EM, Venäläinen JI, Huuskonen J,
Christiaans JAM, Garcia-Horsman JA, Forsberg MM, Järvinen T, Gynther J,
Männistö PT, Wallén EAA:  Journal of Medicinal Chemistry 47: 5605-5607, 2004
 Copyright ã 2004 American Chemical Society
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6.1 Introduction
Several protease inhibitors are recently under investigation as potential drugs. Many of
them have a peptide-like structure, and they suffer from poor bioavailability and
susceptibility to nonspecific degradation. These problems have led to the development
of amino acid mimetics that could be used to replace the natural amino acids. The
unique structure of proline makes it challenging to replace (De Nanteuil et al. 1998,
Leung et al. 2000).
L-Proline is the preferred amino acid at the P2 position of POP inhibitors. Only a
few successful replacements of this proline have been reported (Tsuru et al. 1988, De
Nanteuil 1996, Barelli et al. 1999, Wallén et al. 2003). The L-prolyl residue has been
replaced by groups that contain a five-membered carbon ring, such as a
cyclopentanecarbonyl group and a cyclopent-1-enecarbonyl group, but the resulting
compounds had a decreased inhibitory activity (Ohno 1988, Faraci 1991). In the present
study, the pyrrolidine ring was successfully replaced by a cyclopent-2-enecarbonyl
group. The same replacement has previously been studied at the P2 position of thrombin
inhibitors with moderate results (Nöteberg et al. 2000).
6.2 Methods
Synthetic chemistry. The synthetic routes are presented in Scheme 1. (±)-2-Formyl-
cyclopent-2-enecarboxylic acid (1) and (±)-cyclopent-2-ene-1,2-dicarboxylic acid 1-
methyl ester (2) were synthesized as described in the literature with small modifications
(Stevens et al. 1971, Nöteberg et al. 2000). DCC and HOBt were used to couple
benzylamine with 2, and the methyl ester of the obtained product was hydrolyzed with
LiOH to obtain (±)-2-benzylcarbamoylcyclopent-2-enecarboxylic acid (3). Reaction of
1 with (3-phenylpropyl)magnesium bromide (prepared in situ) produced a secondary
alcohol, which was oxidized with oxalyl chloride/DMSO to obtain ((±)-2-(4-
phenylbutyryl)cyclopent-2-enecarboxylic acid (4). Compounds 3 and 4 were activated
with trimethylacetyl chloride and reacted with pyrrolidine to yield end products 9 and 8,
respectively. The enantiomers of 9 and 8 were not separated. Compound 3 was activated
with trimethylacetyl chloride and reacted with 2(S)-(acetoxyacetyl)-pyrrolidine. The
acetyl group was hydrolyzed with K2CO3 in water and methanol, yielding end product
5. The diastereomers of 5 were separated on silica support. The separated compounds
were confirmed to be diastereomers by NMR. Compound 4 was activated with
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Scheme 1. i) CH(OCH3)3, p-TsOH; ii) resorcinol, NaH2PO4·H2O, NaClO2/t-BuOH,
H2O; iii) benzylamine, HOBt, Et3N, DCC/CH3CN, 0-20 ºC; iv) LiOH/MeOH, H2O; v)
1. Et3N, (CH3)3CCOCl/CH2Cl2, 0 ºC, 2. Et3N, an amine or a salt of an amine; vi)
K2CO3/MeOH, H2O, 0-20 ºC; vii) 1. Mg, I2, 1-bromo-3-phenylpropane/Et2O, 2.
compound 1; viii) 1. oxalyl chloride, DMSO/CH2Cl2, -78 ºC, 2. Et3N; ix) 1. Et3N,
C2H5OCOCl/THF, -10 ºC, 2. 25% NH3 aq./THF, room temperature; x) Et3N,
trifluoroacetic anhydride/THF, 0-20 ºC; xi) benzylamine/THF, 0-20 ºC.
trimethylacetyl chloride and reacted with L-proline methyl ester. The methyl ester group
was hydrolyzed with LiOH in water and methanol. Thus, the obtained free carboxylic
acid was activated with ethyl chloroformate and treated with 25% aqueous NH3. The
carboxylic acid amide was then dehydrated with trifluoroacetic anhydride to yield end
product 7. The diastereomers of 7 were separated on silica support. The separated
compounds were confirmed to be diastereomers by NMR. Compound 10 was prepared
from cyclopent-1-ene-1,2-dicarboxylic anhydride and benzylamine. Compound 10 was
then activated with trimethylacetyl chloride and reacted with pyrrolidine to yield
reference compound 11. Reference compounds 6, SUAM-1221 (Houssin et al. 1988,
Saito et al. 1991, Arai et al. 1993), and JTP-4819 (Kobayashi 1996) were prepared as
described in the literature.
The log P values. The partition coefficients (P) were determined in a 1-octanol-
phosphate buffer system with the traditional shake-flask method as described in section
4.5.
6.3 Results and discussion
The inhibitory activities of the novel and reference compounds are shown in Table 1.
The tight-binding inhibitors are highly potent compounds with the IC50 values in the
same range as the enzyme concentration in the in vitro assay. The Ki values were
determined for tight-binding inhibitors to obtain the accurate inhibitory potencies.
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Table 1. Structures, inhibitory activities (95% confidence intervals), and log P values of
the reference and novel compounds.
Compound Structure IC50 (nM) Ki (nM)a Log P
JTP-4819 NN
OO O
OHN
H 0.2 (0.16-0.27) 0.06 (0.023-0.087) 0.2
5ab N
OO O
OHN
H
* 0.3 (0.18-0.56) 0.15 (0.080-0.220) 0.6
5bc N
OO O
OHN
H
* 52 (39-71)
6 NN
OO
CN 0.2 (0.17-0.29) 0.02 (0.014-0.033) 1.6
7ab N
OO
CN* 0.2 (0.12-0.36) 0.03 (0.014-0.043) 2.4
7bc N
OO
CN
* 5.0 (3.9-6.5)
SUAM-
1221
NN
OO
2.2 (1.9-2.5) 1.8
8 N
OO
1.3 (0.7-2.7)
9 N
OO
N
H 9.0 (5.5-15)
11 N
OO
N
H 230 (160-330)
a The Ki-values were determined against purified porcine POP for those tight-binding inhibitors
that had the IC50-value in the subnanomolar range. b The chiral center marked with the asterisk
was assumed to have R-configuration. The absolute configuration was not verified. c The chiral
center marked with the asterisk was assumed to have S-configuration. The absolute
configuration was not verified.
The activities of diastereomers 5a and 5b differed considerably from each other. The
IC50 value of 5a was 0.3 nM, while the IC50 value of 5b was 52 nM. At the P2 position
L-amino acids have repeatedly caused better activities than D-amino acids (Yoshimoto
et al. 1991, Arai et al. 1993, Portevin et al. 1996). Consequently, the configurations of
5a and 5b were assigned assuming that the more active diastereomer 5a has the L-
proline mimetic at the P2 position. The configurations were not verified. Diastereomer
5a was almost equipotent with reference compound JTP-4819.
Compound 7a was equipotent with reference compound 6. It had a Ki value of 0.03
nM and was also assumed to have the L-proline mimetic at the P2 position. The
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absolute configuration was not verified. The other diastereomer 7b was less active with
an IC50 of 5 nM.
The 2(S)-hydroxyacetyl derivative 5a and 2(S)-cyano derivative 7a are tight-binding
inhibitors of prolyl oligopeptidase. Normally, these electrophilic groups increase the
inhibitory activity over 10-fold as compared to an unsubstituted pyrrolidine. Compound
8 has the unsubstituted pyrrolidine at the P1 position. It was tested as a mixture of
enantiomers, and despite that, the IC50 value was as low as 1.30 nM. On the basis of the
activity differences between 5a and 5b and between 7a and 7b, it can be assumed that
the more active enantiomer is even more potent than the reference compound SUAM-
1221.
POP inhibitors, which contain a cyclopent-1-enecarbonyl group at the P2 position,
have been published in the literature (Faraci 1991). One such inhibitor (11) and the
corresponding cyclopent-2-enecarbonyl analogue (9) were synthesized. As expected, 11
was less active, with an IC50 of 230 nM, than 9 with an IC50 of 9 nM. The structure of
the cyclopent-1-enecarbonyl group is not a good proline mimetic and is therefore
moderately active. The cyclopent-2-enecarbonyl group mimics a proline residue rather
well, as observed by the inhibitory activity.
To study the effect of the cyclopent-2-enecarbonyl moiety on the lipophilicity, the
log P values were determined for a selection of compounds (Table 1). The replacement
of the prolyl moiety by the cyclopent-2-enecarbonyl moiety changed the urea group of
JTP-4819 to the amide group of 5a. This change increased the log P value by 0.4 units.
The change of the amide group of 6 to the ketone group of 7a increased the log P value
by 0.8 units. On the basis of these results, it seems that the replacement of a proline with
a cyclopent-2-enecarbonyl group increases the log P value but the magnitude depends
on the substituents.
The replacement of the L-prolyl residue by the cyclopent-2-enecarbonyl group
introduced an a,b-unsaturated ketone or amide to the novel compounds. The a,b-
unsaturated ketones gave valuable information about the structure-activity relationships,
but their stability needs further evaluation because of the activated double bond.
However, the a,b-unsaturated amides are not as reactive because of the electron-
donating effect of the nitrogen atom.
6.4 Conclusions
The L-prolyl moiety was replaced by the cyclopent-2-enecarbonyl structure at the P2
position of prolyl oligopeptidase inhibitors. In all cases, the cyclopent-2-enecarbonyl
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analogue proved to be equipotent with the reference compound. Furthermore, this
replacement increased the lipophilicity of the compounds. This study shows that a
cyclopent-2-enecarbonyl structure can be used to replace a prolyl residue at the P2
position of POP inhibitors.
6.5 Synthetic procedures and analytical data
(±)-2-Formylcyclopent-2-enecarboxylic acid (1). Dichloroacetyl chloride (30.0 ml,
312 mmol) and freshly distilled cyclopentadiene (26.0 ml, 312 mmol) were dissolved in
250 ml of hexane. Et3N (44.0 ml, 316 mmol) in 200 ml of hexane was added at 0 °C
during 2 hours. The reaction was let to proceed overnight at rt. The reaction mixture
was filtered, evaporated and dissolved in 1 l of 1 M NaHCO3. The mixture was stirred
for 4 hours at 75 °C and, after cooling, filtered, washed with Et2O and acidified with 3
M HCl. Water was then evaporated and the residue was stirred overnight with DCM and
Na2SO4. The mixture was filtered and evaporated. The product was first purified by
flash chromatography (EtOAc:toluene:CH3COOH 50:50:1) and then crystallized from
cyclohexane, yielding the product as white needles (9.7 g, 22%). 1H NMR ? 2.32-2.46
(m, 2 H), 2.63-2.71 (m, 1 H), 2.77-2.85 (m, 1 H), 3.81-3.85 (m, 1 H), 7.11-7.12 (m, 1
H), 9.77 (s, 1 H).
(±)-2-Formylcyclopent-2-enecarboxylic acid methyl ester. To a solution of 1
(4.5 g, 32 mmol) in 70 ml of trimethyl orthoformate was added p-toluenesulfonic acid
(3.1 g, 16 mmol) and the mixture was stirred for three days. 20 ml of water was added
and the mixture was stirred for 30 min. More water was added and the product was
extracted with DCM and the organic phase was dried over Na2SO4 and evaporated. The
product was purified by flash chromatography (25% EtOAc in PE) Yield 3.6 g, 72%. 1H
NMR ? 2.14-2.21 (m, 1 H), 2.33-2.41 (m, 1 H), 2.60-2.68 (m, 1 H), 2.74-2.82 (m, 1 H),
3.70 (s, 3 H), 3.75-3.80 (m, 1 H), 7.02-7.03 (m, 1 H), 9.77 (s, 1 H).
(±)-Cyclopent-2-ene-1,2-dicarboxylic acid 1-methyl ester (2). To a solution of
(±)2-formylcyclopent-2-enecarboxylic acid methyl ester (3.6 g, 23 mmol) in t-BuOH
(70 ml) and H2O (35 ml) were added resorcinol (4.5 g, 41 mmol), NaH2PO4·H2O (4.8 g,
35 mmol) and 80% NaClO2  (3.1 g, 34 mmol). The mixture was stirred for 5 hours at rt.
10 ml of sat. Na2SO3 aq. was added, the mixture was acidified with 2 M HCl and
extracted with DCM. The organic phase was extracted with sat. NaHCO3 aq., which
was acidified with 2 M HCl and extracted with DCM. The second organic phase was
dried over Na2SO4 and evaporated. Crystallization from diethyl ether-hexane gave the
product as white crystals. Yield 2.7 g, 68%. 1H NMR ? (DMSO) 1.89-1.95 (m, 1 H),
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2.26-2.34 (m, 1 H), 2.45-2.59 (m, 2 H), 3.59 (s, 3 H), 3.62-3.67 (m, 1 H), 6.82-6.83 (m,
1 H).
(±)-2-Benzylcarbamoyl-cyclopent-2-enecarboxylic acid methyl ester. 2 (0.68 g,
4.00 mmol), benzylamine (0.65 ml, 5.95 mmol), HOBt (contained 12% of H2O, 0.92 g,
6.0 mmol) and Et3N (0.85 ml, 6.10 mmol) were dissolved in 30 ml of CH3CN. DCC in
10 ml of CH3CN was added dropwise at 0 °C and the mixture was stirred overnight at
rt. The mixture was filtered and evaporated and the residue was dissolved in DCM. The
organic phase was washed with 30% citric acid, sat. NaCl and sat. NaHCO3, dried over
Na2SO4 and evaporated. The methyl ester was purified by flash chromatography (50%
EtOAc in PE). Yield 1 g, 96%. 1H NMR ? 2.20-2.31 (m, 2 H), 2.45-2.53 (m, 1 H), 2.60-
2.68 (m, 1 H), 3.65 (s, 3 H), 3.79-3.83 (m, 1 H), 4.46 (dd, J = 5.6, 14.8 Hz, 1 H), 4.53
(dd, J = 5.9, 14.8 Hz, 1 H), 6.53 (br s, 1 H), 6.65-6.67 (m, 1 H), 7.24-7.34 (m, 5 H).
(±)-2-Benzylcarbamoyl-cyclopent-2-enecarboxylic acid (3). To a solution of (±)-
2-benzylcarbamoyl-cyclopent-2-enecarboxylic acid methyl ester (1.0 g, 3.9 mmol) in 6
ml of MeOH was added LiOH·H2O (0.24 g, 5.72 mmol) in 2 ml of H2O at rt. The
mixture was stirred overnight. Methanol was evaporated and the mixture was diluted
with water and washed with Et2O. The aqueous phase was acidified with 2 M HCl and
extracted with Et2O. The organic phase was dried over Na2SO4, filtered and evaporated.
Yield 0.86 g, 91%.
2-(1-Hydroxy-4-phenyl-butyl)-cyclopent-2-enecarboxylic acid. Catalytic amount
of I2 and magnesium (0.51 g, 21 mmol) were placed in a flask under nitrogen
atmosphere. 1-Bromo-3-phenylpropane (3.2 ml, 21 mmol) in 4 ml of Et2O was added
and the mixture was heated until reaction started. When the reaction had ended, 1 (1.4 g,
10 mmol) in 50 ml of Et2O was added dropwise and the mixture was stirred for 2 h. The
mixture was poured into 100 ml of ice cold, sat. NH4Cl solution. The aqueous phase
was acidified with 2 M HCl and the layers were separated. The aqueous phase was
extracted with DCM and the combined organic phases were dried over Na2SO4 and
evaporated. The product was purified by flash chromatography (PE:EtOAc:CH3COOH
66:33:1). Yield 1.8 g, 69%. 1H NMR ? 1.53-1.80 (m, 4 H), 2.18-2.25 (m, 2 H), 2.29-
2.37 (m, 1 H), 2.46-2.52 (m, 1 H), 2.58-2.68 (m, 2 H), 3.44-3.47 (m, 0.3 H), 3.55-3.58
(m, 0.7 H), 4.29-4.31 (m, 0.3 H), 4.36-4.39 (m, 0.7 H), 5.79-5.80 (m, 0.7 H), 5.83-5.85
(m, 0.3 H), 7.16-7.19 (m, 3 H), 7.25-7.28 (m, 2 H).
(±)-2-(4-Phenylbutyryl)-cyclopent-2-enecarboxylic acid (4). To a solution of
oxalyl chloride (0.6 ml, 6.9 mmol) in 30 ml of DCM was added DMSO (1.47 ml, 20.7
mmol) at -78 ºC. The mixture was stirred for 15 min. 2-(1-Hydroxy-4-phenyl-butyl)-
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cyclopent-2-enecarboxylic acid (1.8 g, 6.9 mmol) was added dropwise and the mixture
was stirred for 2 h. Et3N (3.8 ml, 27.6 mmol) was added and the mixture was stirred for
5 min and was let to warm up to rt. The product was extracted with 5% NaOH aq.
solution. The aqueous phase was acidified with 2 M HCl and extracted with DCM. The
organic phase was dried over Na2SO4 and evaporated. The product was purified by flash
chromatography (0.5% CH3COOH in DCM). Yield 0.91 g, 51%. 1H NMR ? 1.77-1.83
(m, 2 H), 1.87-1.94 (m, 1 H), 2.20-2.28 (m, 1 H), 2.49-2.64 (m, 4 H), 2.67-2.70 ( m, 2
H), 3.54-3.59 (m, 1 H), 6.96-6.97 (m, 1 H), 7.15-7.19 (m, 3 H), 7.25-7.29 (m, 2 H).
TFA salt of 2(S)-(acetoxyacetyl)-pyrrolidine. To a solution of Boc-protected 2(S)-
(acetoxyacetyl)-pyrrolidine (0.95 g, 3.50 mmol) in 18 ml of DCM was added 7 ml of
TFA at 0 ºC, the mixture was stirred for 2.5 h and evaporated. The salt was stored under
vacuum not longer than 24 h.
Cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-[2(S)-(acetoxyacetyl)-
pyrrolidine] amide. To a solution of 3 (0.86 g, 3.51 mmol) and Et3N (0.54 ml, 3.87
mmol) in DCM was added trimethylacetyl chloride (0.43 ml, 3.49 mmol) dropwise at 0
ºC and the mixture was stirred for 2.5 h. Et3N (1.6 ml, 11.6 mmol) and TFA salt of 2(S)-
(acetoxyacetyl)-pyrrolidine (3.5 mmol) in DCM were added in this order and the
icebath was removed. The mixture was stirred for 3 h at rt. The mixture was washed
with 30% citric acid, sat. NaCl and sat. NaHCO3, dried over Na2SO4 and evaporated.
The product was purified by flash chromatography (20% PE in EtOAc) monitoring
carefully that the distereomers were not separated. Yield 0.82 g, 60%.
Cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-[2(S)-(hydroxyacetyl)-
pyrrolidine] amide (5). To a solution of cyclopent-2-ene-1,2-dicarboxylic acid 2-
benzylamide 1-[2(S)-(acetoxyacetyl)-pyrrolidine] amide (0.82 g, 2.06 mmol) in 8.5 ml
of MeOH and 8.5 ml of H2O was slowly added K2CO3 (0.32 g, 2.3 mmol) at 0 ºC. The
mixture was stirred 10 min at 0 ºC and 30 min at rt. Methanol was evaporated and the
product was dissolved in DCM. The organic phase was washed with sat. NaCl, dried
over Na2SO4 and evaporated. The product was first purified by flash chromatography
(EtOAc). Yield 0.74 g, 99%. The diastereomers 5a and 5b were then separated by flash
chromatography (4% 2-propanol in DCM). Analytical data for 5a: 1H NMR ? 1.83-1.89
(m, 1 H), 1.97-2.18 (m, 4 H), 2.27-2.34 (m, 1 H), 2.49-2.56 (m, 1 H), 2.62-2.69 (m, 1
H), 3.65-3.69 (m, 1 H), 3.90-3.95 (m, 1 H), 4.07-4.10 (m, 1 H), 4.23-4.41 (m, 3 H),
4.54-4.60 (m, 2 H), 6.40-6.41 (m, 1 H), 6.45-6.51 (m, 1 H), 7.25-7.33 (m, 5 H). 13C
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NMR ? 25.3, 27.6, 28.5, 32.9, 43.4*, 43.4, 47.6, 49.0, 60.9, 67.1*, 67.1, 127.4, 127.4*,
127.6, 127.7*, 128.7, 128.7*, 137.6*, 137.6, 138.3*, 138.4, 139.4*, 139.4, 165.2*, 165.2,
173.8*, 173.8, 209.2, 209.2*. Anal. (C20H24N2O4·0.1 H2O) C, H, N. ESI-MS m/z 357.1
[M + H]+. Analytical data for 5b: 1H NMR ? 1.96-2.18 (m, 5 H), 2.23-2.30 (m, 1 H),
2.49-2.56 (m, 1 H), 2.65-2.73 (m, 1 H), 3.61-3.66 (m, 1 H), 3.95-3.99 (m, 1 H), 4.04-
4.07 (m, 1 H), 4.26 (dd, J = 5.0, 19.1 Hz, 1 H), 4.33 (dd, J = 5.0, 19.1 Hz, 1 H), 4.45-
4.55 (m, 3 H), 6.34-6.38 (m, 1 H), 6.48-6.50 (m, 1 H), 7.24-7.34 (m, 5 H). 13C NMR ?
25.2, 28.0, 28.4, 32.9, 43.6, 47.8, 48.9, 62.9, 67.0, 127.4, 127.9, 128.7, 138.2, 138.7,
139.4, 165.2, 173.8, 209.4. Anal. (C20H24N2O4·0.2 H2O) C, H, N. ESI-MS m/z 357.1 [M
+ H]+.
1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-2(S)-carboxylic
acid methyl ester. The product was synthesized from 4 (0.58 g, 2.25 mmol) and HCl
salt of L-proline methyl ester (0.72 g, 2.25 mmol) as described for cyclopent-2-ene-1,2-
dicarboxylic acid 2-benzylamide 1-[2(S)-(acetoxyacetyl)-pyrrolidine] amide. The
product was purified by flash chromatography (50% EtOAc in PE). Yield 0.64 g, 77%.
1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-2(S)-carboxylic
acid. To a solution of 1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-
2(S)-carboxylic acid methyl ester (0.64 g, 1.7 mmol) in 10 ml of MeOH was added
LiOH·H2O (0.11 g, 2.6 mmol) in 3.5 ml of H2O at rt. The mixture was stirred overnight.
Methanol was evaporated and the mixture was diluted with water and washed with
DCM. The aqueous phase was acidified with 3 M HCl and extracted with DCM. The
organic phase was dried over Na2SO4, filtered and evaporated. Yield 0.58 g, 94%.
1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-2(S)-carboxylic
amide. To a solution of 1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-
2(S)-carboxylic acid (0.58 g, 1.63 mmol) and Et3N (0.23 ml, 1.65 mmol) in THF was
added ethyl chloroformate (0.16 ml, 1.67 mmol) in THF dropwise at -10 ºC. After 20
min 25% NH3 aq. (0.55 ml, 8.1 mmol) was added and the mixture was stirred overnight
at rt. THF was evaporated and the residue was dissolved in DCM. The organic phase
was washed with sat. NaHCO3, dried over Na2SO4 and evaporated. The product was
purified by flash chromatography (10% MeOH in EtOAc). Yield 0.50 g, 86%. 1H NMR
? 1.88-1.98 (m, 3 H), 1.99-2.15 (m, 3 H), 2.17-2.29 (m, 1 H), 2.35-2.43 (m, 0.8 H),
2.47-2.52 (m, 0.2 H), 2.56-2.67 (m, 3 H), 2.68-2.74 (m, 2 H), 2.75-2.85 (m, 1 H), 3.53-
3.77 (m, 1.5 H) 3.84-3.99 (m, 1.5 H), 4.34-4.36 (m, 0.2 H), 4.58-4.61 (m, 0.8 H), 5.89
* Minor rotamer.
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(br s, 0.8 H), 5.64 (br s, 0.2 H), 6.81-6.85 (m, 0.5 H), 6.88-6.89 (m, 0.5 H), 7.04 (br s,
0.8 H), 7.15-7.20 (m, 3 H), 7.25-7.29 (m, 2 H), 7.72 (br s, 0.2 H).
1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-2(S)-nitrile (7). To
a solution of 1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine-2(S)-
carboxylic amide (0.50 g, 1.41 mmol) and Et3N (0.59 ml, 4.23 mmol) in dry THF was
added trifluoroacetic anhydride (0.30 ml, 2.16 mmol) in dry THF dropwise at 0 ºC. The
mixture was stirred for 3 h at rt. 5 ml of water was added and THF was evaporated. The
product was dissolved in DCM and the organic phase was washed with 30% citric acid,
sat. NaCl and sat. NaHCO3, dried over Na2SO4 and evaporated. The product was
purified and the diastereomers were separated by flash chromatography (33% EtOAc in
PE). Yield 0.46 g, 96%. Analytical data for 7a: 1H NMR ? 1.89-1.95 (m, 2 H), 2.09-
2.15 (m, 1 H), 2.18-2.27 (m, 5 H), 2.55-2.64 (m, 3 H), 2.67-2.70 (m, 2 H), 2.80-2.88 (m,
1 H), 3.66-3.69 (m, 1 H), 3.83-3.87 (m, 1 H), 3.89-3.94 (m, 1 H), 4.75-4.77 (m, 1 H),
6.83-6.85 (m, 1 H), 7.16-7.19 (m, 3 H), 7.26-7.29 (m, 2 H). 13C NMR ? 25.2, 25.7,
27.9, 30.0, 33.7, 35.1, 37.8, 46.5, 46.8, 47.5, 118.8, 125.9, 128.3, 128.5, 141.6, 144.6,
146.4, 173.7, 198.3. Anal. (C21H24N2O2·0.1 H2O) C, H, N. ESI-MS m/z 337.0 [M + H]+.
Analytical data for 7b*: 1H NMR ? 1.88-2.00 (m, 2 H), 2.05-2.44 (m, 6 H), 2.53-2.73
(m, 5 H), 2.81-2.92 (m, 1 H), 3.45-3.54 (m, 1 H), 3.56-3.61 (m, 0.6 H), 3.87-3.93 (m, 1
H), 4.19-4.23 (m, 0.4 H), 4.66-4.68 (dd, J = 2.1, 8.3 Hz, 0.4 H), 5.35-5.37 (dd, J = 2.9,
7.4 Hz, 0.6 H), 6.80-6.82 (m, 0.4 H), 6.86-6.88 (m, 0.6 H), 7.15-7.20 (m, 3 H), 7.25-
7.29 (m, 2 H). 13C NMR ? 23.4, 25.1, 25.8, 25.8, 28.1. 28.5, 30.3, 32.2, 33.7, 33.9, 35.1,
35.1, 37.8, 37.9, 46.3, 46.6, 46.7, 47.6, 47.7, 48.0, 118.0, 119.5, 125.8, 126.0, 128.3,
128.4, 128.5, 128.6, 141.5, 141.8, 144.9, 144.9, 145.7, 147.3, 173.7, 173.9, 197.9,
198.8. Anal. (C21H24N2O2·0.2 H2O) C, H, N. ESI-MS m/z 337.1 [M + H]+.
(±)-1-[2-(4-Phenylbutyryl)-cyclopent-2-enecarbonyl]-pyrrolidine (8). The
product was synthesized from 4 (0.23 g, 0.89 mmol) and pyrrolidine (75 ml, 0.9 mmol)
as described for cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-[2(S)-
(acetoxyacetyl)-pyrrolidine] amide, but in the 2nd addition of Et3N, 1.1 eq instead of 3.3
eq was used. The product was purified by flash chromatography (50% EtOAc in PE).
Yield 0.21 g, 77%. 1H NMR ? 1.80-2.08 (m, 7 H), 2.14-2.22 (m, 1 H), 2.50-2.57 (m, 1
H), 2.59-2.74 (m, 4 H), 2.77-2.84 (m, 1 H), 3.38-3.51 (m, 3 H), 3.84-3.93 (m, 2 H),
6.78-6.80 (m, 1 H), 7.15-7.18 (m, 3 H), 7.25-7.28 (m, 2 H). 13C NMR ? 24.4, 25.7, 26.1,
* Compound 7b clearly shows two rotamers for each carbon.
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28.1, 33.6, 35.2, 38.0, 45.8, 46.9, 47.8, 125.8, 128.3, 128.5, 141.8, 145.3, 145.4, 172.9,
198.3. Anal. (C20H25NO2) C, H, N. ESI-MS m/z 312.2 [M + H]+.
(±)-Cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-pyrrolidine amide
(9). The product was synthesized from 3 (0.46 g, 1.88 mmol) and pyrrolidine (0.16 ml,
1.92 mmol) as described for cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-
[2(S)-(acetoxyacetyl)-pyrrolidine] amide, but in the 2nd addition of Et3N, 1.1 eq instead
of 3.3 eq was used. The product was purified by flash chromatography (EtOAc). Yield
0.39 g, 69%. 1H NMR ? 1.80-1.86 (m, 2 H), 1.89-2.07 (m, 3 H), 2.23-2.30 (m, 1 H),
2.46-2.53 (m, 1 H), 2.62-2.69 (m, 1 H),  3.37-3.50 (m, 3 H), 3.77-3.81 (m, 1 H), 4.03-
4.07 (m, 1 H), 4.32 (dd, J = 5.3, 15.0 Hz, 1 H), 4.57 (dd, J = 6.4, 15.0 Hz, 1 H), 6.45-
6.46 (m, 1 H), 6.69 (br t, 1 H), 7.22-7.26 (m, 1 H), 7.27-7.32 (m, 4 H). 13C NMR ? 24.4,
26.1, 28.1, 32.8, 43.4, 45.9, 46.9, 49.5, 127.2, 127.6, 128.6, 137.6, 138.6, 140.0, 165.6,
173.2. Anal. (C18H22N2O2·0.2 H2O) C, H, N. ESI-MS m/z 299.2 [M + H]+.
2-Benzylcarbamoyl-cyclopent-1-enecarboxylic acid (10). To a solution of
benzylamine (1.2 ml, 10.9 mmol) in 5 ml of THF was added cyclopent-1-ene-1,2-
dicarboxylic anhydride (0.5 g, 3.6 mmol) in 8 ml of THF dropwise at 0 ºC. The mixture
was stirred overnight at rt. THF was evaporated and the residue was dissolved in 2 M
NaOH aq. The aqueous phase was washed with DCM, acidified with 3 M HCl and
extracted with DCM. The organic phase was dried over Na2SO4 and evaporated. Yield
0.74 g, 83%.
1-[2-Benzylcarbamoyl-cyclopent-1-enecarbonyl]-pyrrolidine (11). The product
was synthesized from 10 (0.25 g, 1.02 mmol) and pyrrolidine (85 ?L, 1.0 mmol) as
described for cyclopent-2-ene-1,2-dicarboxylic acid 2-benzylamide 1-[2(S)-
(acetoxyacetyl)-pyrrolidine] amide, but in the 2nd addition of Et3N, 1.1 eq instead of 3.3
eq was used. The product was purified by flash chromatography (EtOAc). Yield 0.20 g,
66%. 1H NMR ? 1.79-1.83 (m, 4 H), 1.97 (qui, J = 7.6 Hz, 2 H), 2.71-2.78 (m, 4 H),
3.28-3.30 (m, 2 H), 3.34-3.37 (m, 2 H), 4.45 (d, J = 5.9 Hz, 2 H), 7.22-7.31 (m, 5 H).
13C NMR ? 22.2, 24.1, 25.8, 33.8, 35.7, 43.2, 45.4, 47.3, 127.3, 127.7, 128.6, 136.9,
138.6, 142.0, 165.0, 168.2. Anal. (C18H22N2O2) C, H, N. ESI-MS m/z 299.1 [M + H]+.
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7 AN INTRODUCTION OF A PYRIDINE GROUP INTO THE
STRUCTURE OF PROLYL OLIGOPEPTIDASE INHIBITORS*
Abstract. A series of ionizable prolyl oligopeptidase inhibitors were developed through
the introduction of a pyridyl group to the P3 position of the prolyl oligopeptidase
inhibitor structure. The study was performed on previously developed prolyl
oligopeptidase inhibitors with proline mimetics at the P2 position. The 3-pyridyl group
resulted in equipotent compounds as compared to the parent compounds. It was shown
that the pyridyl group improves water solubility, and in combination with a 5(R)-tert-
butyl-L-prolyl group at the P2 position, good lipophilicity can be achieved.
* Reproduced with permission from: Jarho EM, Venäläinen JI, Juntunen J, Yli-Kokko
AL, Vepsäläinen J, Christiaans JAM, Forsberg MM, Järvinen T, Männistö PT, Wallén
EAA:  Bioorganic & Medicinal Chemistry Letters 16: 5590–5593, 2006
 Copyright ã 2006 Elsevier Ltd.
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7.1 Introduction
Unlike many small-molecule drugs, typical POP inhibitors are unionizable compounds.
An ionizable group may improve water solubility and it also allows salt formation. In
later stages of drug development, the proper choice of salt can be used to modify
stability, solubility, and pharmaceutical processing properties.
Two unionizable POP inhibitors with different proline mimetics at the P2 positions
(Figure 1) were earlier presented by our group (Wallén et al. 2003, Chapter 6). These
compounds were further investigated as to whether an ionizable pyridyl group could be
introduced into the structure. The pKa value of pyridine is 5.2 and thus, it is mostly in
the unionized form at the physiological pH 7.4. However, a significant fraction is in the
ionized form in the slightly acidic environment of the duodenum (Dressman et al.
1990), which allows dissolution that is a prerequisite for the absorption.
A literature search revealed that a pyridyl moiety has occasionally been included in
some series of POP inhibitors, but no systematic study regarding the position and the
substitution of the pyridine group has been performed (Tsuru et al. 1988, Saito et al.
1991, Nakajima et al. 1992, Tsutsumi et al. 1994, Tsuda et al. 1996a, Tsuda et al.
1996b, Vendeville et al. 2002). One potent peptide-like POP inhibitor, which possessed
a pyridine-2-carboxyl amide moiety at the P3 position, was reported by Tsuda et al.
(1996a). In the present study, the phenyl group at the P3 site was successfully replaced
by a pyridyl group in two series of POP inhibitors. The chain length and the substitution
pattern were optimized. The effect of the pyridyl moiety on lipophilicity and water
solubility was also studied.
NN
O O
NN
H
O O
P3 P2 P1 P3 P2 P1
IC50 = 9.0 nM (compound 4) IC50 = 1.2 nM (compound 12)
Figure 1. Previously published POP inhibitors, which possess proline mimetics at the
P2 site.
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7.2 Methods
The synthetic routes for the novel compounds are presented in Scheme 1. Compounds 1,
4 (Chapter 6), and 12 (Wallén et al. 2003) were synthesized as described earlier.
Compound 1 was activated with trimethylacetyl chloride and reacted with pyrrolidine at
0 °C to obtain (±)-5-(pyrrolidine-1-carbonyl)-cyclopent-1-enecarbaldehyde (2). The
aldehyde group of compound 2 was oxidized with NaClO2 to obtain (±)-5-(pyrrolidine-
1-carbonyl)-cyclopent-1- enecarboxylic acid (3). Compound 3 was reacted with DCC,
HOBt, and an appropriate amine to yield compounds 5a–c, 6, and 7a–c. Boc-5(R)-tert-
butyl-L-proline (8) was prepared according to published procedures (Beausoleil et al.
1996, Sim and Rapoport 1999), with slight modifications as described earlier (Wallén et
al. 2003). Boc-5(R)-tert-butyl-L-proline (8) and Boc-L-proline (9) were activated with
trimethylacetyl chloride and reacted with pyrrolidine to yield compounds 10 and 11,
respectively. Compounds 10 and 11 were deprotected in HCl-saturated ethyl acetate to
yield 5(R)-tert-butyl-L-prolyl-pyrrolidine and L-prolyl-pyrrolidine. 4-(Pyridin-3-yl)
butyric acid and 3-(pyridin-3-yl)propionic acid were reacted with EDC, HOBt, and
5(R)-tert-butyl-L-prolyl-pyrrolidine to yield compounds 13a and 13b, respectively. 4-
(Pyridin-3-yl)butyric acid was prepared according to a published procedure (Menghin et
al. 2003) with small modifications. L-Prolyl-pyrrolidine was reacted with 3-(pyridin-3-
N
OO
OHN
OO
HOH
OO
H N
OO
N
H
nX
NN
OO
O
R
NN
OO
n
N
R
N
OO
O
R
OH
n = 1, X = N
5a: 2-subst.
5b: 3-subst.
5c: 4-subst.
n = 2
6: X=C
7a: X=N, 2-subst.
7b: X=N, 3-subst.
7c: X=N, 4-subst.
R = H
14a: n=2
14b: n=1
14c: n=0
R = t-Bu
13a: n=3
13b: n=2
1 2 3
i ii iii
8: R=t-Bu
9: R=H
iv
10: R=t-Bu
11: R=H
v
vi for 13a-b, 14b
vii for 14a
viii for 14c
Scheme 1. (i) 1. Et3N, (CH3)3CCOCl/CH2Cl2, 0 °C, 2. Et3N, pyrrolidine/CH2Cl2, 0 °C;
(ii) resorcinol, NaH2PO4×H2O, NaClO2/t-BuOH, H2O; (iii) an appropriate amine, Et3N,
HOBt, DCC/CH3CN, 0–20 °C; (iv) 1. Et3N, (CH3)3CCOCl/CH2Cl2, 0 °C, 2. Et3N,
pyrrolidine/CH2Cl2, room temperature; (v) HCl/EtOAc; (vi) an appropriate carboxylic
acid, Et3N, HOBt, EDC×HCl/CH2Cl2, 0–20 °C; (vii) 3-pyridin-3-yl-propionyl chloride
HCl, Et3N/CH2Cl2, 0–20 °C; (viii) DMAP, nicotinoyl chloride HCl/pyridine.
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yl)propionyl chloride and nicotinoyl chloride to yield compounds 14a and 14c,
respectively. EDC and HOBt were used to couple L-prolyl-pyrrolidine with (pyridin-3-
yl)acetic acid to obtain compound 14b.
7.3 Results and discussion
Compound 4 (Chapter 6) possesses a cyclopentenecarbonyl moiety at the P2 position.
The IC50 value of compound 4 is 9 nM for the racemic mixture. It was chosen as the
parent compound for the first series of compounds presented in Table 1. The
replacement of the phenyl group of compound 4 with a 2- or 4-pyridyl group gave
compounds 5a and 5c, respectively. These substitutions resulted in over 2 times lower
potency. However, the replacement with a 3-pyridyl group gave compound 5b, which
was equipotent with the parent compound 4. In order to further optimize the position of
the pyridyl group, the chain length of compounds 4 and 5a–5c was extended by one
methylene group, which resulted in compounds 6 and 7a–c, respectively. The extension
of the chain of compound 4 caused a 6-fold increase in potency; the IC50 value of
Table 1. Inhibitory activities with 95% confidence intervals and log P values of the (±)-
5-(pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid amides.
N
OO
N
nX
Compound X Subst n IC50 (nM)a log Pb
4 C - 1   9.0 (5.5-15) 1.6c
5a N 2 1 24 (22-26) 0.3d
5b N 3 1   9.7 (8.5-11) 0.4d
5c N 4 1 19 (15-26) 0.4d
6 C - 2   1.5 (1.3-1.9) 1.9c
7a N 2 2   5.2 (4.4-6.2) 0.6d
7b N 3 2   2.2 (1.9-2.6) 0.6d
7c N 4 2   4.8 (3.8-6.1) 0.5d
a The IC50 values were determined against POP from porcine brain (Venäläinen et al. 2002).
b The reported values are for the unionized species.
c Determined with the shake-flask method.
d Determined with pH metric titration using a Sirius PCA200 automatic titrator.
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compound 6 was 1.5 nM. Again, the replacement of the P3 phenyl group by the 3-
pyridyl moiety gave the most potent compound 7b (2.2 nM), while the 2- and 4-pyridyl
analogs, 7a and 7c, were less active. Compound 7b was almost equipotent with
compound 6 and over 4 times more potent than its shorter counterpart 5b. These results
confirmed that the 3-pyridyl group can be used to replace the phenyl group at the P3
position of POP inhibitors and the optimal chain length is the same as for the phenyl
group, despite the difference in their polarities.
High lipid solubility is a prerequisite for the passive brain penetration of small-
molecule drugs (Pardridge 2005) and the theoretical optimum for the log P value is near
2 (Tute 1996). Although lipophilicity is not the only factor that determines brain
penetration and the optimal lipophilicity can vary between compound classes, it should
be taken into account when novel CNS targeted compounds are designed. The log P
values were determined for compounds 4, 5a–c, 6, and 7a–c (Table 1). The presented
log P values for compounds 5a–c and 7a–c are values for the unionized species, which
are mainly found at the physiological pH 7.4 (the pKa values range between 4.4 and
5.5). The log P value of compound 4 was 1.6. The replacement of the phenyl moiety by
the more polar pyridyl moiety dropped the log P values to 0.3–0.4 for compounds 5a–
5c. The extension of the chain increased the log P value to 1.9 for compound 6, but
again the replacement of the phenyl moiety by the pyridyl moiety dropped the log P
values to 0.5–0.6 for compounds 7a–7c.
Compound 12 (Wallén et al. 2003) possesses a lipophilic 5(R)-tert-butyl-L-prolyl
moiety at the P2 position. The IC50 value of compound 12 is 1.2 nM and the log P value
is 3.3. It was chosen as the parent compound for the second series of compounds
presented in Table 2. In this series, only the 3-pyridyl group was studied because it had
given the most potent compounds in the first series. The replacement of the P3 phenyl
group of compound 12 by the 3-pyridyl group resulted in compound 13a having an IC50
value of 2.1 nM. It was only slightly less potent than compound 12 and equipotent with
compound 7b, which was the most potent pyridyl derivative in the first series. However,
it has to be kept in mind that 13a possesses the more active configuration of L-proline,
while 7b was tested as a racemic mixture. To study whether the change of the skeleton
affects the optimal position of the pyridyl group, the P3 chain of compound 13a was
shortened by one methylene group resulting in compound 13b. The results were
consistent with the first series; a decrease in the chain length decreased the potency and
the IC50 value of compound 13b was 13 nM. The effect of even shorter chain lengths
was studied with compounds 14a–c, which have an L-prolyl residue at the P2 site. The
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Table 2. Inhibitory activities with 95% confidence intervals and log P values of the N-
alkanoyl 5(R)-tert-butyl-L-prolyl-pyrrolidines and N-alkanoyl L-prolyl-pyrrolidines.
NN
OO
n
X
R
Compound X n R IC50 (nM)a log Pb
12 C 3 t-Bu   1.2 (1.0-1.4) 3.3c
13a N 3 t-Bu   2.1 (1.9-2.4) 2.0d
13b N 2 t-Bu 13 (8.4-20) 1.8d
14a N 2 H 30 (24-39) 0.3d
14b N 1 H 56 (46-70) -0.2d
14c N 0 H 44 (29-67) -0.3d
15 C 3 H   2.2 (1.9-2.5) 1.8c
a The IC50 values were determined against POP from porcine brain (Venäläinen et al. 2002).
b The reported values are for the unionized species.
c Determined with the shake-flask method.
d Determined with pH metric titration using a Sirius PCA200 automatic titrator.
change to an L-prolyl group at the P2 site was made to avoid steric hindrance that the
bulky 5(R)-tert-butyl group causes when the P3 ring is brought closer to the P2 ring.
The removal of the 5(R)-tert-butyl group of compound 13b resulted in compound 14a
and in over 2 times lower potency; the IC50 value of 14a was 30 nM. The P3 chain
length of compound 14a was shortened by one and two methylene groups to obtain
compounds 14b and 14c, respectively. Both compounds were less potent than
compound 14a, confirming that the optimal position for the pyridyl moiety is three
carbon atoms away from the carbonyl group.
The log P values of the second series of compounds are presented in Table 2. Again,
the reported log P values are for the unionized species. The replacement of the phenyl
moiety of compound 12 by the polar pyridyl moiety dropped the log P value from 3.3 to
the theoretical optimum 2.0 for compound 13a. The drop was of the same order of
magnitude as in the first series of the compounds; 20-fold drop in partition coefficient P.
Compound 13b with shorter chain length had a log P value 1.8. A comparison between
the log P values of compounds 13b and 14a (log P = 0.3) shows that the tert-butyl
group greatly increases lipophilicity and consequently, the log P values of compounds
14a–c were low. The IC50 and log P values of compound 13a are comparable to those of
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the unionizable reference compound 15, SUAM-1221 (Table 2), which is a potent POP
inhibitor that can penetrate into the CNS (Atack et al. 1991).
The water solubility was determined for the parent compounds of the two series,
compounds 4 and 12, their 3-pyridyl analogs 5b and 13a, and for the reference
compound 15, SUAM-1221. The solubilities were determined after 3-day-shaking in 50
mM phosphate buffer (pH 7.4, ionic strength 0.15 M) up to 6 mg/ml, which can be
considered adequate even for high-dose compounds with poor permeability (Lipinski
2000). While the solubility of compound 15 was at least 6 mg/ml, compounds 4 and 12
with proline mimetics at the P2 sites had decreased values; 3.0 and 0.9 mg/ml,
respectively. However, the change of the phenyl moiety to the 3-pyridyl moiety
overcame this decrease and the solubilities of compounds 5b and 13a were at least 6
mg/ml.
7.4 Conclusions
The present study proved that a pyridyl group can be introduced to the P3 position of
the POP inhibitor structure. However, the inhibitory activity was dependent on the
substitution of the pyridyl group and the P3 chain length. The 3-pyridyl group gave the
most potent compounds and its optimal position was the same as for the phenyl group;
three atoms between the P3 carbonyl group and the aromatic ring. The studied parent
compounds had decreased water solubility. The introduction of an ionizable pyridyl
group gave excellent water solubility to the novel compounds. In conclusion, the
introduction of the 3-pyridyl group at the P3 position in combination with a 5(R)-tert-
butyl-L-prolyl moiety at P2 position was used to optimize the physico-chemical
properties while maintaining an excellent inhibitory activity.
7.5 Synthetic procedures and analytical data
General procedure A. A solution of trimethylacetyl chloride (1 eq.) in DCM is added
dropwise to a solution of carboxylic acid (1.0 eq.) and triethylamine (1.1 eq.) in DCM at
0 °C. The activation of carboxylic acid is let to proceed 1 h at 0 °C. Triethylamine (1.1
eq.) and amine (1.0-1.1 eq.) are added in this order at 0 °C (if the amine is in the form of
a trifluoroacetic acid salt or HCl salt, then 3.3 eq. of triethylamine is used). The reaction
mixture is stirred appropriate time at 0 °C or at room temperature (rt). The DCM
solution is washed with 30% citric acid aq, saturated NaCl aq. and saturated NaHCO3
aq., dried over anhydrous Na2SO4 and evaporated, yielding the crude product.
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General procedure B. Carboxylic acid (1 eq.), amine (1.5 eq.), HOBt (1.5 eq.) and
Et3N (1.5 eq.) were dissolved in CH3CN. DCC (1.5 eq.) in CH3CN was added dropwise
at 0 °C. The reaction mixture was stirred 30 min. at 0 °C and overnight at rt. The
mixture was filtered and evaporated and the residue was dissolved in DCM. The organic
phase was washed with sat. NaCl aq. and sat. NaHCO3 aq., dried over Na2SO4 and
evaporated.
General procedure C. Compound 10 or compound 11 (1 eq.) was dissolved in 2-3
M HCl in EtOAc (1 mmol/2-3 ml). The mixture was stirred for 45-60 min. and
evaporated. The yielded 5(R)-tert-butyl-L-prolyl-pyrrolidine hydrochloride or L-prolyl-
pyrrolidine hydrochloride, carboxylic acid (1 eq.), HOBt·H2O (1.5 eq.) and Et3N (4 eq.)
were dissolved in DCM. EDC hydrochloride (1.5 eq.) in DCM was added dropwise at 0
°C. The reaction mixture was stirred 30 min. at 0 °C and overnight at rt. The mixture
was diluted with DCM and the organic phase was washed with sat. NaCl aq. and sat.
NaHCO3 aq., dried over Na2SO4 and evaporated.
(±)-2-Formylcyclopent-2-enecarboxylic acid (1). Dichloroacetyl chloride (30.0 ml,
312 mmol) and freshly distilled cyclopentadiene (26.0 ml, 312 mmol) were dissolved in
250 ml of hexane. Et3N (44.0 ml, 316 mmol) in 200 ml of hexane was added at 0 °C
during 2 hours. The reaction was let to proceed overnight at rt. The reaction mixture
was filtered, evaporated and dissolved in 1 l of 1 M NaHCO3 aq. The mixture was
stirred for 4 hours at 75 °C and, after cooling, filtered, washed with Et2O and acidified
with 3 M HCl. Water was then evaporated and the residue was stirred overnight with
DCM and Na2SO4. The mixture was filtered and evaporated. The product was first
purified by flash chromatography (EtOAc:toluene:CH3COOH 50:50:1) and then
crystallized from cyclohexane, yielding the product as white needles (9.7 g, 22%). 1H
NMR ? 2.32-2.46 (m, 2 H), 2.63-2.71 (m, 1 H), 2.77-2.85 (m, 1 H), 3.81-3.85 (m, 1 H),
7.11-7.12 (m, 1 H), 9.77 (s, 1 H).
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarbaldehyde (2). Compound 2
was synthesized from compound 1 (2.0 g, 14.3 mmol) and pyrrolidine (1.2 ml, 14.3
mmol) according to the general procedure A. The reaction mixture was stirred 1 h at 0
°C. The product was purified by flash chromatography (2-10% MeOH in EtOAc)
yielding white solid, 2.6 g, 94%. 1H NMR ? 1.81-2.07 (m, 4 H), 2.16-2.30 (m, 2 H),
2.58-2.65 (m, 1 H), 2.85-2.93 (m, 1 H), 3.40-3.53 (m, 3 H), 3.86-3.91 (m, 2 H), 7.04-
7.05 (m, 1 H), 9.75 (s, 1 H).
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (3). To a solution
of compound 2 (900 mg, 4.7 mmol) in t-BuOH (15 ml) and H2O (7 ml) were added
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resorcinol (900 mg, 8.2 mmol), NaH2PO4 (840 mg, 7.0 mmol) and 80% NaClO2 (630
mg, 5.6 mmol). The mixture was stirred overnight at rt. Saturated Na2SO3 aq. (10 ml)
was added and the mixture was washed with Et2O. The mixture was acidified with 2 M
HCl and extracted with CHCl3:EtOH 1:1. The organic phase was dried over Na2SO4 and
evaporated. Yield 900 mg, 91%. 1H NMR ? 1.82-1.87 (m, 2 H), 1.92-2.00 (m, 2 H),
2.04-2.12 (m, 1 H), 2.27-2.34 (m, 1 H), 2.49-2.56 (m, 1 H), 2.70-2.77 (m, 1 H), 3.42-
3.56 (m, 3 H), 3.71-3.76 (m, 1 H), 3.91-3.94 (m, 1 H), 7.01-7.02 (m, 1 H).
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (pyridin-2-
ylmethyl)-amide (5a). Compound 5a was synthesized from compound 3 (120 mg, 0.57
mmol) and 2-(aminomethyl)pyridine (89 ml, 0.86 mmol) according to general procedure
B in 7 ml of CH3CN. The product was purified by flash chromatography (25% MeOH
in EtOAc). Yield 100 mg, 59%. 1H NMR ? 1.81-2.09 (m, 5 H), 2.24-2.31 (m, 1 H),
2.49-2.55 (m, 1 H), 2.68-2.75 (m, 1 H), 3.40-3.53 (m, 3 H), 3.81-3.85 (m, 1 H), 4.04-
4.07 (m, 1 H) 4.56 (dd, J = 5.1, 16.4 Hz, 1 H), 4.62 (dd, J = 5.3, 16.4 Hz, 1 H), 6.54-
6.55 (m, 1 H), 7.16-7.18 (m, 1 H), 7.23 (br, 1 H), 7.26-7.28 (m, 1 H), 7.62-7.66 (m, 1
H), 8.51-8.52 (m, 1 H). 13C NMR ? 24.4, 26.2, 28.2, 32.8, 44.5, 45.9, 46.9, 49.3, 121.9,
122.2, 136.7, 137.9, 139.9, 148.9, 156.8, 165.5, 173.1. Anal. (C17H21N3O2·0.2 H2O) C,
H, N: calcd, 13.87; found, 14.28. ESI-MS m/z 300.2 [M + H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (pyridin-3-
ylmethyl)-amide (5b). Compound 5b was synthesized from compound 3 (190 mg, 0.91
mmol) and 3-(aminomethyl)pyridine (139 ml, 1.36 mmol) according to general
procedure B. The product was purified by flash chromatography (25% MeOH in
EtOAc). Yield 140 mg, 51%. 1H NMR ? 1.80-1.89 (m, 2 H), 1.90-2.03 (m, 3 H), 2.25-
2.33 (m, 1 H), 2.48-2.54 (m, 1 H), 2.59-2.65 (m, 1 H), 3.39 (t, J = 6.9 Hz, 2 H), 3.46-
3.50 (m, 1 H), 3.75-3.80 (m, 1 H), 4.04-4.07 (m, 1 H), 4.25 (dd, J = 5.5, 15.2 Hz, 1 H),
4.60 (dd, J = 6.5, 15.2 Hz, 1 H), 6.52-6.53 (m, 1 H), 7.22 (dd, J = 4.8, 7.7 Hz, 1 H), 7.33
(br, 1 H), 7.65 (d, J = 7.7 Hz, 1 H), 8.48 (dd, J = 1.3, 4.8 Hz, 1 H), 8.54 (d, J = 1.5 Hz, 1
H). 13C NMR ? 24.4, 26.1, 28.1, 32.8, 40.7, 46.0, 46.9, 49.5, 123.5, 134.6, 135.4, 138.2,
139.7, 148.5, 149.2, 165.8, 173.4. Anal.( C17H21N3O2·0.2 H2O) C, H, N. ESI-MS m/z
300.2 [M + H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (pyridin-4-
ylmethyl)-amide (5c). Compound 5c was synthesized from compound 3 (150 mg, 0.72
mmol) and 4-(aminomethyl)pyridine (110 ml, 1.08 mmol) according to general
procedure B. The product was purified by flash chromatography (MeOH:EtOAc 1:1).
Yield 170 mg, 79%. 1H NMR ? 1.81-1.86 (m, 2 H), 1.90-2.06 (m, 3 H), 2.28-2.35 (m, 1
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H), 2.50- 2.57 (m, 1 H), 2.62-2.69 (m, 1 H), 3.39 (t, J = 6.9 Hz, 2 H), 3.46-3.50 (m, 1
H), 3.73-3.78 (m, 1 H), 4.05-4.08 (m, 1 H), 4.30 (dd, J = 5.8, 16.1 Hz, 1 H), 4.57 (dd, J
= 6.5, 16.1 Hz, 1 H), 6.55-6.56 (m, 1 H), 7.15 (t, 1 H), 7.21 (d, J = 5.6 Hz, 2 H), 8.52 (d,
2 H). 13C NMR ? 24.3, 26.0, 28.0, 32.8, 42.0, 45.9, 46.9, 49.5, 122.1, 138.4, 139.6,
148.1, 149.7, 165.8, 173.5. Anal.(C17H21N3O2·0.2 H2O) C, H, N. ESI-MS m/z 300.2 [M
+ H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid phenethyl-amide
(6). Compound 6 was synthesized from compound 3 (167 mg, 0.80 mmol) and
phenethylamine (150 ml, 1.20 mmol) according to general procedure B in 11 ml of
CH3CN. The residue was dissolved in EtOAc and the organic phase was washed with
30% citric acid, sat. NaCl aq. and sat. NaHCO3 aq. The product was purified by flash
chromatography (5% MeOH in EtOAc). Yield 130 mg, 52%. 1H NMR ? 1.80-2.04 (m,
5 H), 2.21-2.28 (m, 1 H), 2.44-2.50 (m, 1 H), 2.59-2.65 (m, 1 H), 2.81 (t, J = 7.0 Hz, 2
H), 3.35-3.49 (m, 4 H), 3.56-3.63 (m, 1 H), 3.75-3.80 (m, 1 H), 3.99-4.02 (m, 1 H),
6.33-6.34 (m, 1 H), 6.48 (t, 1 H), 7.18-7.21 (m, 3 H), 7.27-7.30 (m, 2 H). 13C NMR ?
24.4, 26.1, 28.1, 32.7, 35.7, 40.6, 45.9, 46.9, 49.4, 126.3, 128.5, 128.8, 137.3, 139.2,
140.1, 165.6, 173.3. Anal.(C19H24N2O2·0.2 H2O) C, H, N. ESI-MS m/z 313.1 [M + H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (2-pyridin-2-yl-
ethyl)-amide (7a). Compound 7a was synthesized from compound 3 (150 mg, 0.72
mmol) and 2-(2-aminoethyl)pyridine (130 ml, 1.09 mmol) according to general
procedure B in 14 ml of CH3CN. The product was purified by flash chromatography
(25% MeOH in EtOAc). Yield 183 mg, 81%. 1H NMR ? 1.79-2.06 (m, 5 H), 2.19-2.27
(m, 1 H), 2.44-2.51 (m, 1 H), 2.63-2.71 (m, 1 H), 3.00 (t, J = 6.4 Hz, 2 H), 3.39-3.52
(m, 3 H), 3.57-3.63 (m, 1 H), 3.69-3.75 (m, 1 H), 3.80-3.84 (m, 1 H), 3.99-4.02 (m, 1
H), 6.35-6.37 (m, 1 H), 7.03 (t, 1 H), 7.13-7.15 (m, 1 H), 7.17 (d, J = 7.7 Hz, 1 H), 7.61
(dt, J = 1.8, 7.7 Hz, 1 H), 8.52 (d, J = 4.9 Hz, 1 H). 13C NMR (solvent as an internal
standard, 77.16 ppm) ? 24.3, 26.1, 28.1, 32.7, 36.9, 38.7, 45.8, 46.8, 49.1, 121.5, 123.5,
136.6, 137.1, 140.2, 149.1, 159.7, 165.3, 173.1. Anal.(C18H23N3O2·0.3 H2O) C, H, N:
calcd, 13.18; found, 13.73. ESI-MS m/z 314.2 [M + H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (2-pyridin-3-yl-
ethyl)-amide (7b). Compound 7b was synthesized from compound 3 (600 mg, 2.9
mmol) and 3-(2-aminoethyl)pyridine (530 mg, 4.3 mmol) according to general
procedure B in 14 ml of CH3CN. The product was purified by flash chromatography
(20% MeOH in EtOAc). Yield 225 mg, 25%. 1H NMR ? 1.82-2.05 (m, 5 H), 2.24-2.31
(m, 1 H), 2.45-2.51 (m, 1 H), 2.57-2.63 (m, 1 H), 2.83 (t, J = 7.1 Hz, 2 H), 3.34-3.49
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(m, 4 H), 3.56-3.62 (m, 1 H), 3.73-3.78 (m, 1 H), 3.99-4.01 (m, 1 H), 6.37-6.38 (m, 1
H), 6.73 (t, 1 H), 7.21-7.24 (m, 1 H), 7.55 (d, J = 7.8 Hz, 1 H), 8.44-8.46 (m, 2 H). 13C
NMR ? 24.4, 26.1, 28.1, 32.6, 32.9, 40.3, 46.0, 46.9, 49.5, 123.5, 134.8, 136.4, 137.7,
139.9, 147.7, 150.1, 165.9, 173.3. Anal.(C18H23N3O2·0.8 H2O) C, H, N. ESI-MS m/z
314.2 [M + H]+.
(±)-5-(Pyrrolidine-1-carbonyl)-cyclopent-1-enecarboxylic acid (2-pyridin-4-yl-
ethyl)-amide (7c).  Compound 7c was synthesized from compound 3 (470 mg, 2.2
mmol) and 4-(2-aminoethyl)pyridine (410 mg, 3.4 mmol) according to general
procedure B in 14 ml of CH3CN. The product was purified by flash chromatography
(20% MeOH in EtOAc). Yield 460 mg, 65%. 1H NMR ? 1.82-2.03 (m, 5 H), 2.24-2.32
(m, 1 H), 2.44-2.52 (m, 1 H), 2.57-2.64 (m, 1 H), 2.83 (t, J = 7.1 Hz, 2 H), 3.38-3.49
(m, 4 H), 3.56-3.63 (m, 1 H), 3.71-3.75 (m, 1 H), 3.97-4.01 (m, 1 H), 6.35-6.36 (m, 1
H), 6.62 (t, 1 H), 7.14 (d, J = 5.9 Hz, 2 H), 8.50 (d, J = 5.9 Hz, 2 H). 13C NMR ? 24.4,
26.1, 28.1, 32.6, 35.1, 39.6, 46.0, 46.9, 49.6, 124.3, 137.6, 139.9, 148.4, 149.7, 165.9,
173.2. Anal.(C18H23N3O2·0.6 H2O) C, H, N. ESI-MS m/z 314.1 [M + H]+.
Boc-5(R)-tert-butyl-L-prolyl-pyrrolidine (10). Compound 10 was synthesized
from Boc-5(R)-tert-butyl-L-proline (8) (540 mg, 2.0 mmol) and pyrrolidine (170 ml, 2.0
mmol) according to general procedure A. The reaction mixture was stirred 2.5 h at rt.
The product was purified by flash chromatography (PE:EtOAc 2:1). Yield 650 mg,
100%. 1H NMR ? 1.01 (s, 9 H), 1.42 (s, 9 H), 1.80–2.11 (m, 8 H), 3.36–3.70 (m, 4 H),
3.79 (d, J = 7.9 Hz, 1 H), 4.39 (br s, 1 H).
Boc-L-prolyl-pyrrolidine (11). Compound 11 was synthesized from Boc-L-proline
(9) (1.72 g, 7.99 mmol) and pyrrolidine (670 ml, 8.0 mmol) according to general
procedure A. The reaction mixture was stirred 5 h at rt. The product was purified by
flash chromatography (5% MeOH in DCM). Yield 2.1g, 98%.
4-(Pyridin-3-yl)butyric acid. STEP 1. To a solution of 3-(pyridin-3-yl)propan-1-ol
(1.3 ml, 10 mmol) in DCM (28 ml) was added SOCl2 (3.6 ml, 50 mmol) in DCM (7 ml)
dropwise at 0 °C. The mixture was stirred overnight at rt and evaporated to yield 3-(3-
chloropropyl)pyridine hydrochloride (100%). 13C NMR ? 29.8, 32.7, 43.3, 126.9, 138.9,
140.8. 141.5, 145.8. The product was stored as the HCl salt. It was dissolved in DCM,
washed with sat. NaHCO3 aq., dried over Na2SO4 and evaporated just before further
use. STEP 2. To a suspension of NaCN (280 mg, 5.8 mmol) and KI (catalytic amount)
in dry DMSO (5 ml) was added 3-(3-chloropropyl)pyridine (690 mg, 4.4 mmol) in dry
DMSO (15 ml) dropwise at 80 °C. The mixture was refluxed for 9 h, let to cool down to
rt and evaporated to yield 4-(pyridin-3-yl)butyronitrile. The product was used without
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purification. 13C NMR (DMSO, solvent as an internal standard, 39.52 ppm) ? 15.8,
26.1, 31.0, 120.1, 123.4, 135.7, 135.7, 147.4, 149.5.
STEP 3. All product from STEP 2 was dissolved in EtOH (10 ml) and KOH (1.0 g,
17.8 mmol) in H2O (10 ml) was added. The mixture was refluxed overnight. EtOH was
evaporated and the aqueous phase washed with DCM. The pH of the aqueous phase was
adjusted to 5 with HCl aq. and the product was extracted with DCM (continuous
extraction). Yield (steps 2 and 3) 400 mg, 55%. 13C NMR (solvent as an internal
standard, 77.16 ppm) ? 25.7, 31.6, 32.8, 122.9, 135.6, 136.5, 146.7, 149.1, 174.6.
4-(Pyridin-3-yl)butanoyl-5(R)-tert-butyl-L-prolyl-pyrrolidine (13a). Compound
13a was prepared from compound 10 (280 mg, 0.9 mmol) and 4-(pyridin-3-yl)butyric
acid (140 mg, 0.9 mmol) according to general procedure C. The product was purified by
flash chromatography (3-5% MeOH in EtOAc). Yield 210 mg, 66%. 1H NMR ? 1.00 (s,
5.3 H), 1.02 (s, 3.7 H), 1.73-2.07 (m, 9.5 H), 2.09-2.18 (m, 1 H), 2.29-2.40 (m, 1 H),
2.47-2.53 (m, 0.5 H), 2.58-2.71 (m, 2 H), 3.30-3.51 (m, 3.2 H), 3.58-3.66 (m, 0.8 H),
3.74-3.79 (m, 0.4 H), 4.28-4.31 (m, 1.2 H), 4.57-4.61 (m, 0.4), 7.19-7.22 (m, 1 H), 7.51-
7.53 (m, 1 H), 8.40-8.43 (m, 2 H). 13C NMR ? 23.9, 24.1, 25.9, 26.2, 26.3, 26.4, 26.5,
27.3, 27.7, 28.0, 28.1, 29.6, 32.3, 32.4, 33.0, 33.8, 36.5, 36.6, 45.9, 46.0, 46.0, 46.3,
60.9, 61.1, 65.8, 67.2, 123.4, 123.4, 136.0, 136.2, 137.1, 137.4, 147.3. 147.4, 149.9,
149.9, 170.2, 170.4, 173.5, 173.7. Anal.(C22H33N3O2·0.3 H2O) C, H, N. ESI-MS m/z
372.2 [M + H]+.
3-(Pyridin-3-yl)propionyl-5(R)-tert-butyl-L-prolyl-pyrrolidine (13b). Compound
13b was prepared from compound 10 (350 mg, 1.1 mmol) and 3-(pyridin-3-yl)propionic
acid (150 mg, 1.0 mmol) according to general procedure C. The product was purified by
flash chromatography (10% MeOH in EtOAc). Yield 260 mg, 73%. 1H NMR ? 1.00 (s,
5 H), 1.04 (s, 4 H), 1.66-2.07 (m, 7 H), 2.11-2.17 (m, 0.5 H), 2.29-2.35 (m, 1 H), 2.45-
2.51 (m, 0.5 H), 2.64-2.71 (m, 0.5 H), 2.75-2.81 (m, 0.5 H), 2.93-3.06 (m, 2 H), 3.33-
3.56 (m, 3 H), 3.60-3.65 (m, 1 H), 3.75-3.80 (m, 0.5 H), 4.30-4.33 (m, 1 H), 4.56-4.60
(m, 0.5 H), 7.18-7.23 (m, 1 H), 7.52-7.56 (m, 1 H), 8.42-8.46 (m, 2 H). 13C NMR
(solvent as an internal standard, 77.16 ppm) ? 23.8, 24.0, 26.1, 26.2, 26.3, 27.2, 27.6,
27.9, 28.0, 28.4, 29.0, 29.6, 35.6, 36.2, 36.5, 36.6, 45.9, 45.9, 45.9, 46.3, 60.9, 61.1,
65.8, 67.2, 123.3, 123.4, 136.0, 136.2, 136.8, 137.2, 147.3, 147.5, 149.6, 149.7, 170.1,
170.2, 172.8, 172.8. Anal.(C21H31N3O2) C, H, N. ESI-MS m/z 358.2 [M + H]+.
3-(Pyridin-3-yl)propionyl chloride hydrochloride. 3-(Pyridin-3-yl)propionic acid
(180 mg, 1.2 mmol) was dissolved in thionyl chloride (875 ml, 12.0 mmol). The mixture
was stirred overnight and evaporated.
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3-(Pyridin-3-yl)propionyl-L-prolyl-pyrrolidine (14a). Compound 11 (320 mg, 1.2
mmol) was dissolved in HCl treated EtOAc (4 ml, 2.7 M). The mixture was stirred for
45 min. and evaporated to yield L-prolyl-pyrrolidine hydrochloride. To a solution of 3-
(pyridin-3-yl)propionyl chloride hydrochloride (1.2 mmol) and Et3N (840 ml, 6.0 mmol)
in 2 ml of DCM was added L-prolyl-pyrrolidine hydrochloride in 5 ml of DCM
dropwise at 0 °C. The mixture was stirred overnight at rt. The reaction mixture was
diluted with DCM and washed with saturated NaHCO3 aq. and saturated NaCl aq., dried
over anhydrous Na2SO4 and evaporated. The product was purified by flash
chromatography (10-30% MeOH in EtOAc). Yield 160 mg, 44%. 1H NMR ? 1.80-2.28
(m, 8 H), 2.55-2.62 (m, 1 H), 2.65-2.71 (m, 1 H), 2.97-3.00 (m, 2 H), 3.35-3.46 (m, 3
H), 3.56-3.61 (m, 1 H), 3.63-3.68 (m, 1 H), 3.81-3.85 (m, 1 H), 4.65 (dd, J = 3.5, 8.5
Hz, 1 H), 7.21 (dd, J = 4.9, 7.7 Hz, 1 H), 7.55 (d, J = 7.7 Hz, 1 H), 8.44-8.45 (m, 1 H),
8.48 (br s, 1 H). 13C NMR (solvent as an internal standard, 77.16 ppm) ? 24.1, 24.7,
26.2, 27.8, 28.8, 35.8, 45.9, 46.3, 47.2, 57.8, 123.3, 136.0, 136.8, 147.5, 149.8, 170.1,
170.5. Anal.(C17H23N3O2·0.3 H2O) C, H, N. ESI-MS m/z 302.1 [M + H]+.
(Pyridin-3-yl)acetyl-L-prolyl-pyrrolidine (14b). Compound 14b was prepared
from compound 11 (400 mg, 1.5 mmol) and (pyridin-3-yl)acetic acid hydrochloride
(260 mg, 1.5 mmol) according to general procedure C, using 5 eq. of Et3N. The product
was purified by flash chromatography (10-20% MeOH in EtOAc). Yield 300 mg, 70%.
1H NMR ? 1.78-2.17 (m, 7 H), 2.24-2.33 (m, 1 H), 3.36-3.61 (m, 4 H), 3.68 (d, J = 15.9
Hz, 1 H), 3.71 (d, J = 15.9 Hz, 1 H), 3.75-3.81 (m, 2 H), 4.67 (dd, J = 3.6, 8.3 Hz, 1 H),
7.26 (dd, J = 4.8, 7.8 Hz, 1 H), 7.70 (dt, J = 7.8 Hz, 1 H), 8.47-8.49 (m, 2 H). 13C NMR
(solvent as an internal standard, 77.16 ppm) ? 24.0, 24.8, 26.1, 28.8, 38.5, 45.9, 46.2,
47.6, 58.0, 123.4, 130.5, 137.0, 148.0, 150.3, 168.4, 170.2. Anal.(C16H21N3O2·0.3 H2O)
C, H, N. ESI-MS m/z 288.1 [M + H]+.
Nicotinoyl-L-prolyl-pyrrolidine (14c). Compound 11 (1.1 g, 4.1 mmol) was
dissolved in HCl treated EtOAc (12 ml, 1.9 M) and the mixture was stirred for 40 min.
The mixture was evaporated and dissolved in pyridine (70 ml), DMAP (150 mg, 1.2
mmol) was added. Nicotinoyl chloride hydrochloride (3.6 g, 20 mmol) was added as
five portions and the mixture was stirred overnight. Pyridine was evaporated and the
residue was dissolved in DCM. The organic phase was with sat. NaHCO3 aq., dried over
Na2SO4 and evaporated. The product was purified by flash chromatography
(MeOH:EtOAc 1:1). Yield 610 mg, 56%. 1H NMR (DMSO) ? 1.39-1.47 (m, 0.4 H),
1.54-2.00 (m, 6.6 H), 2.22-2.30 (m, 1 H), 2.69-2.74 (m, 0.4 H), 2.86-2.91 (m, 0.4 H),
3.01-3.06 (m, 0.4), 3.12-3.16 (m, 0.4), 3.26-3.39 (m, 1.2 H), 3.45-3.70 (m, 3.2 H), 4.54
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(dd, J = 4.6, 8.1 Hz, 0.4 H), 4.71 (dd, J = 5.4, 8.4 Hz, 0.6 H), 7.40 (ddd, J = 0.7, 4.8, 7.8
Hz, 0.4 H), 7.48 (ddd, J = 0.7, 4.8, 7.8 Hz, 0.6 H), 7.71 (dt, J = 1.9, 7.8 Hz, 0.4 H), 7.92
(dt, J = 1.9, 7.8 Hz, 0.6 H), 8.51 (dd, J = 0.7, 2.1 Hz, 0.4 H), 8.58 (dd, J = 1.7, 4.8 Hz,
0.4 H), 8.66 (dd, J = 1.7, 4.8 Hz, 0.6 H), 8.70 (dd, J = 0.7, 2.1 Hz, 0.6 H). 13C NMR
(DMSO, solvent as an internal standard, 39.52 ppm) ? 22.5, 23.2, 23.5, 24.8, 25.3, 25.6,
28.3, 30.3, 45.1, 45.2, 45.5, 45.6, 46.9, 49.5, 58.1, 59.5, 122.8, 123.2, 132.2, 133.2,
133.9, 134.6, 147.0, 147.6, 149.9, 150.6, 165.5, 166.8, 169.1, 169.4.
Anal.(C15H19N3O2·0.5 H2O) C, H, N. ESI-MS m/z 274.1 [M + H]+.
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8 2(S)-(CYCLOALK-1-ENECARBONYL)-1-(4-PHENYL-
BUTANOYL)PYRROLIDINES AND 2(S)-(AROYL)-1-(4-
PHENYLBUTANOYL)PYRROLIDINES AS PROLYL
OLIGOPEPTIDASE INHIBITORS*
Abstract. In order to replace the P2-P1 amide group, different 1-cycloalkenyls and 2-
aryls were studied in the place of the P1 pyrrolidine group of a 4-phenylbutanoyl-L-Pro-
pyrrolidine structure, which is a well-known prolyl oligopeptidase inhibitor SUAM-
1221. The 1-cyclopentenyl and the 2-thienyl groups gave novel compounds, which were
equipotent with the corresponding pyrrolidine-analog SUAM-1221. It was shown that
the P2-P1 amide group of POP inhibitors can be replaced by an a,b-unsaturated
carbonyl group or the aryl conjugated carbonyl group.
* Reproduced with permission from: Jarho EM, Venäläinen JI, Poutiainen S, Leskinen
H, Vepsäläinen J, Christiaans JAM, Forsberg MM, Männistö PT, Wallén EAA: Bioorg
Med Chem 15: 2024–2031, 2007
 Copyright ã 2007 Elsevier Ltd.
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8.1 Introduction
POP is a proline specific peptidase and the S1 binding site of POP has evolved to fit the
pyrrolidine ring of an L-prolyl residue (Fülöp et al. 1998). The pyrrolidine group is
unquestionably the most utilized structure at the P1 position of POP inhibitors and only
few successful replacements of the P1 pyrrolidine ring have been described in the
literature (Nakajima et al. 1992, Portevin et al. 1996). An electrophilic substituent, like
a 2(S)-formyl or a 2(S)-cyano group, at the 2-position of the pyrrolidine ring increases
significantly the potency (Wilk and Orlowski 1983, Tanaka et al. 1994). However, these
groups are chemically reactive, which may limit their usability in drugs.
In a peptide chain, a prolyl residue lacks the main chain amide hydrogen.
Consequently, the P1 pyrrolidine group of POP inhibitors (or the substrates of POP) is
not stabilized by hydrogen bonding (Fülöp et al. 1998, Fülöp et al. 2001).  Wallen et al.
have previously replaced the P1 pyrrolidine group of the well-known reference
compound SUAM-1221 1a (Yoshimoto et al. 1991) by a series of alkyl groups and a
phenyl group (Wallén et al. 2002). The cyclopentyl and the phenyl groups gave
equipotent compounds 1b and 1c (Figure 1). These compounds were moderately potent
but still one order of magnitude less potent than the reference compound 1a. In the
present study, the field between these two replacements was further studied, focusing on
mimicking the amide bond geometry.
8.2 Methods
The synthetic routes are presented in Schemes 1, 2 and 3. Cyclopentylidene-hydrazine
(2a) and cyclohexylidene-hydrazine (2b) were prepared by the reaction of hydrazine
monohydrate with cyclopentanone and cyclohexanone, respectively. While the reaction
with cyclopentanone gave N,N'-dicyclopentylidene-hydrazine as a minor side-product
(about 5 mol%) the reaction with cyclohexanone produced a significant amount of N,N'-
N
O O
NN
O O
N
O O
1b; IC50 = 30 nM
1a (SUAM-1221); IC50 = 2.2 nM
1c; IC50 = 23 nM
Figure 1. The reference compound 1a and the previously reported compounds 1b and
1c (Wallén et al. 2002).
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Scheme 1. (i) hydrazine monohydrate/reflux; (ii) 1. I2, tetramethylguanidine/Et2O, 2.
Compound 2a or 2b/Et2O.
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OO
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Boc
4a-6a;
4b-6b;
4c-6c;
4d-6d;
4e-6e;
R = 1-cyclopentenyl
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R = 2-pyridyl
R = 2-thienyl
R = 2-furyl
ii for 5c
iii for 5a,b,d,e iv
4a-e 5a-e 6a-e
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Scheme 2. (i) organolithium reagent (prepared in situ or commercial reagent)/THF, -80
°C; (ii) Et3N, SO3×pyridine/DMSO; (iii) DMP/CH2Cl2; (iv) 1. trifluoroacetic
acid/CH2Cl2, 2. 4-phenylbutyric acid, HOBt×H2O, EDC×HCl, Et3N/CH2Cl2, 0-20 °C.
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N
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N
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O
n
N
O
N
H
Bocn
7a; S, n = 1
7b; R, n = 1
7c; S, n = 2
i ii, iii
Boc-L-proline or
Boc-D-proline
8a; S, n = 1
8b; R, n = 1
8c; S, n = 2
Scheme 3. (i) 1. Et3N, ethyl chloroformate/THF, -15 °C, 2. benzylamine/THF, -15-+20
°C; (ii) 1. trifluoroacetic acid/CH2Cl2, 0 °C; (iii) 1. cyclopent-1-enecarboxylic acid,
Et3N, trimethylacetyl chloride/CH2Cl2, 0 °C, 2. Et3N, trifluoroacetic acid salt of the
deprotected 6 from reaction (ii).
dicyclohexylidene-hydrazine (about 20 mol%). All attempts to distill 2b led to the
decomposition of the product. The unpurified compounds 2a and 2b were reacted with
iodine in the presence of tetramethylguanidine to yield 1-iodocyclopentene (3a) and 1-
iodocyclohexene (3b), respectively, which were distilled before further use (Barton et
al. 1983). Compounds 3a and 3b were treated with tert-BuLi, and 2-bromopyridine and
furan were treated with n-BuLi to obtain the corresponding organolithium reagents,
which were reacted with Boc-L-prolinal to give compounds 4a, 4b, 4c and 4e,
respectively. Compound 4d was obtained from the reaction of the commercially
available 2-thienyllithium and Boc-L-prolinal. Compounds 4a-e were oxidized with
Dess-Martin periodinane or SO3×pyridine/DMSO and deprotected. The resulting amines
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were coupled with 4-phenylbutyric acid using EDC and HOBt to yield compounds 6a-e.
Boc-L-proline and Boc-D-proline were activated with ethyl chloroformate and reacted
with benzylamine or phenethylamine to yield compounds 7a-c. Cyclopent-1-
enecarboxylic acid was activated with trimethylacetyl chloride and reacted with 7a-c
after the removal of the Boc-protection group to yield compounds 8a-c.
8.3 Results and discussion
Compounds 6a-e are presented in Table 1. The P1 pyrrolidine ring of the reference
compound 1a (Figure 1) has been replaced by a 1-cyclopentene ring in compound 6a. A
similar replacement at the P2 position has previously been shown to give potent POP
inhibitors (Chapter 6). Indeed, compound 6a was equipotent with the reference
compound 1a. Compound 6a was one order of magnitude more potent than the
previously reported compound 1b with the cyclopentyl ring at the P1 site. The
difference in their potencies can be explained by differences in geometry and p-
stacking. The P1 amide nitrogen is sp2 hybridized and, although the replacement by an
sp3 carbon was tolerated (IC50 of compound 1b was 30 nM), an sp2 carbon provides a
better mimetic for the amide nitrogen. Furthermore, the double bond may have
beneficial p-stacking with the indole ring of Trp595 (Fülöp et al. 1998).
The enlargement of the 1-cyclopentenyl group of compound 6a resulted in
compound 6b with a 1-cyclohexenyl group at the P1 position. Compound 6b was 20
times less potent than compound 6a, which reflects the limited space in the S1 pocket
(Fülöp et al. 1998). However, Wallén et al. have previously reported that a compound
Table 1. Inhibitory activities with 95% confidence intervals of the compounds with
different 1-cycloalkenyl and 2-aryl groups at the P1 position.
RN
O O
Compound R IC50 (nM)a
6a 1-cyclopentenyl 3.0 (2.7-3.4)
6b 1-cyclohexenyl 59 (52-69)
6c 2-pyridyl 510 (450-570)
6d 2-thienyl 3.0 (2.7-3.4)
6e 2-furyl 5.20 (4.3-6.1)
a The IC50 values were determined against POP from porcine brain (Venäläinen et al. 2002).
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with the same skeleton as 6b but with a fully saturated cyclohexyl group at the P1 site
gives only weak POP inhibitory activity (IC50 = 1.1 mM). Compound 6b was 18 times
more potent than this compound, while it was only 2.6 times less potent than the
reference compound 1c, which has the phenyl group at the P1 site. This small decrease
in potency in relation to compound 1c may be explained by the smaller size of the
phenyl ring or loss in p-stacking with Trp595.
In order to study different aryls at the P1 position, the 2-pyridyl, 2-thienyl and 2-
furyl groups were selected. The pyridyl group has previously been successfully
employed at the P1' and P3 positions of POP inhibitors (Tsutsumi et al. 1994, Chapter
7). As compared to compound 1c with the phenyl group at the P1 site, compound 6c
with the 2-pyridyl group had strongly decreased inhibitory activity. In contrast,
compound 6d, with the 2-thienyl group at the P1 site, was one order of magnitude more
potent than compound 1c and equipotent with compound 6a. The difference between
compounds 6d and 1c can be explained by the smaller size of the 2-thienyl group. The
1-cyclopentenyl and the 2-thienyl groups instead, are almost equal in size and
compound 6d does not seem to have any beneficial p-stacking over 6a. The potency of
compound 6e with the 2-furyl group at the P1 site was slightly decreased but the same
order of magnitude than the potency of compound 6d.
The 2-thienyl group has previously been studied at the P1 position of POP inhibitors
but with opposite results. It gave a poor POP inhibitor against Flavobacterium
meningosepticum POP (Portevin et al. 1996). On the other hand, an unusual POP
inhibitor Y-29794 possesses a 2-thienyl group although it is not known where it binds.
Y-29794 was reported to have a Ki value of 0.95 nM against rat POP (Nakajima et al.
1992). The excellent POP inhibitory activity of compound 6d indicates that the 2-
thienyl group of Y-29794 may bind to the S1 pocket of POP. It also seems that the S1
subsites of the mammalian and the bacterial POP have differences.
The use of the 1-cyclopentenyl group at the P1 position allowed further
modifications on the backbone. Compounds 8a-c (Table 2) were prepared in order to
study whether it is possible to reverse the P2 prolyl residue; the P1-P2 carbonyl group
was kept in the original position but the direction of the amide bond was changed.
Consequently, compounds 8a-c possess the a,b-unsaturated amide group instead of the
a,b-unsaturated ketone group. a,b-Unsaturated ketones are usually avoided in drug
design because of their ability to undergo Michael additions to the double bond. a,b-
Unsaturated amides may be less reactive due to the electron-donating effect of the
amide nitrogen. Compound 8a with a reversed L-prolyl residue at the P2 position had an
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Table 2. Inhibitory activities with 95% confidence intervals of the compounds with the
reversed prolyl residue at the P2 position.
N
OO
N
H
n
*
Compound n Stereocenter IC50 (nM)a
8a 1 S 210 (180-240)
8b 1 R 44 000 (28000-67000)
8b 2 S 110 (91-130)
a The IC50 values were determined against POP from porcine brain (Venäläinen et al. 2002).
IC50 value of 210 nM. The potency was significantly decreased as compared to
compound 6a. A D-prolyl residue was also studied but the resulting compound 8b was
over 200 times less active than compound 8a with the L-prolyl residue. The P3 chain of
compound 8a was elongated with one methylene group resulting in compound 8c,
which had improved inhibitory activity. This reflects the known structure-activity
relationships of the P3 site suggesting that the 1-cyclopentenyl group of compounds
8a-c also binds to the S1 site of POP.
8.4 Conclusions
The 1-cycloalkenyl groups at the P1 position gave better POP inhibitory activities than
the corresponding fully saturated cycloalkyl groups. The 1-cyclopentenyl group gave
the most potent compound, which was equipotent with the reference compound 1a. In
the series of the aromatic groups, the 2-thienyl group gave the most potent compound.
This confirms again that the 5-membered ring is preferred. The reversed P2 L-prolyl
residue decreased potency significantly but the effect of the reversed D-prolyl residue
was much more pronounced. In conclusion, the P2-P1 amide group of POP inhibitors
can be replaced by the a,b-unsaturated carbonyl group or the aryl conjugated carbonyl
group.
8.5 Synthetic procedures and analytical data
Method A. 1-Iodo-cyclopentene (3a). STEP 1 (2a). Cyclopentanone (8.8 ml, 100
mmol) was added dropwise to hydrazine monohydrate (30 ml, 620 mmol) under
vigorous stirring. The mixture was refluxed for 2 h and cooled down to room
temperature (rt). DCM was cautiously added at cold water bath and the phases were
separated. The organic phase was washed with saturated (sat.) NaCl aq., dried over
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Na2SO4, filtered and evaporated. The product was used without further purification.
Crude product 7.1 g. STEP 2 (3a). Tetramethylguanidine (75 ml, 600 mmol) in Et2O
(110 ml) was added dropwise to iodine (28 g, 110 mmol) in Et2O (160 ml) during 1.5 h
and the mixture was stirred for 2.5 h. 2a (4.9 g, about 50 mmol) in Et2O (50 ml) was
added dropwise during 2 h and the mixture was stirred overnight. The mixture was
refluxed for 2 h, cooled down to rt and filtered. The filtrate was concentrated from Et2O,
heated up to 90-95 °C for 3 h, cooled to rt and diluted with Et2O. The organic phase was
washed with 1 M HCl aq., 20% Na2S2O3, sat. NaHCO3 aq. and sat. NaCl aq., dried over
Na2SO4, filtered and evaporated (with a rotary evaporator at 40 °C and 100 mbar as the
lowest pressure point). The product was stored at -18 °C under argon and was distilled
before further use at 39 °C and 6 mbar. Yield 5.6 g, 42% for 2 steps. 1H NMR ? 1.90-
1.96 (m, 2 H), 2.30-2.34 (m, 2 H), 2.58-2.62 (m, 2 H), 6.09-6.11 (m, 1 H).
1-Iodo-cyclohexene (3b). Prepared according to method A from cyclohexanone
(10.4 ml, 100.0 mmol). STEP 1 (3a). Crude product 10.8 g. STEP 2 (3b).
Tetramethylguanidine (1.16 mol), I2 (212 mmol). Compound 3b  was distilled at 50 °C
and 1 mbar. Yield 9.9 g, 47% for 2 steps. 1H NMR ? 1.63-1.72 (m, 4 H), 2.07-2.11 (m,
2 H), 2.48-2.52 (m, 2 H), 6.33-6.35 (m, 1 H).
Method B. ((S)-1-Boc-pyrrolidin-2-yl)-cyclopent-1-enyl-methanol (4a). 1.7 M
tert-BuLi (17 ml, 29 mmol) was added dropwise to 3a (5.6 g, 29 mmol) in THF (30 ml)
and the mixture was stirred for 1 h at -80 °C. Boc-L-prolinal (1.9 g, 9.5 mmol) in THF
(10 ml) was added dropwise and the mixture was stirred for 3 h at -80 °C. The reaction
was quenched with sat. NH4Cl aq. at -80 °C. The mixture was let to warm up to rt,
diluted with H2O and extracted with DCM. The organic phase was washed with sat.
NaCl aq., dried over Na2SO4, filtered and evaporated. The product was purified by flash
chromatography (15-50% EtOAc in hexane). Yield 1.9 g, 75%.
((S)-1-Boc-pyrrolidin-2-yl)-cyclohex-1-enyl-methanol (4b). Prepared according to
method B from 3b (3.1 g, 15 mmol) and Boc-L-prolinal (1.0 g, 5 mmol). The product
was purified twice by flash chromatography. One diastereomer was purified with 15%
EtOAc in PE but the other diastereomer co-eluted with the unreacted Boc-prolinal. The
other diastereomer was purified with 5% acetonitrile in DCM. The diasteromers were
combined giving the total yield of 0.54 g, 38%.
((S)-1-Boc-pyrrolidin-2-yl)-pyridin-2-yl-methanol (4c). To a solution of 2-
bromopyridine (3.2 g, 20 mmol) in 40 ml of THF was added dropwise 1.6 M n-BuLi
(12.5 ml, 20.0 mmol) at -70 °C and the mixture was stirred for 1 h. Boc-L-prolinal (3.6
g, 18 mmol) in THF (40 ml) was added and the mixture was stirred for 2 h at -70 °C.
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The mixture was poured in water and THF was evaporated. The aqueous phase was
extracted with DCM and the organic phase was extracted with 0.1 M HCl aq. The
aqueous phase was made basic with 2 M NaOH aq., extracted with DCM, dried over
Na2SO4, filtered and evaporated. Yield 2.8 g, 56%.
((S)-1-Boc-pyrrolidin-2-yl)-thiophen-2-yl-methanol (4d). To a solution of Boc-L-
prolinal (0.31 g, 1.56 mmol) in THF was added 1 M 2-thienyllithium solution in THF
(1.75 ml, 1.75 mmol) at -70 °C. The mixture was stirred for 3 h and quenched with sat.
NH4Cl aq. at -70 °C. The mixture was let to warm up to rt, diluted with H2O and
extracted with DCM. The organic phase was washed with sat. NaCl aq., dried over
Na2SO4, filtered and evaporated. The product was purified by the flash chromatography
(1% MeOH in DCM). Yield 0.32 g, 71%.
Method C. 1-Boc-2(S)-(cyclopent-1-enecarbonyl)pyrrolidine (5a). To a solution
of Dess-Martin periodinane (DMP) (1.4 g, 3.3 mmol) in DCM (16 ml) was added 4a
(0.80 g, 2.99 mmol) in DCM (10 ml) and the mixture was stirred for 1 h at rt. 30 %
Na2S2O3 aq. was added and the mixture was stirred for 5 min. The phases were
separated and the organic phase was washed with 30% Na2S2O3 aq. and sat. NaHCO3
aq., dried over Na2SO4, filtered and evaporated. The product was purified by flash
chromatography (20% EtOAc in PE). Yield 0.58 g, 73%. 1H NMR ? 1.34 (s, 5 H), 1.45
(s, 4 H), 1.80-1.96 (m, 5 H), 2.13-2.25 (m, 1 H), 2.50-2.69 (m, 4 H), 3.38-3.61 (m, 2 H),
4.77-4.80 (m, 0.5 H), 4.95-4.97 (m, 0.5 H), 6.76-6.78 (m, 0.5 H), 6.82-6.85 (m, 0.5 H).
1-Boc-2(S)-(cyclohex-1-enecarbonyl)pyrrolidine (5b). Prepared according to
method C from 4b (0.54 g, 1.92 mmol) using 1.3 eq. of DMP. No chromatographic
purification was performed. Yield 0.54 g, 100%. 1H NMR ? 1.34 (s, 4.7 H), 1.45 (s, 4.3
H), 1.57-1.69 (m, 4 H), 1.75-1.94 (m, 3 H), 2.12-2.39 (m, 5 H), 3.38-3.43 (m, 0.5 H),
3.46-3.62 (m, 1.5 H), 4.90 (dd, J = 4.1 Hz, 8.8 Hz, 0.5 H), 5.05 (dd, J = 3.4 Hz, 9.1 Hz,
0.5 H), 6.89-6.91 (m, 0.5 H), 6.95-6.97 (m, 0.5 H).
1-Boc-2(S)-(pyridine-2-carbonyl)pyrrolidine (5c). To a solution of 4c (0.60 g,
2.16 mmol) and Et3N (0.9 ml, 6.5 mmol) in 2.2 ml of DMSO was added SO3×pyridine
(1.03 g, 6.5 mmol) in DMSO (2.2 ml). The mixture was stirred for 1 h and then poured
in ice cold water (25 ml). The aqueous phase was extracted with CHCl3 and the organic
phase was washed with water and sat. NaHCO3 aq., dried over Na2SO4, filtered and
evaporated. The product was purified with a chromatotron (1% EtOH in CHCl3). Yield
0.37 g, 61%. 1H NMR ? 1.24 (s, 5.4 H), 1.46 (s, 3.6 H), 1.88-1.98 (m, 3 H), 2.38-2.45
(m, 1 H), 3.48-3.70 (m, 2 H), 5.68-5.70 (m, 0.6 H), 5.77-5.79 (m, 0.4 H), 7.44 (ddd, J =
1.0 Hz, 4.8 Hz, 7.6 Hz, 0.4 H), 7.48 (ddd, J =  1.1 Hz, 4.8 Hz, 7.7 Hz, 0.6 H), 7.82 (td, J
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= 1.6 Hz, 7.7 Hz, 0.4 H), 7.86 (td, J = 1.7 Hz, 7.8 Hz, 0.6 H), 8.08 (dt, J = 1.0 Hz, 7.8
Hz, 1 H), 8.66 (d, 0.4 H), 8.68 (d, J = 4.8 Hz, 0.6 H).
1-Boc-2(S)-(thiophene-2-carbonyl)pyrrolidine (5d). Prepared according to method
C from 4d (0.32 g, 1.13 mmol) using 1.3 eq. of DMP. The product was purified by flash
chromatography (0.5% MeOH in DCM). Yield 0.27 g, 87%. 1H NMR ? 1.25 (s, 5.4 H),
1.46 (s, 3.6 H), 1.87-2.05 (m, 3 H), 2.25-2.38 (m, 1 H), 3.41-3.50 (m, 0.4 H), 3.56-3.69
(m, 1.6 H), 4.88 (dd, J = 5.0 Hz, 8.6 Hz, 0.6 H), 5.10 (dd, J = 3.2 Hz, 8.9 Hz, 0.4 H),
7.12-7.16 (m, 1 H), 7.63-7.66 (m, 1 H), 7.78 (d, J = 3.8 Hz, 0.6 H), 7.81 (d, J = 3.5 Hz,
0.4 H).
1-Boc-2(S)-(furan-2-carbonyl)pyrrolidine (5e). 1.6 M n-BuLi (4.7 ml, 7.5 mmol)
was added dropwise to furan (10 ml) at 0 °C and the mixture was stirred for 1 h. Boc-L-
prolinal (0.30 g, 1.51 mmol) in THF (10 ml) was added dropwise at -80 °C and the
mixture was stirred for 3 h. Sat. NH4Cl aq. was added and the mixture was let to warm
up to rt and diluted with DCM. The organic phase was washed with sat. NaCl aq., dried
over Na2SO4 and evaporated to yield 4e. Without further purification, the residue was
dissolved in DCM, added to a solution of DMP (0.95 g, 2.24 mmol) in DCM (4 ml) and
then continued according to method C. The product was purified by flash
chromatography (10% EtOAc in PE). Yield 110 mg, 28% (two steps). 1H NMR ? 1.26
(s, 5.4 H), 1.46 (s, 3.6 H), 1.87-2.01 (m, 3 H), 2.23-2.36 (m, 1 H), 3.43-3.67 (m, 2 H),
4.90 (dd, J =  4.6 Hz, 8.6 Hz, 0.6 H), 5.08-5.10 (m, 0.4 H), 6.53 (dd, J = 1.5 Hz, 3.3 Hz,
0.4 H), 6.56 (dd, J = 1.6 Hz, 3.5 Hz, 0.6 H), 7.23 (d, J = 3.5 Hz, 0.6 H), 7.26 (m, 0.4 H),
7.58 (d, 0.4 H), 7.61 (d, 0.6).
Method D. 2(S)-(Cyclopent-1-enecarbonyl)-1-(4-phenylbutanoyl)pyrrolidine
(6a). To a solution of 5a (110 mg, 0.35 mmol) in DCM (2.5 ml) was added
trifluoroacetic acid (TFA) (0.7 ml, 9.4 mmol) at 0 °C. The mixture was stirred for 2.5 h
at 0 °C and evaporated. TFA salt of the amine, 4-phenylbutyric acid (58 mg, 0.35
mmol), HOBt×H2O (81 mg, 0.53 mmol) and EDC×HCl (102 mg, 0.53 mmol) were
dissolved/suspended in DCM. Et3N (240 ml, 1.75 mmol) was added at 0 °C and the
mixture was stirred for 0.5 h at 0 °C and for 5 h at rt. The reaction mixture was washed
with 30% citric acid, sat. NaCl aq. and sat. NaHCO3, dried over Na2SO4, filtered and
evaporated. The product was purified with a chromatotron (40-50% EtOAc in PE).
Yield 50 mg, 46%. 1H NMR ? 1.81-2.06 (m, 7 H), 2.10-2.18 (m, 1 H), 2.23-2.38 (m, 2
H), 2.50-2.69 (m, 6 H), 3.40-3.45 (m, 0.9 H), 3.56-3.62 (m, 1 H), 3.65-3.70 (m, 0.1 H),
4.78 (dd, J = 3.0 Hz, 9.2 Hz, 0.1 H), 5.16 (dd, J = 3.8 Hz, 8.8 Hz, 0.9 H), 6.64-6.66 (m,
0.1 H), 6.86-6.88 (m, 0.9 H), 7.12-7.29 (m, 5 H). 13C NMR ? 22.5, 24.6, 26.0, 29.4,
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30.9, 33.3, 34.2, 35.1, 47.2, 61.2, 125.8, 128.3, 128.6, 141.9, 143.4, 144.2, 171.1, 196.4.
Anal. (C20H25NO2·0.1 H2O) CHN. ESI-MS m/z 312.1 [M + H]+.
2(S)-(Cyclohex-1-enecarbonyl)-1-(4-phenylbutanoyl)pyrrolidine (6b). Prepared
according to method D from 5b (325 mg, 1.16 mmol) having 20 h reaction time. The
product was purified by flash chromatography (50% EtOAc in PE). Yield 160 mg, 49%.
1H NMR ? 1.56-1.67 (m, 4 H), 1.77-1.83 (m, 1 H), 1.87-2.05 (m, 4 H), 2.09-2.38 (m, 7
H), 2.59-2.69 (m, 2 H), 3.40-3.45 (m, 0.9 H), 3.56-3.62 (m, 1 H), 3.64-3.69 (m, 0.1 H),
4.88 (dd, J = 2.9 Hz, 9.2 Hz, 0.1 H), 5.24 (dd, J = 3.7 Hz, 8.9 Hz, 0.9 H), 6.75-6.77 (m,
0.1 H), 6.99-7.01 (m, 0.9 H), 7.13-7.28 (m, 5 H). 13C NMR ? 21.5, 21.8, 23.2, 24.6,
26.0, 26.1, 29.5, 33.4, 35.1, 47.1, 59.6, 125.8, 128.3, 128.6, 137.4, 140.5, 141.9, 171.0,
198.6. Anal. (C21H27NO2·0.1 H2O) CHN. ESI-MS m/z 326.1 [M + H]+.
1-(4-Phenylbutanoyl)-2(S)-(pyridine-2-carbonyl)pyrrolidine (6c). Prepared
according to method D from 5c (280 mg, 1.0 mmol) having a 20 h reaction time. The
reaction mixture was not washed with 30% citric acid. The product was purified by
flash chromatography (50% EtOAc in PE). Yield 130 mg, 40%. 1H NMR ? 1.79-2.17
(m, 5.5 H), 2.28-2.49 (m, 2.5 H), 2.54-2.59 (m, 0.4 H) 2.68 (t, J = 7.5 Hz, 1.6 H), 3.50-
3.55 (m, 0.8 H), 3.64-3.71 (m, 1 H), 3.73-3.78 (m, 0.2 H), 5.85 (dd, J = 3.0 Hz, 9.4 Hz,
0.2 H), 5.91-5.94 (m, 0.8 H), 7.05-7.08 (m, 0.5 H), 7.13-7.21 (m, 2.5 H), 7.26-7.29 (m,
2 H), 7.46 (ddd, J = 1.2 Hz, 4.8 Hz, 7.6 Hz, 0.8 H), 7.53 (ddd, J = 1.2 Hz, 4.7 Hz, 7.6
Hz, 0.2 H), 7.83 (td, J = 1.7 Hz, 7.7 Hz, 0.8 H), 7.89 (td, J = 1.7 Hz, 7.7 Hz, 0.2 H),
8.04-8.08 (m, 1 H), 8.66-8.69 (m, 1 H). 13C NMR ? 25.0, 26.1, 29.3, 33.4, 35.1, 47.5,
60.4, 122.7, 125.8, 127.1, 128.3, 128.6, 136.9, 141.9, 148.8, 152.3, 171.0, 198.6. Anal.
(C20H22N2O2) CHN. ESI-MS m/z 323.2 [M + H]+.
1-(4-Phenylbutanoyl)-2(S)-(thiophene-2-carbonyl)pyrrolidine (6d). Prepared
according to method D from 5d (270 mg, 1.0 mmol) having a 20 h reaction time and
using 2.5 eq. of EDC and HOBt. The product was purified by flash chromatography
(15-50% EtOAc in PE). Yield 155 mg, 47%. 1H NMR ? 1.88-2.15 (m, 5.3 H), 2.22-2.44
(m, 2.7 H), 2.52-2.63 (m, 0.3 H), 2.69 (t, J = 7.5 Hz, 1.7 H), 3.46-3.51 (m, 0.85 H),
3.63-3.69 (m, 1 H), 3.73-3.77 (m, 0.15 H), 4.93 (dd, J = 3.2 Hz, 9.1 Hz, 0.15 H), 5.32
(dd, J = 3.6 Hz, 9.0 Hz, 0.85 H), 7.07-7.21 (m, 4 H), 7.26-7.29 (m, 2 H), 7.64 (dd, J =
0.9 Hz, 5.0 Hz, 0.85 H), 7.65-7.66 (m, 0.15 H), 7.72 (dd, J = 0.9 Hz, 5.0 Hz, 0.15 H),
7.83 (dd, J = 0.9 Hz, 3.8 Hz, 0.85 H). 13C NMR ? 24.8, 26.0, 29.6, 33.3, 35.1, 47.2,
61.8, 125.8, 128.1, 128.3, 128.6, 132.3, 133.8, 141.7, 141.8, 171.4, 191.1. Anal.
(C19H21NO2S×0.8 H2O) CHN. ESI-MS m/z  328.1 [M + H]+.
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2(S)-(Furan-2-carbonyl)-1-(4-phenylbutanoyl)pyrrolidine (6e). Prepared
according to method D from 5e (100 mg, 0.37 mmol) having a 20 h reaction time. The
product was purified by flash chromatography (27% EtOAc in PE). Yield 42 mg, 36%.
1H NMR ? 1.86-2.12 (m, 5.4 H), 2.17-2.40 (m, 2.6 H), 2.53-2.64 (m, 0.3 H), 2.69 (t, J =
7.5 Hz, 1.7 H), 3.45-3.50 (m, 0.85 H), 3.61-3.67 (m, 1 H), 3.71-3.76 (m, 0.15 H), 4.97
(dd, J = 3.0 Hz, 9.2 Hz, 0.15 H), 5.30 (dd, J = 3.9 Hz, 8.8 Hz, 0.85 H), 6.54 (dd, J = 1.6
Hz, 3.6 Hz, 0.85 H), 6.59 (dd, J = 1.6 Hz, 3.5 Hz, 0.15 H), 7.09-7.22 (m, 3.7 H), 7.26-
7.29 (m, 2.3 H), 7.59 (d, J = 1.6 Hz, 0.85 H), 7.63 (d, J = 1.6 Hz, 0.15 H). 13C NMR ?
24.8, 26.0, 29.1, 33.3, 35.1, 47.2, 60.9, 112.3, 117.9, 125.7, 128.2, 128.6, 141.9, 146.5,
151.4, 171.3, 187.1. Anal. (C19H21NO3×0.1 H2O) CHN. ESI-MS m/z  312.1 [M + H]+.
Method E. 1-Boc-L-proline benzylamide (7a). To a solution of Boc-L-proline
(430 mg, 2.0 mmol) and Et3N (310 ml, 2.2 mmol) in THF (4 ml) was added ethyl
chloroformate (190 ml, 2.0 mmol) in THF (3 ml) dropwise at -15 °C, and the mixture
was stirred for 30 min. Benzylamine (440 ml, 4.0 mmol) in THF (1 ml) was added at -15
°C and the mixture was stirred overnight at rt. The mixture was diluted with DCM,
washed with 30% citric acid, sat. NaCl aq. and sat. NaHCO3, dried over Na2SO4,
filtered and evaporated. Yield 0.55 g, 90%.
1-Boc-D-proline benzylamide (7b). Prepared according to method E from Boc-D-
proline (900 mg, 4.2 mmol). At the end of the reaction, the mixture was diluted with
EtOAc. Yield 1.08 g, 84%.
1-Boc-L-proline phenethyl amide (7c). Prepared according to method E from Boc-
L-proline (250 mg, 2.5 mmol) and phenethylamine (0.63 ml, 5.0 mmol). At the end of
the reaction, the mixture was diluted with EtOAc. Yield 0.80 g, 100%.
Method F. 1-(Cyclopent-1-enecarbonyl)-L-proline benzylamide (8a). STEP 1.
To a solution of 7a (550 mg, 1.8 mmol) in DCM (4 ml) was added TFA (3.6 ml, 48
mmol) in DCM (4 ml) dropwise at 0 °C. The mixture was stirred for 1 h at 0 °C and
evaporated. STEP 2. To a solution of cyclopent-1-enecarboxylic acid (200 mg, 1.8
mmol) and Et3N (0.28 ml, 2.0 mmol) in DCM (4 ml) was added trimethylacetyl chloride
(0.22 ml, 1.8 mmol) in DCM (4 ml) dropwise at 0 °C. The mixture was stirred for 1 h at
0 °C and the ice bath was removed. Et3N (0.82 ml, 5.9 mmol) and the product of STEP
1 in DCM (4 ml) were added in this order and the mixture was stirred for 2 h. The
mixture was washed with 30% citric acid, sat. NaCl aq. and sat. NaHCO3, dried over
Na2SO4, filtered and evaporated. The product was purified by flash chromatography
(40-80% EtOAc in PE). Yield 380 mg, 71%. 1H NMR ? 1.85-1.98 (m, 4 H), 2.07-2.15
(m, 1 H), 2.45-2.61 (m, 4 H), 2.66-2.74 (m, 1 H), 3.56-3.65 (m, 2 H), 4.39 (dd, J = 5.0
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Hz, 15.1 Hz, 1 H), 4.48 (dd, J = 5.7 Hz, 15.1 Hz, 1 H), 4.70-4.74 (m, 1 H), 6.15-6.18
(m, 1 H), 7.24-7.32 (m, 5 H), 7.39-7.45 (m, 1 H). 13C NMR ? 22.7, 25.4, 26.8, 33.7,
33.9, 43.4, 49.2, 59.9, 127.2, 127.4, 128.6, 136.3, 138.5, 139.1, 168.7, 171.2. Anal.
(C18H22N2O2) CHN. ESI-MS m/z 299.0 [M + H]+.
1-(Cyclopent-1-enecarbonyl)-D-proline benzylamide (8b). Prepared according to
method F from 7b (300 mg, 1.0 mmol). The product was purified by flash
chromatography (50-60% EtOAc in hexane). Yield 180 mg, 60%. 1H NMR ? 1.85-1.98
(m, 4 H), 2.07-2.15 (m, 1 H), 2.45-2.61 (m, 4 H), 2.66-2.74 (m, 1 H), 3.56-3.65 (m, 2
H), 4.39 (dd, J = 5.2 Hz, 15.1 Hz, 1 H), 4.48 (dd, J = 5.9 Hz, 15.1 Hz, 1 H), 4.70-4.74
(m, 1 H), 6.15-6.18 (m, 1 H), 7.24-7.32 (m, 5 H), 7.39-7.45 (m, 1 H). 13C NMR ? 22.7,
25.4, 26.8, 33.7, 33.9, 43.4, 49.2, 59.9, 127.2, 127.4, 128.6, 136.3, 138.5, 139.1, 168.7,
171.2. Anal. (C18H22N2O2) CHN. ESI-MS m/z 299.0 [M + H]+.
1-(Cyclopent-1-enecarbonyl)-L-proline phenethyl amide (8c). Prepared
according to method F from 7c (0.40 g, 1.25 mmol). The product was purified by flash
chromatography (50% EtOAc in PE). Yield 330 mg, 85%. 1H NMR ? 1.82-2.05 (m, 5
H), 2.33-2.73 (m, 5 H), 2.75-2.85 (m, 2 H), 3.44-3.66 (m, 4 H), 4.38-4.45 (m, 0.2 H),
4.60-4.65 (m, 0.8 H), 5.87-5.96 (m, 0.2 H), 6.11-6.15 (m, 0.8 H), 6.19-6.29 (m, 0.2 H),
7.00-7.07 (m, 0.8 H), 7.17-7.21 (m, 3 H), 7.25-7.28 (m, 2 H). 13C NMR ? 22.7, 25.3,
27.1, 33.7, 33.8, 35.7, 40.6, 49.2, 60.0, 126.3, 128.4, 128.8, 136.4, 139.1, 139.1, 168.3,
171.3. Anal. (C19H24N2O2) CHN. ESI-MS m/z 313.0 [M + H]+.
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9 GENERAL DISCUSSION
9.1 Modifications at the P3 position and beyond it
A set of POP inhibitors were developed from the previously published larger POP
inhibitors (Figure 1). The potencies of the novel compounds did not significantly differ
from the potencies of the larger compounds. The common feature of these inhibitors
was that they did not have the typical aryl-alkanoyl moiety at the P3 site and the
CoMSIA model was created in order to provide information about the binding mode of
these inhibitors. Two binding modes, which differed from each other beyond the P3
position, were found. Binding mode A favored lipophilic structures beyond the P3
position and the studied reference compounds occupied this binding mode. On the other
hand, binding mode B favored hydrophilic structures beyond the P3 position and was
occupied by 40% of the studied inhibitors. Binding mode B has not been described in
the literature.
Many POP inhibitors possess a phenyl group at the P3 position. In order to introduce
an ionizable group into the POP inhibitor structure, the phenyl group was replaced by a
pyridyl group. It was found that the pyridyl moiety gives compounds that are equipotent
with their phenyl analogs. Both groups are six-membered aromatic structures but the
pyridyl group is more polar and it caused a 20-fold decrease in partition coefficient. The
introduction of a polar group is not necessarily a straightforward procedure. At the P1
position, the replacement of the phenyl group by the 2-pyridyl group caused an over 20-
fold decrease in potency. Furthermore, the replacement of the azepane or the pyrrolidine
moiety by the morpholine moiety decreased the inhibitory activity significantly (Figure
2). The optimal chain length for the pyridyl group reflected the optimal chain length for
the phenyl group. This indicates that both groups may bind in a similar manner.
N NN
O
R
OO
N N
O
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O
NN
OO
Figure 1. Design of the POP inhibitors with an atypical P3 and beyond structures.
NX
NN
OO
O
n
1; X=C, n=1, IC50 = 110 nM
2; X=C, n=3, IC50 = 41 nM
3; X=O, n=2, IC50 = 1200 nM
Figure 2. The decreased potency caused by the polar morpholine group.
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Figure 3. The combination of the 5-tert-butyl-L-proline at the P2 position and the 3-
pyridyl group at the P3 position gave a potent POP inhibitor with excellent water-
solubility and theoretically optimal lipophilicity.
However, according to the CoMSIA model, the P3 site favors the alkyl groups. When
the chain of either the pyridyl- or the phenyl-containing compound is shortened, the
aromatic ring is brought to this area. Thus, it is also possible that the pyridyl group is
positioned into a different area than the phenyl group.
The P3 pyridyl group was studied with two different proline mimetics, the 5-tert-
butyl-L-prolyl and the cyclopent-1-enecarbonyl groups, at the P2 position. When the
pyridyl group was combined with the 5-tert-butyl-L-prolyl moiety (Figure 3), the
theoretical optimum for lipophilicity was reached. It was also shown that both proline
mimetics decreased water-solubility but the introduction of the pyridyl group overcame
this decrease. The reference compound SUAM-1221 had also an excellent water-
solubility but it is an oily compound, which makes it difficult to handle. The introduced
pyridyl group enables salt formation and a solid form can be obtained.
9.2 The amide bond replacements
In the typical POP inhibitor structure, there are pyrrolidine rings at the P2 and P1
positions and the pyrrolidine nitrogens are both involved in the amide bonds. The
carbonyl oxygens of these amide bonds form hydrogen bonds with the enzyme and are
important for the POP inhibitory activity. Instead, the amide nitrogens do not form
hydrogen bonds with POP and the replacements of the P2 and P1 pyrrolidine rings by
different carbon rings have been described in the literature. However, these
replacements have led to decreased POP inhibitory activities.
The relative potencies of different P1 and P2 pyrrolidine replacements are presented
in Figure 4. Amide nitrogens are sp2 hybridized and amide bonds are planar. Instead, an
sp3 hybridized carbon is tetrahedral and is not able to well mimic the amide nitrogen.
This change in geometry can explain the decreased potency of POP inhibitors
possessing a cyclopentane ring at the P2 or P1 positions (the data for the P2 position is
not from our assay). When the cyclopentane ring with the sp3 hybridized carbon was
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Figure 4. The relative potencies of different P1 and P2 pyrrolidine replacements of the
POP inhibitor structure.
replaced by a cyclopentene ring with an sp2 hybridized carbon, the potencies were
increased back to the level of the reference compounds. However, the poor POP
inhibitory activity caused by the 1-cyclopentene ring at the P2 position cannot be
explained by the wrong geometry at that carbon, which mimics the amide nitrogen. The
more probable explanation is the changed hybridization of the neighbouring carbon
because it has lost the L-proline mimicking configuration. The relatively poor inhibitory
activity of the phenyl group at the P1 position reflects only the fact that the S1 pocket of
POP is specific for the 5-membered ring and indeed, the smaller aromatic rings turned
out to be one order of magnitude more potent. However, the phenyl group was slightly
more potent than the cyclopentyl group and the 1-cyclohexenyl group was more potent
than the cyclohexyl group confirming the importance of the sp2 hybridization.
The beneficial p-stacking with Trp595 was suggested to play some role in the
relative potencies of the pyrrolidine replacements at the P1 position. In the literature,
there are examples where the replacement of the P1 pyrrolidine ring by a
2,5-dihydropyrrole ring slightly increases inhibitory activity. However, in the present
study the aromatic 2-thienyl and 2-furyl groups did not have any beneficial p-stacking
effect over the 1-cyclopentene group. It is possible that the increased amount of p-
orbitals improves potency but the effect is much smaller than the effect of the
hybridization.
The studied amide bond replacements can be used to modify different properties of
the compounds. They make the compounds less peptide-like and the replacement of the
amide nitrogen by a carbon atom also increases lipophilicity, as was shown with the
cyclopent-2-enecarbonyl group at the P2 position. Furthermore, when the P2 L-prolyl
residue was changed to the cyclopent-2-enecarbonyl group, it was found that the
dissociation half-life of the enzyme-inhibitor complex was decreased (Table 1,
unpublished results by Dr. Jarkko Venäläinen). The 5-tert-butyl-L-prolyl group has
previously been shown to increase the dissociation half-life of the enzyme-inhibitor
complex.
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Table 1. The effect of the replacement of the P2 L-prolyl group of JTP-4819 by the
cyclopent-2-enecarbonyl group on the enzyme-inhibitor binding kinetics.a
Structure Ki (nM) Kon (M-1s-1) Koff (s-1) EI t1/2 (h)
NN
OO
N
H
O
OH 0.043 5.59 x 105 2.41 x 10-5 7.99
N
OO
N
H
O
OH 0.074 7.11 x 105 5.27 x 10-5 3.65
a Published with the permission of Dr. Jarkko Venäläinen.
The a,b-unsaturated carbonyl groups are able to undergo Michael addition and are
normally avoided in the drug design. The a,b-unsaturated amides may be less reactive
than the a,b-unsaturated ketones because of the electron-donating effect of the amide
nitrogen. However, this remains to be clarified and it is possible that the further
protection of the double bond is needed. An obvious way to provide the further
protection would be the substitution of the double bond. An alkyl substituent would
most probably be allowed at the P2 position, where the 5-alkyl-L-prolines have been
shown to give good inhibitory activities. At the P1 position, the substitution may not be
allowed because of the limited space in the S1 pocket. However, the aryl-conjugated
carbonyl group should be more stable than the a,b-unsaturated ketone group and
provides a useful alternative for the P1 position.
9.3  Conclusions
Novel groups that were able to mimic their parent structures were found for all studied
positions. It is concluded that:
1. The P3 position and the positions beyond it give more freedom to drug design than
the P1 and P2 positions, and this freedom should be exploited when lead structures
are optimized.
2. The amide nitrogens of the P3-P2 and P2-P1 amide bonds of the POP inhibitor
structure can be replaced by the sp2 hybridized carbons and still maintain an
excellent POP inhibitory activity.
3. The physico-chemical properties were determined for the selected compounds and it
was shown that the studied groups can be used to modify these properties.
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9.4 Future perspectives
The research and the development of prolyl oligopeptidase inhibitors have produced a
wide variety of extremely potent compounds. Many of these compounds are based on
the N-acyl-L-Pro-pyrrolidine structure, which have been shown to be highly specific for
prolyl oligopeptidase. Furthermore, many compounds based on this structure have
undergone pharmacological or clinical studies and have been well-tolerated. However,
the physiological role of POP has remained unclear although POP inhibitors have
repeatedly been shown to enhance memory in different animal models.
The research should now be focused on the clarification of the physiological role of
POP and to get the proof-of-concept of the memory-enhancing (or other) effects of POP
inhibitors, possibly in long-term studies. The already developed inhibitors provide good
pharmacological tools to perform these studies. The N-acyl-L-Pro-pyrrolidine structure
and its mimetics have proven to give so potent and specific POP inhibitors that the
search for a different kind of lead structures does not seem necessary. The next step in
the development of POP inhibitors should be the optimization of the ADMET
properties, at the same time or after the proof-of-concept.
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